HDM2-inhibitor complexes and uses thereof

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH DEVELOPMENT

[0002] Not applicable.

FIELD OF THE INVENTION

[0003] The present invention generally pertains to the fields of molecular biology, protein crystallization, X-ray diffraction analysis, three-dimensional structural determination, molecular modeling and structure based rational drug design. The present invention provides crystallized HDM2 peptides as well as descriptions of the X-ray diffraction patterns. The X-ray diffraction patterns of the crystals in question are of sufficient resolution so that the three-dimensional structure of HDM2 can be determined at atomic resolution, ligand binding sites on HDM2 can be identified, and the interactions of ligands with HDM2 amino acid residues can be modeled.

[0004] The high resolution maps provided by the present invention and the models prepared using such maps also permit the design of ligands which can function as active agents. Thus, the present invention has applications to the design of active agents which include, but are not limited to, those that find use as inhibitors of MDM2 and HDM2 oncoproteins.

BACKGROUND OF THE INVENTION

[0005] HDM2: Structure and Function

[0006] HDM2 (human double minute 2 protein) is the expression product of hdm2, an oncogene that is overexpressed in a subset of human tumors including soft tissue sarcomas, glioblastomas and mammary carcinomas (Oliner, J. D. et al., Nature, 358(6381):80-83 (1992); Reifenberger, G. et al., Cancer Res., 53:2736-2739 (1993); Bueso-Ramos, C. E. et al., Breast Canc. Res. Treat., 37(2):179-188 (1996)).

[0007] Functional characterization of this oncogene revealed an interaction between HDM2 and p53, a tumor suppressor central to cell growth arrest and apoptosis (Momand, G. P. et al., Cell, 69:1237 (1992)). HDM2 is a transcriptional target of p53, and as such, HDM2 and p53 form a precisely regulated loop (Wu, X. et al., Genes and Dev., 7:1126-1132 (1992)). HDM2 is further regulated by ubiquitination and by complex formation with Arf, which sequesters HDM2 to the nucleolus (Tao, W. and Levine, A. J., Proc. Natl. Acad. Sci. USA, 96(12):6937-6941 (1999); Weber, J. D. et al., Nat. Cell Biol., 1(1):20-26 (1999)).

[0008] There are several lines of evidence that suggest that HDM2 can also function independently of p53. Splice variants of HDM2 not containing the p53-binding domain have been found in human tumors and have been shown to possess transforming ability (Sigalas, I. et al. Nat. Med. 2(8):912-917 (1996)). In vivo studies have also demonstrated that the spectrum of tumors that develop in transgenic mice overexpressing HDM2 is different from the spectrum found in p53-null mice and that HDM2 can drive sarcomagenesis in p53-null animals (Jones, S. N. et al., Proc. Natl. Acad. Sci. USA, 95(26):15608-15612 (1998)). Lastly, other binding partners of HDM2 could assist HDM2 function along an oncogenic pathway, for example, HDM2 inhibition of MTBP-induced p53-independent G1 arrest (Boyd, M. T. et al., J. Biol. Chem. 275(41):31883-31890 (2000)).

[0009] Reports of enhanced tumor cell death following hdm2 inhibition by antisense nucleotides (Chen, L. et al., Proc. Natl. Acad Sci. USA, 95(1):195-200 (1998); Chen, L. et al., Mol. Med., 5(1):21-34 (1999); Tortora, G. et al., Int. J. Cancer, 88(5):804-809 (2000)) and HDM2-binding mini-proteins (Bottger, A. et al., Curr. Biol., 7(11):860-869 (1997)) substantiate a prediction that inhibition of HDM2 will activate p53 and in turn trigger apoptosis. Following on this idea, a small molecule inhibitor generated against the p53 binding groove of HDM2 would be expected to prevent the interaction of the two proteins and induce p53 activity. It has been further suggested that inhibiting the interaction between p53 and HDM2 will act additively or synergistically with standard chemotherapeutic agents in the treatment of neoplasm, and this too is supported by work utilizing antisense hdm2 constructs (Wang, H. et al., Clin. Canc. Res. 7(11):3613-3624 (2001)).

[0010] MDM2: Structure and Function

[0011] mdm2, the murine homolog of HDM2 was originally found on mouse double minute chromosomes and was initially identified as one of three genes amplified in a tumorigenic cell line (Cahilly-Snyder., L. et al., Somatic Cell Mol. Genet. 13:235-244 (1987)). Its protein product was subsequently found to form a complex with p53, which was first observed in a rat fibroblast cell line (Clone 6) previously transfected with a temperature sensitive mouse p53 gene (Michalovitz, D. et al., Cell 62:671-680 (1990)). The rat cell line grew well at 37° C. but exhibited a G1 arrest when shifted down to 32° C., which was entirely consistent with an observed temperature dependent switch in p53 conformation and activity. However, the p53-MDM2 complex was only observed in abundance at 32° C., at which temperature p53 was predominantly in a functional or “wild-type” form (Barak, Y. et al., EMBO J. 11:2115-2121 (1992) and Momand, J. et al., Cell 69:1237-1245 (1992)). By shifting the rat cell line down to 32° C. and blocking de novo protein synthesis it was shown that only “wild-type” p53 induced expression of the mdm2 gene, thereby accounting for the differential abundance of the complex in terms of p53 transcriptional activity (Barak, Y. et al., EMBO J. 12:461-468 (1993)). The explanation was further developed by the identification of a DNA binding site for wild-type p53 within the first intron of the mdm2 gene (Wu, X. et al., Genes Dev. 7:1126-1132 (1993)). Reporter constructs employing this p53 DNA binding site revealed that they were inactivated when wild-type p53 was co-expressed with MDM2.

[0012] This inhibition of the transcriptional activity of p53 may be caused by MDM2 blocking the activation domain of p53 and/or the DNA binding site. Consequently, it was proposed that mdm2 expression is autoregulated, via the inhibitory effect of MDM2 protein on the transcriptional activity of wild-type p53. This p53-mdm2 autoregulatory feedback loop provided a novel insight as to how cell growth might be regulated by p53. Up to a third of human sarcomas are considered to overcome p53-regulated growth control by amplification of the mdm2 gene (Oliner, J. D. et al., Nature 358:80-83 (1992)). Hence, the interaction between p53 and MDM2 represents a key potential therapeutic target.

[0013] p53: Interaction with HDM2 and MDM2

[0014] p53 is a transcription factor for a number of proteins that cause cell cycle arrest or cell death by apoptosis, such as p21, 14-3-3σ, and bax. The level and transcriptional activity of p53 are increased by damage to cellular DNA. The MDM2 protein inhibits p53 function by binding to an amphipathic N-terminal helix of p53, abrogating the interaction of p53 with other proteins and its trans activation activity. The interaction with MDM2 also targets p53 for ubiquitin dependent protein degradation. MDM2 exhibits p53 independent effects on cell cycling as well, possibly by direct interaction with some of the downstream effectors such as pRB and EF2 (Reviewed in Zhang, R. and Wang, H., Cur. Pharm. Des. 6:393-416 (2000)).

[0015] Mutations of the p53 protein occur in 50% of all human cancers (reviewed in Agarwal, M. L. et al. J. Biol. Chem. 273:1-4 (1998); Levine, A. J., Cell 88:323-331(1997); and, references cited in Oren, M., J. Biol. Chem. 274:36031-36034 (1999)). Under normal circumstances, p53 is latent and a very labile protein, which turns over with a very short half-life of a few minutes (Rogel, A. et al., Mol. Cell. Biol. 5:2851-2855 (1985)). DNA damage or stress induces a remarkable increase in the stability of p53 (Kastan, M. B. et al., Cancer Res. 51:6304-6311 (1991)). Furthermore, these signals, also activate the function of p53 as a transcriptional activator of the apoptotic machinery, a function normally suppressed by autoregulatory inhibition of its transactivation domain. The amount of p53 present in the cell is tightly regulated by a negative feedback loop between p53 and the oncogene hdm2.

[0016] p53 is located in the cell nucleus and induces the expression of hdm2 through its transactivation domain. Expressed hdm2 subsequently binds to residues 19-26 of the p53 transactivation domain, inactivates it (Chen, J. et al., Mol. Cell. Biol. 16:2445-2452 (1996); Haupt, Y. et al., EMBO J. 15:1596-1606 (1996); Momand, J. et al., Cell 69:1237-1245 (1992)) and blocks recruitment of transcription factors necessary for gene expression (Lu, H. et al., PNAS 92:5154-5158 (1995); Thut, C. J. et al., Science 267:00-104 (1995)). Furthermore, the p53-hdm2-complex is shuttled to the cytoplasm where degradation occurs. This tight control through negative feedback is critical for the survival of the organism. Inactivation of hdm2 in hdm2-knockout mice leads to early embryonal lethality, but is completely prevented by simultaneous inactivation of p53 (Jones, S. N. et al., Nature 378:206-208 (1995); Montes de Oca Luna, R. et al., Nature 378:203-206 (1995)). On the other hand, excessive expression of hdm2 can lead to constitutive inhibition of p53 and promote cancer. Excess HDM2 also promotes cancer independently of p53 (Lundgren, K. et al., Genes and Dev. 11:714-725 (1997); Sun, P. et al., Science 282:2270-2272 (1998)).

[0017] As discussed above, inhibition of the interaction between HDM2 and p53 is an attractive target for cancer therapy (Lane, D. P., TIBS 22: 372-374 (1997)). It has been shown that inhibition of the complex formation between p53 and HDM2 raises the levels of p53 in the cell (Bottger, A. et al., Current Biol. 7:860-869 (1997)). Also, blocking HDM2 from binding p53 would be therapeutically useful in restoring cell cycle control to cells that overexpress HDM2 as a front line cancer treatment. More generally, inhibition of HDM2 may increase the effectiveness of chemotherapy and radiation in p53 normal cancers by enhancing apoptosis and growth arrest signaling pathways. This approach may render tumor cells containing functional p53 more susceptible to chemotherapeutic agents.

[0018] One method of identifying inhibitors of the p53/HDM2 protein complex is to determine the amino acid specificities of HDM2 binding pockets by crystallography in order to establish a model for the interaction. Using this method, Kussie et al. identified p53 based peptide antagonists (Kussie, P. H. et al., Science 274:948-953 (1996)). A crystal structure of a truncated form of HDM2 (residues 17-125) and a 15′mer peptide derived from the N-terminal transactivation domain of p53 was published by Kussie et al. (Kussie et al., (1996)). Kussie et al. also published a crystal structure of MDM2 (Kussie et al., (1996)) derived from Xenopus laevis (residues 13 to 118), having a 71% sequence identity towards HDM2. Based on molecular modeling, Garcia-Echeverrìa et al. published a model of an 8′mer peptidomimetic, derived from the 15′mer wild-type p53 peptide, bound to the N-terminal domain of hdm2 (Garcia-Echeverrìa, C. et al., J. Med. Chem. 43:3205-3208 (2000)). No crystal structure of HDM2 with inhibitory compounds, such as small molecule inhibitors, for example, or other peptides is believed to have been disclosed.

[0019] Therefore, a need continues to exist for the development of modeling systems to design and select potent, small molecules that inhibit the interactions between HDM2 (and homologs thereof) and natural binding ligands such as p53.

SUMMARY OF THE INVENTION

[0020] The present invention includes methods of producing and using three-dimensional structure information derived from human MDM2 protein (HDM2) and inhibitory compounds which form a complex with HDM2 and prevent HDM2 from interacting with the p53 protein. The present invention also includes specific crystallization conditions to obtain crystals of the inhibitor-HDM2 complex. The crystals are subsequently used to obtain a 3-dimensional structure of the complex using X-ray crystallography (or NMR) and the obtained data is used for rational drug discovery design with the aim to improve the complex formation between HDM2 and the inhibitor, and, also to improve the inhibition of the binding of HDM2 to p53.

[0021] The present invention includes a crystal comprising HDM2, or a fragment, or target structural motif or derivative thereof, and a ligand, wherein the ligand is a small molecule inhibitor. In another embodiment, the crystal has a spacegroup selected from the group consisting of a trigonal spacegroup of P3221 and a tetragonal spacegroup P43212. The present invention also includes a crystal comprising HDM2 which comprises a peptide having at least 95% sequence identity to SEQ ID NO. 2.

[0022] In another aspect of the invention, the invention includes a computer system comprising: (a) a database containing information on the three dimensional structure of a crystal comprising HDM2, or a fragment or a target structural motif or derivative thereof, and a ligand, wherein the ligand is a small molecule inhibitor, stored on a computer readable storage medium; and, (b) a user interface to view the information.

[0023] The present invention also includes a method of evaluating the potential of an agent to associate with HDM2 comprising: (a) exposing HDM2 to the agent; and (b) detecting the association of said agent to HDM2 amino acid residues Ser17, Ile19, Leu82 and Arg97thereby evaluating the potential.

[0024] The invention further includes a method of evaluating the potential of an agent to associate with the peptide having aa16-SEQ ID NO: 2, comprising: (a) exposing aa16-SEQ ID NO: 2 to the agent; and (b) detecting the level of association of the agent to aa 16-SEQ ID NO: 2, thereby evaluating the potential.

[0025] Further included in the present invention is a method of identifying a potential agonist or antagonist against HDM2 comprising: (a) employing the three dimensional structure of HDM2 cocrystallized with a small molecule inhibitor to design or select said potential agonist or antagonist.

[0026] The instant invention comprises a method of locating the attachment site of an inhibitor to HDM2, comprising: (a) obtaining X-ray diffraction data for a crystal of HDM2; (b) obtaining X-ray diffraction data for a complex of HDM2 and an inhibitor; (c) subtracting the X-ray diffraction data obtained in step (a) from the X-ray diffraction data obtained in step (b) to obtain the difference in the X-ray diffraction data; (d) obtaining phases that correspond to X-ray diffraction data obtained in step (a); (e) utilizing the phases obtained in step (d) and the difference in the X-ray diffraction data obtained in step (c) to compute a difference Fourier image of the inhibitor; and, (f) locating the attachment site of the inhibitor to HDM2 based on the computations obtained in step (e).

[0027] The present invention further comprises a method of obtaining a modified inhibitor comprising: (a) obtaining a crystal comprising HDM2 and an inhibitor; (b) obtaining the atomic coordinates of the crystal; (c) using the atomic coordinates and one or more molecular modeling techniques to determine how to modify the interaction of the inhibitor with HDM2; and, (d) modifying the inhibitor based on the determinations obtained in step (c) to produce a modified inhibitor.

[0028] In another aspect of the invention, the invention includes an isolated protein fragment comprising a binding pocket or active site defined by structure coordinates of HDM2 amino acid residues Ser17, Ile19, Leu82 and Arg97.

[0029] In another aspect of the invention, the invention includes an isolated nucleic acid molecule encoding the fragment which comprises a binding pocket or active site defined by structure coordinates of HDM2 amino acid residues Ser17, Ile19, Leu82 and Arg97. In another aspect of the invention, the invention includes a method of screening for an agent that associates with HDM2, comprising: (a) exposing a protein molecule fragment to the agent; and (b) detecting the level of association of the agent to the fragment. In another aspect of the invention, the invention includes a kit comprising a protein molecule fragment.

[0030] The invention additionally comprises a method for the production of a crystal complex comprising an HDM2 polypeptide-ligand comprising: (a) contacting the HDM2 polypeptide with said ligand in a suitable solution comprising PEG and NaSCN; and, b) crystallizing said resulting complex of HDM2 polypeptide-ligand from said solution.

[0031] The invention further includes a method for the production of a crystal comprising HDM2 and a ligand wherein the ligand is a small molecule inhibitor comprising crystallizing a peptide comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO:4 with a potential inhibitor.

[0032] The instant invention includes a method for identifying a potential inhibitor of HDM2 comprising: a) using a three dimensional structure of HDM2 as defined by atomic coordinates according to table 1 or table 2; b) replacing one or more HDM2 amino acids selected from Ser17, Ile19, Leu82 and Arg97 in said three-dimensional structure with a different amino acid to produce a modified HDM2; c) using said three-dimensional structure to design or select said potential inhibitor; d) synthesizing said potential inhibitor; and, e) contacting said potential inhibitor with said modified HDM2 in the presence of a substrate to test the ability of said potential inhibitor to inhibit HDM2 or said modified HDM2. Also included in the invention is an inhibitor identified by the method.

BRIEF DESCRIPTION OF THE DRAWINGS

[0033]
FIG. 1 Ribbon representation of HDM2 bound to compound 338437.

[0034]
FIG. 2 Fit of compound 338437 into the active site of HDM2 represented as a molecular surface.

[0035]
FIG. 3 Ribbon representation of a superposition between hdm2 in the trigonal crystal form and in the tetragonal form. The RMS deviation between C-alpha atom positions is 0.25 Angstroms.

DETAILED DESCRIPTION OF THE INVENTION

[0036] Definitions

[0037] As is generally the case in biotechnology and chemistry, the description of the present invention has required the use of a number of terms of art. Although it is not practical to do so exhaustively, definitions for some of these terms are provided here for ease of reference. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Definitions for other terms also appear elsewhere herein. However, the definitions provided here and elsewhere herein should always be considered in determining the intended scope and meaning of the defined terms. Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods and materials are described.

[0038] As used herein, the term “atomic coordinates” or “structure coordinates” refers to mathematical coordinates that describe the positions of atoms in crystals of HDM2 in Protein Data Bank (PDB) format, including X, Y, Z and B, for each atom. The diffraction data obtained from the crystals are used to calculate an electron density map of the repeating unit of the crystal. The electron density maps may be used to establish the positions (i.e. coordinates X, Y and Z) of the individual atoms within the crystal. Those of skill in the art understand that a set of structure coordinates determined by X-ray crystallography is not without standard error. For the purpose of this invention, any set of structure coordinates for HDM2 from any source having a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2 are considered substantially identical or homologous. In a more preferred embodiment, any set of structure coordinates for HDM2 from any source having a root mean square deviation of non-hydrogen atoms of less than about 0.75 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2 are considered substantially identical or homologous.

[0039] The term “atom type” refers to the chemical element whose coordinates are measured. The first letter in a column in Table 1 identifies the element.

[0040] The terms “X,” “Y” and “Z” refer to the crystallographically-defined atomic position of the element measured with respect to the chosen crystallographic origin. The term “B” refers to a thermal factor that measures the mean variation of an atom's position with respect to its average position.

[0041] As used herein, the term “crystal” refers to any three-dimensional ordered array of molecules that diffracts X-rays.

[0042] As used herein, the term “carrier” in a composition refers to a diluent, adjuvant, excipient, or vehicle with which the product is mixed.

[0043] As used herein, the term “composition” refers to the combining of distinct elements or ingredients to form a whole. A composition comprises more than one element or ingredient. For the purposes of this invention, a composition will often, but not always, comprise a carrier.

[0044] As used herein, “mdm2” is used to mean the murine double minute 2 gene, and homologous genes found in other animals.

[0045] As used herein, “MDM2” is used to mean a protein obtained as a result of expression of the mdm2 oncogene. Within the meaning of this term, it will be understood that MDM2 encompasses all proteins encoded by mdm2, mutants thereof, conservative amino acid substitutions, alternative splice proteins thereof, and phosphorylated proteins thereof. Additionally, as used herein, it will be understood that the term “MDM2” includes MDM2 homologues of other animals.

[0046] As used herein, “hdm2” is used to mean the human gene, which is homologous to the mouse mdm2 gene.

[0047] As used herein, “HDM2” is used to mean a protein obtained as a result of expression of the hdm2 oncogene. Within the meaning of this term, it will be understood that HDM2 encompasses all proteins encoded by hdm2, mutants thereof, conservative amino acid substitutions, alternative splice proteins thereof, and phosphorylated proteins thereof. As an example, HDM2 includes the protein comprising SEQ ID NO: 2 and variants thereof comprising at least about 70% amino acid sequence identity to SEQ ID NO: 2, or preferably 80%, 85%, 90% and 95% sequence identity to SEQ ID NO: 2, or more preferably, at least about 95% or more sequence identity to SEQ ID NO: 2.

[0048] As used herein, the term “SAR,” an abbreviation for Structure-Activity Relationships, collectively refers to the structure-activity/structure property relationships pertaining to the relationship(s) between a compound's activity/properties and its chemical structure.

[0049] As used herein, the term “molecular structure” refers to the three dimensional arrangement of molecules of a particular compound or complex of molecules (e.g., the three dimensional structure of HDM2 and ligands that interact with HDM2).

[0050] As used herein, the term “molecular modeling” refers to the use of computational methods, preferably computer assisted methods, to draw realistic models of what molecules look like and to make predictions about structure activity relationships of ligands. The methods used in molecular modeling range from molecular graphics to computational chemistry.

[0051] As used herein, the term “molecular model” refers to the three dimensional arrangement of the atoms of a molecule connected by covalent bonds or the three dimensional arrangement of the atoms of a complex comprising more than one molecule, e.g., a protein-ligand complex.

[0052] As used herein, the term “molecular graphics” refers to 3D representations of the molecules, for instance, a 3D representation produced using computer assisted computational methods.

[0053] As used herein, the term “computational chemistry” refers to calculations of the physical and chemical properties of the molecules.

[0054] As used herein, the term “molecular replacement” refers to a method that involves generating a preliminary model of a crystal of HDM2 whose coordinates are unknown, by orienting and positioning the said atomic coordinates described in the present invention so as best to account for the observed diffraction pattern of the unknown crystal. Phases can then be calculated from this model and combined with the observed amplitudes to give an approximate Fourier synthesis of the structure whose coordinates are unknown. (Rossmann, M. G., ed., “The Molecular Replacement Method”, Gordon & Breach, New York, 1972).

[0055] As used herein, the term “homolog” refers to the HDM2 protein molecule or the nucleic acid molecule which encodes the protein, or a functional domain from said protein from a first source having at least about 30%, 40% or 50% sequence identity, or at least about 60%, 70% or 75% sequence identity, or at least about 80% sequence identity, or more preferably at least about 85% sequence identity, or even more preferably at least about 90% sequence identity, and most preferably at least about 95%, 97% or 99% amino acid or nucleotide sequence identity, with the protein, encoding nucleic acid molecule or any functional domain thereof, from a second source. The second source may be a version of the molecule from the first source that has been genetically altered by any available means to change the primary amino acid or nucleotide sequence or may be from the same or a different species than that of the first source.

[0056] As used herein, the term “active site” refers to regions on HDM2 or a structural motif of HDM2 that are directly involved in the function or activity of HDM2.

[0057] As used herein, the terms “binding site” or “binding pocket” refer to a region of HDM2 or a molecular complex comprising HDM2 that, as a result of the primary amino acid sequence of HDM2 and/or its three-dimensional shape, favorably associates with another chemical entity or compound including ligands or inhibitors.

[0058] For the purpose of this invention, any active site, binding site or binding pocket defined by a set of structure coordinates for HDM2 or for a homolog of HDM2 from any source having a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2 are considered substantially identical or homologous. In a more preferred embodiment, any set of structure coordinates for HDM2 or a homolog of HDM2 from any source having a root mean square deviation of non-hydrogen atoms of less than about 0.75 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2 are considered substantially identical or homologous.

[0059] The tem “root mean square deviation” means the square root of the arithmetic mean of the squares of the deviations from the mean.

[0060] As used herein, the term “amino acids” refers to the L-isomers of the naturally occuring amino acids. The naturally occurring amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, γ-carboxylglutamic acid, arginine, ornithine, and lysine. Unless specifically indicated, all amino acids are referred to in this application are in the L-form.

[0061] As used herein, the term “nonnatural amino acids” refers to amino acids that are not naturally found in proteins. For example, selenomethionine.

[0062] As used herein, the term “positively charged amino acid” includes any amino acids having a positively charged side chain under normal physiological conditions. Examples of positively charged naturally occurring amino acids are arginine, lysine, and histidine.

[0063] As used herein, the term “negatively charged amino acid” includes any amino acids having a negatively charged side chains under normal physiological conditions. Examples of negatively charged naturally occurring amino acids are aspartic acid and glutamic acid.

[0064] As used herein, the term “hydrophobic amino acid” includes any amino acids having an uncharged, nonpolar side chain that is relatively insoluble in water. Examples of naturally occurring hydrophobic amino acids are alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.

[0065] As used herein, the term “hydrophilic amino acid” refers to any amino acids having an uncharged, polar side chain that is relatively soluble in water. Examples of naturally occurring hydrophilic amino acids are serine, threonine, tyrosine, asparagine, glutamine and cysteine.

[0066] As used herein, the term “hydrogen bond” refers to two hydrophilic atoms (either O or N), which share a hydrogen that is covalently bonded to only one atom, while interacting with the other.

[0067] As used herein, the term “hydrophobic interaction” refers to interactions made by two hydrophobic residues or atoms (such as C).

[0068] As used herein, the term “conjugated system” refers to more than two double bonds are adjacent to each other, in which electrons are completely delocalized with the entire system. This also includes and aromatic residues.

[0069] As used herein, the term “aromatic residue” refers to amino acids with side chains having a delocalized conjugated system. Examples of aromatic residues are phenylalanine, tryptophan, and tyrosine.

[0070] As used herein, the phrase “inhibiting the binding” refers to preventing or reducing the direct or indirect association of one or more molecules, peptides, proteins, enzymes, or receptors, or preventing or reducing the normal activity of one or more molecules, peptides, proteins, enzymes or receptors, e.g., preventing or reducing the direct or indirect association of HDM2 and p53.

[0071] As used herein, the term “competitive inhibitor” refers to inhibitors that bind to HDM2 at the same sites as its binding partner(s) (e.g., p53), thus directly competing with them. Competitive inhibition may, in some instances, be reversed completely by increasing the substrate concentration.

[0072] As used herein, the term “uncompetitive inhibitor” refers to one that inhibits the functional activity of HDM2 by binding to a different site than does its substrate(s) e.g. (p53).

[0073] As used herein, the term “non-competitive inhibitor” refers to one that can bind to either the free or p53 bound form of HDM2.

[0074] Those of skill in the art may identify inhibitors as competitive, uncompetitive, or non-competitive by computer fitting enzyme kinetic data using standard methods. See, for example, Segel, I. H., Enzyme Kinetics, J. Willey & Sons, (1975).

[0075] As used herein, the term “R or S-isomer” refers to two possible stereroisomers of a chiral carbon according to the Cahn-Ingold-Prelog system adopted by International Union of Pure and Applied Chemistry (IUPAC). Each group attached to the chiral carbon is first assigned to a preference or priority a, b, c, or d on the basis of the atomic number of the atom that is directly attached to the chiral carbon. The group with the highest atomic number is given the highest preference a, the group with next highest atomic number is given the next highest preference b; and so on. The group with the lowest preference (d) is then directed away from the viewer. If the trace of a path from a to b to c is counter clockwise, the isomer is designated (S); in the opposite direction, clockwise, the isomer is designated (R).

[0076] As used herein, the term “ligand” refers to any molecule, or chemical entity which binds with or to HDM2, a subunit of HDM2, a domain of HDM2, a target structual motif of HDM2 or a fragment of HDM2. Thus, ligands include, but are not limited to, small molecule inhibitors, for example.

[0077] As used herein, the term “small molecule inhibitor” refers to compounds useful in the present invention having measurable MDM2 or HDM2 inhibiting activity. In addition to small organic molecules, peptides, antibodies, cyclic peptides and peptidomimetics are contemplated as being useful in the disclosed methods. Excluded from the invention are the p53 peptides disclosed in Kussie et al., Garcia-Echeverrìa et al., and the peptides derived from phage display which inhibit the binding of mdm2 to p53 (Böttger, V. A., et al., Oncogene 13(10): 2141-2147 (1996)). Preferred inhibitors are small molecules, preferably less than 700 Daltons, and more preferably less than 450 Daltons. Examples of classes of compounds having this property include compounds disclosed in U.S. Provisional Application No. 60/275,629; in U.S. Provisional Application No. 60/331,235; in U.S. Provisional Application No. 60/379,617; and, in U.S. application Ser. No. 10/097,249, incorporated herein in their entirety.

[0078] As used herein the terms “bind,” “binding,” “bond,” or “bonded” when used in reference to the association of atoms, molecules, or chemical groups, refer to any physical contact or association of two or more atoms, molecules, or chemical groups.

[0079] As used herein, the terms “covalent bond” or “valence bond” refer to a chemical bond between two atoms in a molecule created by the sharing of electrons, usually in pairs, by the bonded atoms.

[0080] As used herein, “noncovalent bond” refers to an interaction between atoms and/or molecules that does not involve the formation of a covalent bond between them.

[0081] As used herein, the term “native protein” refers to a protein comprising an amino acid sequence identical to that of a protein isolated from its natural source or organism.

SPECIFIC EMBODIMENTS

DETAILED EMBODIMENTS

[0082] The present invention includes a crystal comprising HDM2, or a fragment, or target structural motif or derivative thereof, and a ligand, wherein the ligand is a small molecule inhibitor. In one embodiment, the fragment or derivative thereof is a peptide selected from the group consisting of SEQ ID NO: 1 (amino acid sequence of full length HDM2), SEQ ID NO: 2 (amino acid residues 17-111 of SEQ ID NO: 1), SEQ ID NO. 3 (amino acid residues 23-114 of SEQ ID NO: 1) and SEQ ID NO. 4 (Gly16-SEQ ID NO: 2).

[0083] In another embodiment, the crystal has a spacegroup selected from the group consisting of a trigonal spacegroup of P3221 and a tetragonal spacegroup of P43212. In a different embodiment, the crystal effectively diffracts X-rays for determination of atomic coordinates to a resolution of at least about 3.0 Å. In a preferred embodiment, the ligand is in crystalline form. In a highly preferred embodiment, the ligand is selected from the group consisting of (4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid; [8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid, and, derivatives thereof.

[0084] The present invention also includes a crystal comprising HDM2 which comprises a peptide having at least 95% sequence identity to SEQ ID NO. 2. In a preferred embodiment, the crystal comprising SEQ ID NO: 2 comprises an atomic structure characterized by the coordinates of Table 1 or Table 2. In another preferred embodiment, the crystal comprises a unit cell selected from the group consisting of: a cell having dimensions of about 98.6 Å, 98.6 Å and 74.7 Å, and about alpha=90°, beta=90° and gamma=120°; and, a cell having dimensions of about 54.3 Å, 54.3 Å, 83.3 Å and about alpha=90°, beta=90° and gamma=90°.

[0085] In another aspect of the invention, the invention includes a computer system comprising: (a) a database containing information on the three dimensional structure of a crystal comprising HDM2, or a fragment or a target structural motif or derivative thereof, and a ligand, wherein the ligand is a small molecule inhibitor, stored on a computer readable storage medium; and, (b) a user interface to view the information. In one embodiment, the information comprises diffraction data obtained from a crystal comprising SEQ ID NO:2. In another embodiment, the information comprises an electron density map of a crystal form comprising SEQ ID NO:2. In a different embodiment, the information comprises the structure coordinates of Table 1 or Table 2 or homologous structure coordinates comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 A when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2. In a preferred embodiment, the information comprises structure coordinates comprising a root mean square deviation of non-hydrogen atoms of less than about 0.75 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2. In a highly preferred embodiment, the information comprises the structure coordinates for amino acids Ser17, Ile19 , Leu82 and Arg97 according to Table 1 or Table 2 or similar structure coordinates for said amino acids comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2. In another embodiment, the information further comprises the structure coordinates for amino acids Val53, Leu54, Phe55, Leu57, Gly58, Gln59, Ile61, Met62, Tyr67, Gln72, His73, Ile74, Val75, Phe86, Phe91, Val93, Lys94, Glu95, His96, Ile99, Tyr100, Ile103 according to Table 1 or Table 2 or similar structure coordinates for said amino acids comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2.

[0086] The present invention also includes a method of evaluating the potential of an agent to associate with HDM2 comprising: (a) exposing HDM2 to the agent; and (b) detecting the association of said agent to HDM2 amino acid residues Ser17, Ile19, Leu82 and Arg97 thereby evaluating the potential. In one embodiment of the invention, the agent is a virtual compound. In another embodiment of the invention, step (a) comprises comparing the atomic structure of the compound to the three dimensional structure of HDM2. In a different embodiment, the comparing comprises employing a computational means to perform a fitting operation between the compound and at least one binding site of HDM2. In a preferred embodiment, the binding site is defined by structure coordinates for amino acids Ser17, Ile19, Leu82 and Arg97 according to Table 1 or Table 2 similar structure coordinates for said amino acids comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2. In another different embodiment, the binding site is further defined by structure coordinates for amino acids Val53, Leu54, Phe55, Leu57, Gly58, Gln59, Ile61, Met62, Tyr67, Gln72, His73, Ile74, Val75, Phe86, Phe91, Val93, Lys94, Glu95, His96, Ile99, Tyr100, Ile103 according to Table 1 or Table 2 or similar structure coordinates for said amino acids comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2. In a highly preferred embodiment, the agent is exposed to crystalline SEQ ID NO:2 and the detecting of step (b) comprises determining the three dimensional structure of the agent-SEQ ID NO: 2 complex.

[0087] The invention further includes a method of evaluating the potential of an agent to associate with the peptide having aa16-SEQ ID NO: 2, comprising: (a) exposing aa16-SEQ ID NO: 2 to the agent; and (b) detecting the level of association of the agent to aa 16-SEQ ID NO: 2, thereby evaluating the potential. In one embodiment, the agent is a virtual compound.

[0088] The present invention includes a method of identifying a potential agonist or antagonist against HDM2 comprising: (a) employing the three dimensional structure of HDM2 cocrystallized with a small molecule inhibitor to design or select said potential agonist or antagonist. In one embodiment, the three dimensional structure corresponds to the atomic structure characterized by the coordinates of Table 1 or similar structure coordinates comprising a root mean square deviation of non-hydrogen atoms of less than about 1.5 Å when superimposed on the non-hydrogen atom positions of the corresponding atomic coordinates of Table 1 or Table 2. In a different embodiment, the method further comprises the steps of: (b) synthesizing the potential agonist or antagonist; and (c) contacting the potential agonist or antagonist with HDM2.

[0089] The instant invention comprises a method of locating the attachment site of an inhibitor to HDM2, comprising: (a) obtaining X-ray diffraction data for a crystal of HDM2; (b) obtaining X-ray diffraction data for a complex of HDM2 and an inhibitor; (c) subtracting the X-ray diffraction data obtained in step (a) from the X-ray diffraction data obtained in step (b) to obtain the difference in the X-ray diffraction data; (d) obtaining phases that correspond to X-ray diffraction data obtained in step (a); (e) utilizing the phases obtained in step (d) and the difference in the X-ray diffraction data obtained in step (c) to compute a difference Fourier image of the inhibitor; and, (f) locating the attachment site of the inhibitor to HDM2 based on the computations obtained in step (e).

[0090] The present invention further comprises a method of obtaining a modified inhibitor comprising: (a) obtaining a crystal comprising HDM2 and an inhibitor; (b) obtaining the atomic coordinates of the crystal; (c) using the atomic coordinates and one or more molecular modeling techniques to determine how to modify the interaction of the inhibitor with HDM2; and, (d) modifying the inhibitor based on the determinations obtained in step (c) to produce a modified inhibitor. In one embodiment, the crystal comprises a peptide selected from the group consisting of: a peptide having SEQ ID NO: 2; a peptide having SEQ ID NO: 3 and a peptide having SEQ ID NO:4. In a different embodiment, the one or more molecular modeling techniques are selected from the group consisting of graphic molecular modeling and computational chemistry. In a preferred embodiment, step (a) comprises detecting the interaction of the inhibitor to HDM2 amino acid residues Ser17, Ile19, Leu82 and Arg97. In another embodiment of the invention, the invention includes an HDM2 inhibitor identified by this method.

[0091] In another aspect of the invention, the invention includes an isolated protein fragment comprising a binding pocket or active site defined by structure coordinates of HDM2 amino acid residues Ser17, Ile19, Leu82 and Arg97. In one embodiment, the isolated fragment is linked to a solid support.

[0092] In another aspect of the invention, the invention includes an isolated nucleic acid molecule encoding the fragment which comprises a binding pocket or active site defined by structure coordinates of HDM2 amino acid residues Ser17, Ile19, Leu82 and Arg97. In one embodiment, a vector comprises the nucleic acid molecule. In another embodiment, a host cell comprises the vector. In yet another aspect of the invention, the invention includes a method of producing a protein fragment, comprising culturing the host cell under conditions in which the fragment is expressed. In another aspect of the invention, the invention includes a method of screening for an agent that associates with HDM2, comprising: (a) exposing a protein molecule fragment to the agent; and (b) detecting the level of association of the agent to the fragment. In another aspect of the invention, the invention includes a kit comprising a protein molecule fragment.

[0093] In another aspect of the invention, the invention includes a method for the production of a crystal complex comprising an HDM2 polypeptide-ligand comprising: (a) contacting the HDM2 polypeptide with said ligand in a suitable solution comprising PEG and NaSCN; and, b) crystallizing said resulting complex of HDM2 polypeptide-ligand from said solution. In one embodiment, the HDM2 polypeptide is a polypeptide having SEQ ID NO: 2. In another embodiment, PEG has an average molecular weight range from 100 to 1000, wherein said PEG is present in solution at a range from about 0.5% w/v to about 10% w/v and said NaSCN is present in solution at a range of from about 50 mM to about 150 mM. In a preferred embodiment, PEG has an average molecular weight of about 400 and is present in solution at about 2% w/v and said NaSCN is present in solution at about 100 mM. In a highly preferred embodiment, the solution further comprises about 1.8-2.4 M (NH4)2SO4 and about 100 mM buffer.

[0094] The invention further includes a method for the production of a crystal comprising HDM2 and a ligand wherein the ligand is a small molecule inhibitor comprising crystallizing a peptide comprising a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO:4 with a potential inhibitor.

[0095] The invention includes a method for identifying a potential inhibitor of HDM2 comprising: a) using a three dimensional structure of HDM2 as defined by atomic coordinates according to table 1; b) replacing one or more HDM2 amino acids selected from Ser17, Ile19, Leu82 and Arg97 in said three-dimensional structure with a different amino acid to produce a modified HDM2; c) using said three-dimensional structure to design or select said potential inhibitor; d) synthesizing said potential inhibitor; and, e) contacting said potential inhibitor with said modified HDM2 in the presence of a substrate to test the ability of said potential inhibitor to inhibit HDM2 or said modified HDM2. In one embodiment, replacing one or more amino acid residues further comprises replacing SEQ ID NO: 2 amino acids selected from the group consisting of Val53, Leu54, Phe55, Leu57, Gly58, Gln59, Ile61, Met62, Tyr67, Gln72, His73, Ile74, Val75, Phe86, Phe91, Val93, Lys94, Glu95, His96, Ile99, Tyr100, and Ile103. In another embodiment, the potential inhibitor is selected from a database. In a preferred embodiment, the potential inhibitor is designed de novo. In another preferred embodiment, the potential inhibitor is designed from a known inhibitor. In a highly preferred embodiment, the step of employing said three-dimensional structure to design or select said potential inhibitor comprises the steps of: a) identifying chemical entities or fragments capable of associating with modified HDM2; and b) assembling the identified chemical entities or fragments into a single molecule to provide the structure of said potential inhibitor. In one embodiment, the potential inhibitor is a competitive inhibitor of SEQ ID NO:4 (Gly16-SEQ ID NO: 2). In a different embodiment, the potential inhibitor is a non-competitive or uncompetitive inhibitor of SEQ ID NO:4 (Gly16-SEQ ID NO: 2). In yet another embodiment, an inhibitor is identified by the method.

[0096] A. Modeling the Three-Dimensional Structure of HDM2

[0097] The atomic coordinate data provided in Table 1, Table 2 or the coordinate data derived from homologous proteins may be used to build a three-dimensional model of HDM2. Any available computational methods may be used to build the three dimensional model. As a starting point, the X-ray diffraction pattern obtained from the assemblage of the molecules or atoms in a crystalline version of HDM2 or an HDM2 homolog can be used to build an electron density map using tools well known to those skilled in the art of crystallography and X-ray diffraction techniques. Additional phase information extracted either from the diffraction data and available in the published literature and/or from supplementing experiments may then used to complete the reconstruction.

[0098] For basic concepts and procedures of collecting, analyzing, and utilizing X-ray diffraction data for the construction of electron densities see, for example, Campbell et al., 1984, Biological Spectroscopy, The Benjamin/Cummings Publishing Co., Inc., Menlo Park, Calif.; Cantor et al., 1980, Biophysical Chemistry, Part II: Techniques for the study of biological structure and function, W. H. Freeman and Co., San Francisco, Calif.; A. T. Brunger, 1993, X-Flor Version 3.1: A system for X-ray crystallography and NMR, Yale Univ. Pr., New Haven, Conn.; M. M. Woolfson, 1997, An Introduction to X-ray Crystallography, Cambridge Univ. Pr., Cambridge, UK; J. Drenth, 1999, Principles of Protein X-ray Crystallography (Springer Advanced Texts in Chemistry), Springer Verlag; Berlin; Tsirelson et al., 1996, Electron Density and Bonding in Crystals: Principles, Theory and X-ray Diffraction Experiments in Solid State Physics and Chemistry, Inst. of Physics Pub.; U.S. Pat. No. 5,942,428; U.S. Pat. No. 6,037,117; U.S. Pat. No. 5,200,910 and U.S. Pat. No. 5,365,456 (“Method for Modeling the Electron Density of a Crystal”), each of which is herein specifically incorporated by reference in their entirety.

[0099] For basic information on molecular modeling, see, for example, M. Schlecht, Molecular Modeling on the PC, 1998, John Wiley & Sons; Gans et al., Fundamental Principals of Molecular Modeling, 1996, Plenum Pub. Corp.; N. C. Cohen (editor), Guidebook on Molecular Modeling in Drug Design, 1996, Academic Press; and W. B. Smith, Introduction to Theoretical Organic Chemistry and Molecular Modeling, 1996. U.S. Patents which provide detailed information on molecular modeling include U.S. Pat. Nos. 6,093,573; 6,080,576; 6,075,014; 6,075,123; 6,071,700; 5,994,503; 5,612,894; 5,583,973; 5,030,103; 4,906,122; and 4,812,12, each of which are incorporated by reference herein in their entirety.

[0100] B. Methods of Using the Atomic Coordinates to Identify and Design Ligands of Interest

[0101] The atomic coordinates of the invention, such as those described in Table 1, Table 2, Table 3 or coordinates substantially identical to or homologous to those of Table 1, Table 2, or Table 3 may be used with any available methods to prepare three dimensional models of HDM2 as well as to identify and design HDM2 ligands, inhibitors or antagonists or agonist molecules.

[0102] For instance, three-dimensional modeling may be performed using the experimentally determined coordinates derived from X-ray diffraction patterns, such as those in Table 1 or Table 2, for example, wherein such modeling includes, but is not limited to, drawing pictures of the actual structures, building physical models of the actual structures, and determining the structures of related subunits and HDM2/ligand and HDM2 subunit/ligand complexes using the coordinates. Such molecular modeling can utilize known X-ray diffraction molecular modeling algorithms or molecular modeling software to generate atomic coordinates corresponding to the three-dimensional structure of HDM2.

[0103] As described above, molecular modeling involves the use of computational methods, preferably computer assisted methods, to build realistic models of molecules that are identifiably related in sequence to the known crystal structure. It also involves modeling new small molecule inhibitors bound to HDM2 starting with the structures of HDM2 and or HDM2 complexed with known ligands or inhibitors. The methods utilized in ligand modeling range from molecular graphics (i.e., 3D representations) to computational chemistry (i.e., calculations of the physical and chemical properties) to make predictions about the binding of ligands or activities of ligands; to design new ligands; and to predict novel molecules, including ligands such as drugs, for chemical synthesis, collectively referred to as rational drug design.

[0104] One approach to rational drug design is to search for known molecular structures that might bind to an active site. Using molecular modeling, rational drug design programs can look at a range of different molecular structures of drugs that may fit into the active site of an enzyme, and by moving them in a three-dimensional environment it can be decided which structures actually fit the site well. See, for example, U.S. Appl. Nos. 60/275,629; 60/331,235; 60/379,617; and, 10/097,249. See, also, for example, data in Tables 1, 2 and 3.

[0105] An alternative but related rational drug design approach starts with the known structure of a complex with a small molecule ligand and models modifications of that small molecule in an effort to make additional favorable interactions with HDM2.

[0106] The present invention include the use of molecular and computer modeling techniques to design and select and design ligands, such as small molecule agonists or antagonists or other therapeutic agents that interact with HDM2. Such agents include, but are not limited to 1,4 benzodiazepines and derivatives thereof. For example, the invention as herein described includes the design of ligands that act as competitive inhibitors of at least one HDM2 function by binding to all, or a portion of, the active sites or other regions of HDM2.

[0107] This invention also includes the design of compounds that act as uncompetitive inhibitors of at least one function of HDM2. These inhibitors may bind to all, or a portion of, the active sites or other regions of HDM2 already bound to its substrate and may be more potent and less non-specific than competitive inhibitors that compete for HDM2 active sites. Similarly, non-competitive inhibitors that bind to and inhibit at least one function of HDM2 whether or not it is bound to another chemical entity may be designed using the atomic coordinates of HDM2 or complexes comprising HDM2 of this invention.

[0108] The atomic coordinates of the present invention also provide the needed information to probe a crystal of HDM2 with molecules composed of a variety of different chemical features to determine optimal sites for interaction between candidate inhibitors and/or activators and HDM2. For example, high resolution X-ray diffraction data collected from crystals saturated with solvent allows the determination of where each type of solvent molecule sticks. Small molecules that bind to those sites can then be designed and synthesized and tested for their inhibitory activity (Travis, J., Science 262:1374(1993)).

[0109] The present invention also includes methods for computationally screening small molecule databases and libraries for chemical entities, agents, ligands, or compounds that can bind in whole, or in part, to HDM2. In this screening, the quality of fit of such entities or compounds to the binding site or sites may be judged either by shape complementarity or by estimated interaction energy (Meng, E. C. et al., J. Coma. Chem. 13:505-524 (1992)).

[0110] The design of compounds that bind to promote or inhibit the functional activity of HDM2 according to this invention generally involves consideration of two factors. First, the compound must be capable of physically and structurally associating with HDM2. Non-covalent molecular interactions important in the association of HDM2 with the compound, include hydrogen bonding, van der Waals and hydrophobic interactions. Second, the compound must be able to assume a conformation that allows it to associate with HDM2. Although certain portions of the compound may not directly participate in the association with HDM2, those portions may still influence the overall conformation of the molecule. This, in turn, may have a significant impact on binding affinities, therapeutic efficacy, drug-like qualities and potency. Such conformational requirements include the overall three-dimensional structure and orientation of the chemical entity or compound in relation to all or a portion of the active site or other region of HDM2, or the spacing between functional groups of a compound comprising several chemical entities that directly interact with HDM2.

[0111] The potential, predicted, inhibitory agonist, antagonist or binding effect of a ligand or other compound on HDM2 may be analyzed prior to its actual synthesis and testing by the use of computer modeling techniques. If the theoretical structure of the given compound suggests insufficient interaction and association between it and HDM2, synthesis and testing of the compound may be obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to interact with HDM2. In this manner, synthesis of inoperative compounds may be avoided. In some cases, inactive compounds are synthesized predicted on modeling and then tested to develop a SAR (structure-activity relationship) for compounds interacting with a specific region of HDM2.

[0112] One skilled in the art may use one of several methods to screen chemical entities fragments, compounds, or agents for their ability to associate with HDM2 and more particularly with the individual binding pockets or active sites of HDM2. This process may begin by visual inspection of, for example, the active site on the computer screen based on the atomic coordinates of HDM2 or HDM2 complexed with a ligand. Selected chemical entities, compounds, or agents may then be positioned in a variety of orientations, or docked within an individual binding pocket of HDM2. Docking may be accomplished using software such as Quanta and Sybyl, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.

[0113] Specialized computer programs may also assist in the process of selecting chemical entities. These include but are not limited to: GRID (Goodford, P. J., “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,” J. Med. Chem. 28:849-857 (1985), available from Oxford University, Oxford, UK); MCSS (Miranker, A. and M. Karplus, “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method.” Proteins: Structure, Function and Genetics 11: 29-34 (1991), available from Molecular Simulations, Burlington, Mass.); AUTODOCK (Goodsell, D. S. and A. J. Olsen, “Automated Docking of Substrates to Proteins by Simulated Annealing” Proteins: Structure. Function, and Genetics 8:195-202 (1990), available from Scripps Research Institute, La Jolla, Calif.); and DOCK (Kuntz, I. D. et al., “A Geometric Approach to Macromolecule-Ligand Interactions,” J.-Mol. Biol. 161:269-288 (1982), available from University of California, San Francisco, Calif.).

[0114] The use of software such as GRID, a program that determines probable interaction sites between probes with various functional group characteristics and the macromolecular surface, is used to analyze the surface sites to determine structures of similar inhibiting proteins or compounds. The GRID calculations, with suitable inhibiting groups on molecules (e.g., protonated primary amines) as the probe, are used to identify potential hotspots around accessible positions at suitable energy contour levels. The program DOCK may be used to analyze an active site or ligand binding site and suggest ligands with complementary steric properties.

[0115] Once suitable chemical entities, compounds, or agents have been selected, they can be assembled into a single ligand or compound or inhibitor or activator. Assembly may proceed by visual inspection of the relationship of the fragments to each other on the three-dimensional image. This may be followed by manual model building using software such as Quanta or Sybyl.

[0116] Useful programs to aid in connecting the individual chemical entities, compounds, or agents include but are not limited to: CAVEAT (Bartlett, P. A. et al., “CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules.” In Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc., 78, pp. 82-196 (1989)); 3D Database systems such as MACCS-3D (MDL Information Systems, San Leandro, Calif. and Martin, Y.C., “3D Database Searching in Drug Design”, J. Med. Chem. 35: 2145-2154 (1992); and HOOK (available from Molecular Simulations, Burlington, Mass.).

[0117] Several methodologies for searching three-dimensional databases to test pharmacophore hypotheses and select compounds for screening are available. These include the program CAVEAT (Bacon et al., J. Mol. Biol. 225:849-858 (1992)). For instance, CAVEAT uses databases of cyclic compounds which can act as “spacers” to connect any number of chemical fragments already positioned in the active site. This allows one skilled in the art to quickly generate hundreds of possible ways to connect the fragments already known or suspected to be necessary for tight binding.

[0118] Instead of proceeding to build an inhibitor activator, agonist or antagonist of HDM2 in a step-wise fashion one chemical entity at a time as described above, such compounds may be designed as a whole or “de novo” using either an empty active site or optionally including some portion(s) of a known molecules. These methods include: LUDI (Bohm, H.-J., “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors”, J. ComR. Aid. Molec. Design, 6, pp. 61-78 (1992), available from Biosym Technologies, San Diego, Calif.); LEGEND (Nishibata, Y. and A. Itai, Tetrahedron 47:8985 (1991), available from Molecular Simulations, Burlington, Mass.); and LeapFrog (available from Tripos Associates, St. Louis, Mo.).

[0119] For instance, the program LUDI can determine a list of interaction sites into which to place both hydrogen bonding and hydrophobic fragments. LUDI then uses a library of linkers to connect up to four different interaction sites into fragments. Then smaller “bridging” groups such as —CH2- and —COO— are used to connect these fragments. For example, for the enzyme DHFR, the placements of key functional groups in the well-known inhibitor methotrexate were reproduced by LUDI. See also, Rotstein and Murcko, J. Med. Chem. 36: 1700-1710 (1992).

[0120] Other molecular modeling techniques may also be employed in accordance with this invention. See, e.g., Cohen, N. C. et al., “Molecular Modeling Software and Methods for Medicinal Chemistry, J. Med. Chem. 33:883-894 (1990). See also, Navia, M. A. and M. A. Murcko, “The Use of Structural Information in Drug Design,” Current Opinions in Structural Biology, 2, pp. 202-210 (1992).

[0121] Once a compound has been designed or selected by the above methods, the affinity with which that compound may bind or associate with HDM2 may be tested and optimized by computational evaluation and/or by testing biological activity after synthesizing the compound. Inhibitors or compounds may interact with the HDM2 in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy of the free compound and the average energy of the conformations observed when the compound binds to HDM2.

[0122] A compound designed or selected as binding or associating with HDM2 may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with HDM2. Such non-complementary (e.g., electrostatic) interactions include repulsive charge-charge, dipole-dipole and charge-dipole interactions. Specifically, the sum of all electrostatic interactions between the inhibitor and HDM2 when the inhibitor is bound, preferably make a neutral or favorable contribution to the enthalpy of binding. Weak binding compounds will also be designed by these methods so as to determine SAR. See, for example, U.S. Appl. Nos. 60/275,629; 60/331,235; 60/379,617; and, 10/097,249.

[0123] Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interaction. Examples of programs designed for such uses include: Gaussian 92, revision C (M. J. Frisch, Gaussian, Inc., Pittsburgh, Pa., COPYRGT 1992); AMBER, version 4.0 (P. A. Kollman, University of California at San Francisco, COPYRGT 1994); QUANTA/CHARMM (Molecular Simulations, Inc., Burlington, Mass. COPYRGT 1994); and Insight II/Discover (Biosysm Technologies Inc., San Diego, Calif. COPYRGT 1994). Other hardware systems and software packages will be known to those skilled in the art.

[0124] Once a compound that associates with HDM2 has been optimally selected or designed, as described above, substitutions may then be made in some of its atoms or side groups in order to improve or modify its binding properties. Generally, initial substitutions are conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. It should, of course, be understood that components known in the art to alter conformation may be avoided. Such substituted chemical compounds may then be analyzed for efficiency of fit to HDM2 by the same computer methods described in detail, above.

[0125] C. Use of Homology Structure Modeling to Design Ligands with Modulated Binding or Activity to HDM2

[0126] The present invention includes the use of the atomic coordinates and structures of HDM2 and/or HDM2 complexed with an inhibitor to design modifications to starting compounds, such as (4-Choloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid; [8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid; and derivatives thereof that will bind more tightly or interact more specifically to the target enzyme. See, U.S. Appl. Nos. 60/275,629; 60/331,235; 60/379,617; and, 10/097,249, disclosing compounds 1 and 2 and derivatives thereof, all of which are incorporated herein in their entirety.

[0127] Compound 1 (338437): (4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid

[0128] Compound 2 (876273): [8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid

[0129] The structure of a complex between the HDM2 and the starting compound can be used to guide the modification of that compound to produce new compounds that have other desirable properties for applicable industrial and other uses (e.g., as pharmaceuticals), such as chemical stability, solubility or membrane permeability. (Lipinski et al., Adv. Drug Deliv. Rev. 23:3 (1997)).

[0130] Binding compounds, agonists, antagonists and such that are known in the art include but are not limited to p53 peptides and small molecule antagonists. See, for example, U.S. Appl. Nos. 60/275,629; 60/331,235; 60/379,617; and, 10/097,249 incorporated by reference herein in their entirety. Such compounds can be diffused into or soaked with the stabilized crystals of HDM2 to form a complex for collecting X-ray diffraction data. Alternatively, the compounds, known and unknown in the art, can be cocrystallized with HDM2 by mixing the compound with HDM2 before precipitation.

[0131] To produce custom high affinity and very specific compounds, the structure of HDM2 can be compared to the structure of a selected non-targeted molecule and a hybrid constructed by changing the structure of residues at the binding site for a ligand for the residues at the same positions of the non-target molecule. The process whereby this modeling is achieved is referred to as homology structure modeling. This is done computationally by removing the side chains from the molecule or target of known structure and replacing them with the side chains of the unknown structure put in sterically plausible positions. In this way it can be understood how the shapes of the active site cavities of the targeted and non-targeted molecules differ. This process, therefore, provides information concerning how a bound ligand can be chemically altered in order to produce compounds that will bind tightly and specifically to the desired target but will simultaneously be sterically prevented from binding to the non-targeted molecule. Likewise, knowledge of portions of the bound ligands that are facing to the solvent would allow introduction of other functional groups for additional pharmaceutical purposes. The use of homology structure modeling to design molecules (ligands) that bind more tightly to the target enzyme than to the non-target enzyme has wide spread applicability.

[0132] D. High Throughput Assays

[0133] Any high throughput screening may be utilized to test new compounds which are identified or designed for their ability to interact with HDM2. For general information on high-throughput screening see, for example, Devlin, 1998, High Throughput Screening, Marcel Dekker; and U.S. Pat. No. 5,763,263. High throughput assays utilize one or more different assay techniques including, but not limited to, those described below.

[0134] Immunodiagnostics and Immunoassays. These are a group of techniques used for the measurement of specific biochemical substances, commonly at low concentrations in complex mixtures such as biological fluids, that depend upon the specificity and high affinity shown by suitably prepared and selected antibodies for their complementary antigens. A substance to be measured must, of necessity, be antigenic—either an immunogenic macromolecule or a haptenic small molecule. To each sample a known, limited amount of specific antibody is added and the fraction of the antigen combining with it, often expressed as the bound:free ratio, is estimated, using as indicator a form of the antigen labeled with radioisotope (radioimmunoassay), fluorescent molecule (fluoroimmunoassay), stable free radical (spin immunoassay), enzyme (enzyme immunoassay), or other readily distinguishable label.

[0135] Antibodies can be labeled in various ways, including: enzyme-linked immunosorbent assay (ELISA); radioimmuno assay (RIA); fluorescent immunoassay (FIA); chemiluminescent immunoassay (CLIA); and labeling the antibody with colloidal gold particles (immunogold).

[0136] Common assay formats include the sandwich assay, competitive or competition assay, latex agglutination assay, homogeneous assay, microtitre plate format and the microparticle-based assay.

[0137] Enzyme-linked immunosorbent assay (ELISA). ELISA is an immunochemical technique that avoids the hazards of radiochemicals and the expense of fluorescence detection systems. Instead, the assay uses enzymes as indicators. ELISA is a form of quantitative immunoassay based on the use of antibodies (or antigens) that are linked to an insoluble carrier surface, which is then used to “capture” the relevant antigen (or antibody) in the test solution. The antigen-antibody complex is then detected by measuring the activity of an appropriate enzyme that had previously been covalently attached to the antigen (or antibody).

[0138] For information on ELISA techniques, see, for example, Crowther, (1995) ELISA—Theory and Practice (Methods in Molecular Biology), Humana Press; Challacombe & Kemeny, (1998) ELISA and Other Solid Phase Immunoassays—Theoretical and Practical Aspects, John Wiley; Kemeny, (1991) A Practical Guide to ELISA, Pergamon Press; Ishikawa, (1991) Ultrasensitive and Rapid Enzyme Immunoassay (Laboratory Techniques in Biochemistry and Molecular Biology) Elsevier.

[0139] Colorimetric Assays for Enzymes. Colorimetry is any method of quantitative chemical analysis in which the concentration or amount of a compound is determined by comparing the color produced by the reaction of a reagent with both standard and test amounts of the compound, often using a colorimeter. A colorimeter is a device for measuring color intensity or differences in color intensity, either visually or photoelectrically.

[0140] Standard colorimetric assays of beta-galactosidase enzymatic activity are well known to those skilled in the art (see, for example, Norton et al., Mol. Cell. Biol. 5:281-290 (1985). A colorimetric assay can be performed on whole cell lysates using O-nitrophenyl-beta-D-galactopyranoside (ONPG, Sigma) as the substrate in a standard colorimetric beta-galactosidase assay (Sambrook et al., (1989) Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory Press). Automated colorimetric assays are also available for the detection of beta-galactosidase activity, as described in U.S. Pat. No. 5,733,720.

[0141] Immunofluorescence Assays. Immunofluorescence or immunofluorescence microscopy is a technique in which an antigen or antibody is made fluorescent by conjugation to a fluorescent dye and then allowed to react with the complementary antibody or antigen in a tissue section or smear. The location of the antigen or antibody can then be determined by observing the fluorescence by microscopy under ultraviolet light.

[0142] For general information on immunofluorescent techniques, see, for example, Knapp et al., (1978) Immunofluorescence and Related Staining Techniques, Elsevier; Allan, (1999) Protein Localization by Fluorescent Microscopy—A Practical Approach (The Practical Approach Series) Oxford University Press; Caul, (1993) Immunofluorescence Antigen Detection Techniques in Diagnostic Microbiology, Cambridge University Press. For detailed explanations of immunofluorescent techniques applicable to the present invention, see U.S. Pat. No. 5,912,176; U.S. Pat. No. 5,869,264; U.S. Pat. No. 5,866,319; and U.S. Pat. No. 5,861,259.

[0143] E. Databases and Computer Systems

[0144] An amino acid sequence or nucleotide sequence of HDM2 and/or X-ray diffraction data, useful for computer molecular modeling of HDM2 or a portion thereof, can be “provided” in a variety of mediums to facilitate use thereof. As used herein, “provided” refers to a manufacture, which contains, for example, an amino acid sequence or nucleotide sequence and/or atomic coordinates derived from X-ray diffraction data of the present invention, e.g., an amino acid or nucleotide sequence of HDM2, a representative fragment thereof, or a homologue thereof. Such a method provides the amino acid sequence and/or X-ray diffraction data in a form which allows a skilled artisan to analyze and molecular model the three-dimensional structure of HDM2 or related molecules, including a subdomain thereof.

[0145] In one application of this embodiment, databases comprising data pertaining to HDM2, or at least one subdomain thereof, amino acid and nucleic acid sequence and/or X-ray diffraction data of the present invention is recorded on computer readable medium. As used herein, “computer readable medium” refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage media, and magnetic tape; optical storage media such as optical discs or CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the presently known computer readable media can be used to create a manufacture comprising computer readable medium having recorded thereon an amino acid sequence and/or X-ray diffraction data of the present invention.

[0146] As used herein, “recorded” refers to a process for storing information on computer readable media. A skilled artisan can readily adopt any of the presently known methods for recording information on computer readable media to generate manufactures comprising an amino acid sequence and/or atomic coordinate/X-ray diffraction data information of the present invention.

[0147] A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon an amino acid sequence and/or atomic coordinate/X-ray diffraction data of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the sequence and X-ray data information of the present invention on computer readable media. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MICROSOFT Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of dataprocessor structuring formats (e.g. text file or database) in order to obtain computer readable media having recorded thereon the information of the present invention.

[0148] By providing computer readable media having sequence and/or atomic coordinates based on X-ray diffraction data, a skilled artisan can routinely access the sequence and atomic coordinate or X-ray diffraction data to model a related molecule, a subdomain, mimetic, or a ligand thereof. Computer algorithms are publicly and commercially available which allow a skilled artisan to access this data provided in a computer readable medium and analyze it for molecular modeling and/or RDD (rational drug design). See, e.g., Biotechnology Software Directory, MaryAnn Liebert Publ., New York (1995).

[0149] The present invention further provides systems, particularly computer-based systems, which contain the sequence and/or diffraction data described herein. Such systems are designed to do structure determination and RDD for HDM2 or at least one subdomain thereof. Non-limiting examples are microcomputer workstations available from Silicon Graphics Incorporated and Sun Microsystems running UNIX based, Windows NT or IBM OS/2 operating systems.

[0150] As used herein, “a computer-based system” refers to the hardware means, software means, and data storage means used to analyze the sequence and/or X-ray diffraction data of the present invention. The minimum hardware means of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate which of the currently available computer-based systems are suitable for use in the present invention. A visualization device, such as a monitor, is optionally provided to visualize structure data.

[0151] As stated above, the computer-based systems of the present invention comprise a data storage means having stored therein sequence and/or atomic coordinate/X-ray diffraction data of the present invention and the necessary hardware means and software means for supporting and implementing an analysis means. As used herein, “data storage means” refers to memory which can store sequence or atomic coordinate/X-ray diffraction data of the present invention, or a memory access means which can access manufactures having recorded thereon the sequence or X-ray data of the present invention.

[0152] As used herein, “search means” or “analysis means” refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence or X-ray data stored within the data storage means. Search means are used to identify fragments or regions of a protein which match a particular target sequence or target motif. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. A skilled artisan can readily recognize that any one of the available algorithms or implementing software packages for conducting computer analyses can be adapted for use in the present computer-based systems.

[0153] As used herein, “a target structural motif,” or “target motif,” refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration or electron density map which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzymatic active sites, inhibitor binding sites, structural subdomains, epitopes, functional domains and signal sequences. Similar motifs are known for RNA. A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention.

[0154] A variety of comparing means can be used to compare a target sequence or target motif with the data storage means to identify structural motifs or electron density maps derived in part from the atomic coordinate/X-ray diffraction data. A skilled artisan can readily recognize that any one of the publicly available computer modeling programs can be used as the search means for the computer-based systems of the present invention.

[0155] F. Target Molecule Fragments and Portions

[0156] Fragments of HDM2, for instance fragments comprising active sites defined by two or more amino acids selected from the group consisting of: Ser17, Ile19, Leu82 and Arg97, may be prepared by any available means including synthetic or recombinant means. Such fragments may then be used in the assays as described above, for instance, high through-put assays to detect interactions between prospective agents and the active site within the fragment.

[0157] For recombinant expression or production of the fragments of the invention, nucleic acid molecules encoding the fragment may be prepared. As used herein, “nucleic acid” is defined as RNA or DNA that encodes a protein or peptide as defined above, or is complementary to nucleic acid sequence encoding such peptides, or hybridizes to such nucleic acid and remains stably bound to it under appropriate stringency conditions.

[0158] Nucleic acid molecules encoding fragments of the invention may differ in sequence because of the degeneracy in the genetic code or may differ in sequence as they encode proteins or protein fragments that differ in amino acid sequence. Homology or sequence identity between two or more such nucleic acid molecules is determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Karlin et al., Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990) and Altschul, et al., J. Mol. Evol. 36:290-300 (1993), fully incorporated by reference) which are tailored for sequence similarity searching.

[0159] The approach used by the BLAST program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al. (Nat. Genet. 6, 119-129 (1994)) which is fully incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al., Proc. Natl. Acad. Sci. USA 89:10915-10919 (1992), fully incorporated by reference). Four blastn parameters were adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every winkth position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings were Q=9; R=2; wink=1; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

[0160] “Stringent conditions” are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% SDS at 50° C. or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42° C. Another example is use of 50% formamide, 5×SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 mg/ml), 0.1% SDS and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC and 0.1% SDS. A skilled artisan can readily determine and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal.

[0161] As used herein, a nucleic acid molecule is said to be “isolated” when the nucleic acid molecule is substantially separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid.

[0162] The encoding nucleic acid molecules of the present invention (i.e., synthetic oligonucleotides) and those that are used as probes or specific primers for polymerase chain reaction (PCR) or to synthesize gene sequences encoding proteins of the invention can easily be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci et al. (J. Am. Chem. Soc. 103: 185-3191 (1981)) or using automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene.

[0163] The encoding nucleic acid molecules of the present invention may further be modified so as to contain a detectable label for diagnostic and probe purposes. A variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled nucleotides and the like. A skilled artisan can employ any of the art-known labels to obtain a labeled encoding nucleic acid molecule.

[0164] The present invention further provides recombinant DNA molecules (rDNA) that contain a coding sequence for a protein fragment as described above. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook et al. Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989). In the preferred rDNA molecules, a coding DNA sequence is operably linked to expression control sequences and/or vector sequences.

[0165] The choice of vector and expression control sequences to which one of the protein encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired (e.g., protein expression, and the host cell to be transformed). A vector of the present invention may be capable of directing the replication or insertion into the host chromosome, and preferably also expression, of the structural gene included in the rDNA molecule.

[0166] Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements. Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient in the host cell's medium.

[0167] The present invention further provides host cells transformed with a nucleic acid molecule that encodes a protein fragment of the present invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a protein of the invention are not limited, so long as the cell line is compatible with cell culture methods and compatible with the propagation of the expression vector and expression of the gene product. Preferred eukaryotic host cells include, but are not limited to, yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human cell line. Preferred eukaryotic host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH-3T3 available from the ATCC as CRL1658, baby hamster kidney cells (BHK), and the like eukaryotic tissue culture cell lines.

[0168] Transformed host cells of the invention may be cultured under conditions that allow the production of the recombinant protein. Optionally the recombinant protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some instances where some impurities may be tolerated.

[0169] Kits may also be prepared with any of the above described nucleic acid molecules, protein fragments, vector and/or host cells optionally packaged with the reagents needed for a specific assay, such as those described above. In such kits, the protein fragments or other reagents may be attached to a solid support, such as glass or plastic beads.

[0170] G. Integrated Procedures Which Utilize the Present Invention

[0171] Molecular modeling is provided by the present invention for rational drug design (RDD) of mimetics and ligands of HDM2. As described above, the drug design paradigm uses computer modeling programs to determine potential mimetics and ligands which are expected to interact with sites on the protein. The potential mimetics or ligands are then screened for activity and/or binding and/or interaction. For HDM2-related mimetics or ligands, screening methods can be selected from assays for at least one biological activity of HDM2, e.g., such as blocking p53 binding, according to known method steps. See, for example, Kussie et al., Science 274:948-953 (1996); Bottger et al., J. Mol. Biol. 269:744-756 (1997).

[0172] Thus, the tools and methodologies provided by the present invention may be used in procedures for identifying and designing ligands which bind in desirable ways with the target. Such procedures utilize an iterative process whereby ligands are synthesized, tested and characterized. New ligands can be designed based on the information gained in the testing and characterization of the initial ligands and then such newly identified ligands can themselves be tested and characterized. This series of processes may be repeated as many times as necessary to obtain ligands with the desirable binding properties.

[0173] The following steps serve as an example of the overall procedure:

[0174] 1. A biological activity of a target is selected (e.g., binding to p53).

[0175] 2. A ligand is identified that appears to be in some way associated with the chosen biological activity (e.g., the ligand may be an inhibitor of a known activity). The activity of the ligand may be tested by in vivo and/or in vitro methods.

[0176] A ligand of the present invention can be, but is not limited to, at least one selected from a lipid, a nucleic acid, a compound, a protein, an element, an antibody, a saccharide, an isotope, a carbohydrate, an imaging agent, a lipoprotein, a glycoprotein, an enzyme, a detectable probe, and antibody or fragment thereof, or any combination thereof, which can be detectably labeled as for labeling antibodies. Such labels include, but are not limited to, enzymatic labels, radioisotope or radioactive compounds or elements, fluorescent compounds or metals, chemiluminescent compounds and bioluminescent compounds. Alternatively, any other known diagnostic or therapeutic agent can be used in a method of the invention. Suitable compounds are then tested for activities in relationship to the target.

[0177] Complexes between HDM2 and ligands are made either by co-crystallization or more commonly by diffusing the small molecule ligand into the crystal. X-ray diffraction data from the complex crystal are measured and a difference electron density map is calculated. This process provides the precise location of the bound ligand on the target molecule. The difference Fourier is calculated using measure diffraction amplitudes and the phases of these reflections calculated from the coordinates.

[0178] 3. Using the methods of the present invention, X-ray crystallography is utilized to create electron density maps and/or molecular models of the interaction of the ligand with the target molecule.

[0179] The entry of the coordinates of the target into the computer programs discussed above results in the calculation of most probable structure of the macromolecule. These structures are combined and refined by additional calculations using such programs to determine the probable or actual three-dimensional structure of the target including potential or actual active or binding sites of ligands. Such molecular modeling (and related) programs useful for rational drug design of ligands or mimetics, are also provided by the present invention.

[0180] 4. The electron density maps and/or molecular models obtained in Step 3 are compared to the electron density maps and/or molecular models of a non-ligand containing target and the observed/calculated differences are used to specifically locate the binding of the ligand on the target or subunit.

[0181] 5. Modeling tools, such as computational chemistry and computer modeling, are used to adjust or modify the structure of the ligand so that it can make additional or different interactions with the target.

[0182] The ligand design uses computer modeling programs which calculate how different molecules interact with the various sites of a target. This procedure determines potential ligands or mimetics of the ligand(s).

[0183] The ligand design uses computer modeling programs which calculate how different molecules interact with the various sites of the target, subunit, or a fragment thereof. Thus, this procedure determines potential ligands or ligand mimetics.

[0184] 6. The newly designed ligand from Step 5 can be tested for its biological activity using appropriate in vivo or in vitro tests, including the high throughput screening methods discussed above.

[0185] The potential ligands or mimetics are then screened for activity relating to HDM2, or at least a fragment thereof. Such screening methods are selected from assays for at least one biological activity of the native target.

[0186] The resulting ligands or mimetics, provided by methods of the present invention, are useful for treating, screening or preventing diseases in animals, such as mammals (including humans) and birds.

[0187] 7. Of course, each of the above steps can be modified as desired by those of skill in the art so as to refine the procedure for the particular goal in mind. Also, additional X-ray diffraction data may be collected on HDM2, HDM2/ligand complexes, HDM2 structural target motifs and HDM2 subunit/ligand complexes at any step or phase of the procedure. Such additional diffraction data can be used to reconstruct electron density maps and molecular models which may further assist in the design and selection of ligands with the desirable binding attributes.

[0188] It is to be understood that the present invention is considered to include stereoisomers as well as optical isomers, e.g., mixtures of enantiomers as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in selected compounds, ligands or mimetics of the present series.

[0189] Some of the compounds or agents disclosed or discovered by the methods herein may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present invention is also meant to encompass all such possible forms as well as their racemic and resolved forms and mixtures thereof. When the compounds described or discovered herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, it is intended to include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.

[0190] As used herein, the term “stereoisomers” is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).

[0191] As used herein, the term “chiral center” refers to to a carbon atom to which four different groups are attached.

[0192] As used herein, the term “enantiomer” or “enantiomeric” refers to a molecule that is nonsuperimposable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction.

[0193] As used herein, the term “racemic” refers to a mixture of equal parts of enantiomers and which is optically active.

[0194] As used herein, the term “resolution” refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule. In the context of this application. the term “resolution” also refers to the amount of detail which can be resolved by the diffraction experiment. Or in other terms, since the inherent disorder of a protein crystal diffraction pattern fades away at some diffraction angle θmax, the corresponding distance dmin of the reciprocal lattices is deterimined by Bragg's law.

d_{\min} = \frac{λ}{2 \sin θ_{\max}}

[0195] In practice in protein crystallography it is usual to quote the nominal resolution of a protein electron density in terms of dmin, the minimum lattice distance to which data is included in the calculation of the map.

[0196] The compounds of the present invention are also useful at inhibiting the interaction between p53 and MDMX. MDMX, also known as MDM4, is a cellular protein involved in the regulation of the cell cycle. For example, see Riemenschneider et al., Cancer Res. 59(24):6091-6096 (1999).

[0197] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

EXAMPLES

Example 1

[0198]

[0199] GST HDM2 Fusion Protein Construction and Expression

[0200] cDNA encoding residues 17-125 of HDM2 were cloned and expressed as follows: PCR was performed using ATCC item number 384988 containing partial human MDM2 sequence as template and the following primers:

1Forward:5′-CTCTCTCGGATCCCAGATTCCAGCTTCGGAACAAGAGReverse:5′-TATATATCTCGAGTCAGTTCTCACTCACAGATGTACCTGAG.

[0201] The PCR product was then digested with BamHI and Xhol (sequence recognition sites underlined in primers), gel purified, and ligated into pGEX4t-3 which had also been digested with BamHI and XhoI. The purified plasmid was transformed into E. coli strain BL21. Protein was produced at 37° C. in 2 L shake flasks containing 800 ml LB (Laura Bertani medium)+100 ∥g/ml ampicillin and supplemented with 0.2% glycerol. Briefly media was inoculated with 16 ml of overnight culture and induced with 1 mM IPTG when the absorbance at 600 reached 0.6-0.8 OD. Cells were harvested 5 hr post induction.

[0202] For HDM2 23-114, the primers used were as follows:

25′-CGACGATTGGATCCGAACAAAGACCCTG3′-GGCTACTACTCCGAGTCATTCCTGCTGATTGACTAC

[0203] For HDM2 17-111, the primers used were

35′-CTCTCTCGGATCCCAGATTCAGCTTCCGGAACAAGAG3′-TTCAGCAGCTCGAGTCAATTGACTACTACCAAGTTC

[0204] The PCR fragments were cloned and expressed as above with a few exceptions. E. coli strain BL21 RIL was used for expression. Cells were grown at 37° C. until A600 of 0.2, then transferred to room temperature and induced at A600 of 0.6-0.8 with 0.1 mM IPTG. Cells were harvested 5 hours post induction, centrifuged, and resuspended in PBS to 10 ml/g cell paste.

[0205] Protein Production

[0206] Cells were lysed in an Avestin microfluidizer, centrifuged, and the supernatant bound to a glutathione sepharose 4B resin (Pharmacia). The resin was washed with PBS and the HDM2 construct of interest was cleaved from the GST-resin by the addition of 2 μg/ml thrombin (Enzyme Research Labs). The cleaved HDM2 was loaded onto a Sepharose SP Fast Flow resin (Pharmacia), and eluted with a 20 mM HEPES pH. 7.5, 150 mM NaCl. Glutathione was added to 5 mM, and the protein stored at −70° C. The resulting protein has an N-terminal Glycine before amino acid 17 (Serine).

[0207] Protein Preparation for Crystallography

[0208] HDM2 17-111 was complexed with the compound of interest by dialysis at a concentration of 0.7 mg/ml, the buffer brought to 20 mM HEPES pH. 7.4, 100 mM NaCl, 5 mM DTT, filtered through a 0.02 μm filter, and concentrated to 10 mg/ml.

Example 2

[0209] Crystallization and Data Collection

[0210] In a typical crystallization experiment, 1-2 μl of HDM2 protein, complexed with a compound and concentrated to ca. 10 mg/ml, was mixed in a 1:1 ratio with well solution (1.8-2.4M (NH4)2SO4, 100 mM buffer pH. 6.5-9.0, 2% PEG 400, 100 mM NaSCN) and placed on a glass cover slip. The cover slip was inverted and sealed over a reservoir of 500-1000 μl of well solution and incubated at 4° C. Crystals usually appeared over night and were ready to harvest after 3-7 days. Crystals were harvested with a nylon loop, placed for less than 30 seconds in cryo-solution (2.2M (NH4)2SO4, 100 mM bis-tris-propane pH. 7.5, 2% PEG 400, 100 mM NaSCN, 15% glycerol) and frozen by immersion in liquid nitrogen or liquid propane. Data were collected at 120K on a Bruker AXS M06XCE rotating anode and a SMART 6000 CCD detector. The diffraction data was processed with the Proteum suite (Bruker AXS).

Example 3

[0211] Assay Methods: Peptide Binding Assay

[0212] The inhibition of MDM2 binding to p53 was measured using a p53 peptide analog binding to MDM2 residues 17-125. The published crystal structure of this complex (Kussie, P. H., et al., Science 274:948-953 (1996)) validates this fragment as containing the p53 binding site, and we have solved the X-ray structure of the p53 peptide analog MPRFMDYWEGLN, described to be a peptide inhibitor of the MDM2 p53 interaction (Böttger, A., et al., J Mol Biol 269:744-756 (1997)). The assay uses N terminal fluorescein RFMDYWEGL peptide (F1 9 mer). Compound was incubated for 15 minutes with 30 nM fluorescein peptide F1 9 mer and 120 nM HDM2 17-125 in 50 mM HEPES pH. 7.5, 150 mM NaCl, 3 mM octyl glucoside. The polarization of the fluorescein label was measured by excitation at 485 nm and emission at 530 nm. Polarization was expressed as a percent of a no compound control, using no MDM2 with F1 9 mer as background.

Example 4

[0213] HDM2 Atomic Coordinates: Table 1 (Compound 1)

[0214] Table 1 describes the 3-dimensional atomic coordinates of HDM2 complexed with compound 1 (338437) ((4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid and bound waters in standard pdb-format. The relevant crystallographic data are contained in the REMARK section of Table 1. Two molecules of HDM2, related by non-crystallographic symmetry, are present in the asymmetric unit and are identified by the CHAINID of A for the first molecule and B for the second molecule. The compound (compound 1) is present under the residue name DCB. Compound 1 and HDM2 molecule sharing the same CHAINID are forming a complex.

Example 5

[0215] HDM2 Atomic Coordinates: Table 2 (Compound 2)

[0216] Compound 2 [8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid (876273) and HDM2 protein were cocrystallized as described above in Example 2. Table 2 describes the 3-dimensional atomic coordinates of HDM2 complexed with compound 2 (876273) ([8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid). The relevant crystallographic data are contained in the REMARK section of Table 2. Data were collected as described above. Different crystal forms can be observed under the same crystallization conditions used to obtain the trigonal crystal form.

Example 6

[0217] HDM2 Atomic Coordinates: Table 3

[0218] Table 3 describes the 3-dimensional atomic coordinates of HDM2 cocrystallized with compound 2 (compound 876273: [8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid) in tetragonal spacegroup aligned to the structure of HDM2 complexed with compound 1 (compound 338437 ((4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid). The relevant crystallographic data are contained in the REMARK section of Table 3. Data were collected as described above.

[0219] The pdb-format is described on various sites on the web. Depending on the program crystallographic application minor modifications to this format may be found. A good primer is provided by this link at CCP4 “www.ccp4.ac.uk/html/pdbformat.html”. A more extended description can be found at the RCSB home page.

Example 7

[0220] Phasing: Model Building and Refinement

[0221] Phases were obtained by molecular replacement using the published HDM2-structure as a search model in CNX (Brunger, A. T., et al., P. D. Acta Cryst D54:905-921 (1998); Accelrys Inc.). Alternating cycles of structure refinement and model building were carried out according to standard protocols using CNX and O (Jones, T. A., et al., Acta Cryst A47: 110-119 (1991)).

Example 8

[0222] Structural Features of HDM2

[0223]
FIG. 1. Ribbon representation of HDM2 bound to compound 1 (compound 338437: ((4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid).

[0224]
FIG. 2. Fit of compound 1 (compound 338437: ((4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-acetic acid into the active site of HDM2 presented as a molecular surface.

[0225] Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. All cited patents, patent applications and publications and other documents cited in this application are herein incorporated by reference in their entirety.

4TABLE 1compound 338437 ((4-Chloro-phenyl)-[3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-aceticacidREMARK coordinates from restrained individual B-factor refinementREMARK refinement resolution: 500.0-2.6 AREMARK starting r = 0.2398 free_r = 0.2763REMARK final r = 0.2390 free_r = 0.2765REMARK B rmsd for bonded mainchain atoms = 1.358 target = 1.5REMARK B rmsd for bonded sidechain atoms = 1.887 target = 2.0REMARK B rmsd for angle mainchain atoms = 2.371 target = 2.0REMARK B rmsd for angle sidechain atoms = 2.965 target = 2.5REMARK rweight = 0.1000 (with wa = 2.71183)REMARK target = mlf steps = 30REMARK sg = P3 (2) 21 a = 98.486 b = 98.486 c = 74.038 alpha = 90 beta = 90gamma = 120REMARK parameter file 1: MSI_CNX_TOPPAR:protein_rep.paramREMARK parameter file 2: dcb.parREMARK parameter file 3: MSI_CNX_TOPPAR:water_rep.paramREMARK molecular structure file: cycle8.psfREMARK input coordinates: minimize.pdbREMARK reflection file = ../M338437_P3221.cvREMARK ncs = noneREMARK B-correction resolution: 6.0-2.6REMARK initial B-factor correction applied to fobs:REMARK B11 = 5.509 B22 = 5.509 B33 = −11.019REMARK B12 = 0.263 B13 = 0.000 B23 = 0.000REMARK B-factor correction applied to coordinate array B: 0.036REMARK bulk solvent: (Mask) density level = 0.372649 e/A{circumflex over ( )}3, B-factor = 25.2844A{circumflex over ( )}2REMARK reflections with |Fobs|/sigma_F < 0.0 rejectedREMARK reflections with |Fobs| > 10000 * rms(Fobs) rejectedREMARK theoretical total number of refl. in resol. range: 13090(100.0%)REMARK number of unobserved reflections (no entry or |F| = 0): 176 (1.3%)REMARK number of reflections rejected: 0 (0.0%)REMARK total number of reflections used: 12914 (98.7%)REMARK number of reflections in working set: 11964 (91.4%)REMARK number of reflections in test set: 950 (7.3%)CRYST1 98.486 98.486 74.038 90.00 90.00 120.00 P 32 2 1REMARK FILENAME = “bindividual.pdb”REMARK Written by CNX VERSION: 2000.12ATOM1CGLYA1647.23517.29323.9531.0068.07ACATOM2OGLYA1648.28416.64623.9071.0068.13AOATOM3NGLYA1644.69817.05623.7261.0066.75ANATOM4CAGLYA1646.04216.90423.0831.0067.77ACATOM5NSERA1747.08318.35224.7441.0067.81ANATOM6CASERA1748.15418.83125.6181.0066.82ACATOM7CBSERA1748.40717.83126.7431.0067.50ACATOM8OGSERA1747.24717.65827.5401.0067.94AOATOM9CSERA1749.45619.11824.8641.0065.58ACATOM10OSERA1749.69920.26524.4761.0066.26AOATOM11NGLNA1850.30418.10824.6571.0063.21ANATOM12CAGLNA1851.54318.36723.9211.0060.51ACATOM13CBGLNA1852.77817.99524.7351.0060.31ACATOM14CGGLNA1853.83319.07024.5741.0059.93ACATOM15CDGLNA1853.20020.45724.5061.0059.70ACATOM16OE1GLNA1852.58420.91925.4641.0059.78AOATOM17NE2GLNA1853.33321.11223.3621.0059.29ANATOM18CGLNA1851.61917.75222.5291.0058.18ACATOM19OGLNA1852.56917.04922.1581.0057.08AOATOM20NILEA1950.57318.06421.7761.0054.61ANATOM21CAILEA1950.38017.67320.3991.0049.59ACATOM22CBILEA1949.13016.77120.2561.0047.27ACATOM23CG2ILEA1948.73016.64318.8021.0046.21ACATOM24CG1ILEA1949.40715.40320.8801.0044.27ACATOM25CD1ILEA1950.56514.67520.2631.0040.62ACATOM26CILEA1950.11219.05619.8061.0048.49ACATOM27OILEA1949.34419.83820.3741.0046.95AOATOM28NPROA2050.76519.39618.6861.0047.71ANATOM29CDPROA2051.68118.61017.8401.0046.47ACATOM30CAPROA2050.52120.72118.1071.0046.58ACATOM31CBPROA2051.07220.57416.6951.0046.92ACATOM32CGPROA2052.25619.66716.9191.0046.74ACATOM33CPROA2049.04121.11218.1341.0045.69ACATOM34OPROA2048.18120.37617.6361.0045.19AOATOM35NALAA2148.75122.26418.7381.0043.36ANATOM36CAALAA2147.37922.75518.8321.0040.68ACATOM37CBALAA2147.37124.19319.3501.0039.15ACATOM38CALAA2146.71022.67617.4601.0039.20ACATOM39OALAA2145.51822.37917.3511.0038.64AOATOM40NSERA2247.49022.93716.4141.0037.13ANATOM41CASERA2246.99622.88115.0421.0034.91ACATOM42CBSERA2248.14023.16714.0771.0036.91ACATOM43OGSERA2249.17722.20214.2081.0039.98AOATOM44CSERA2246.42821.49414.7551.0032.16ACATOM45OSERA2245.34921.35614.1791.0032.41AOATOM46NGLUA2347.17920.47415.1591.0028.39ANATOM47CAGLUA2346.78519.08414.9811.0025.53ACATOM48CBGLUA2347.98618.16715.2801.0024.74ACATOM49CGGLUA2347.65016.69815.5071.0022.09ACATOM50CDGLUA2348.88115.80515.5241.0021.23ACATOM51OE1GLUA2349.95616.27015.9521.0022.29AOATOM52OE2GLUA2348.77514.63115.1201.0019.31AOATOM53CGLUA2345.59718.73315.8791.0023.76ACATOM54OGLUA2344.75617.92815.5011.0021.78AOATOM55NGLNA2445.52419.34517.0591.0022.33ANATOM56CAGLNA2444.42319.08617.9851.0021.86ACATOM57CBGLNA2444.62819.83819.2941.0022.56ACATOM58CGGLNA2445.72119.26720.1571.0026.35ACATOM59CDGLNA2445.89620.01721.4581.0027.27ACATOM60OE1GLNA2444.96420.13122.2621.0027.74AOATOM61NE2GLNA2447.10120.53321.6761.0029.00ANATOM62CGLNA2443.06319.46417.4231.0021.99ACATOM63OGLNA2442.04718.87117.7861.0021.50AOATOM64NGLUA2543.04520.45616.5421.0022.95ANATOM65CAGLUA2541.80020.92115.9391.0024.26ACATOM66CBGLUA2541.87422.43215.6651.0025.71ACATOM67CGGLUA2542.22623.26516.8841.0027.74ACATOM68CDGLUA2541.21823.10718.0061.0030.63ACATOM69OE1GLUA2541.64023.11219.1871.0032.01AOATOM70OE2GLUA2540.00522.98717.7051.0030.20AOATOM71CGLUA2541.47920.17914.6441.0023.62ACATOM72OGLUA2540.47220.46113.9951.0024.16AOATOM73NTHRA2642.33719.23714.2671.0022.53ANATOM74CATHRA2642.12318.46213.0521.0021.97ACATOM75CBTHRA2643.13817.29912.9551.0023.07ACATOM76OG1THRA2644.47217.82812.9721.0022.96AOATOM77CG2THRA2642.92016.49911.6751.0021.12ACATOM78CTHRA2640.70517.89413.0311.0021.66ACATOM79OTHRA2640.28117.21713.9621.0019.94AOATOM80NLEUA2739.97418.18711.9631.0023.11ANATOM81CALEUA2738.60217.71311.8051.0025.25ACATOM82CBLEUA2737.88818.59310.7751.0026.19ACATOM83CGLEUA2736.36218.64610.8281.0028.80ACATOM84CD1LEUA2735.91819.21212.1831.0026.94ACATOM85CD2LEUA2735.84019.5129.6771.0028.47ACATOM86CLEUA2738.62016.24011.3501.0024.95ACATOM87OLEUA2739.27515.90110.3591.0026.23AOATOM88NVALA2837.89815.37312.0641.0022.99ANATOM89CAVALA2837.88213.93811.7491.0020.72ACATOM90CBVALA2838.81013.14312.7191.0018.95ACATOM91CG1VALA2840.21313.72912.7341.0017.23ACATOM92CG2VALA2838.23013.16414.1181.0016.75ACATOM93CVALA2836.50013.28411.8331.0021.21ACATOM94OVALA2835.59313.80512.4861.0019.81AOATOM95NARGA2936.36512.13111.1741.0022.25ANATOM96CAARGA2935.12611.34011.1591.0023.75ACATOM97CBARGA2934.55911.2299.7421.0025.97ACATOM98CGARGA2933.67812.3889.3081.0032.69ACATOM99CDARGA2933.20612.1997.8661.0038.68ACATOM100NEARGA2932.25613.2317.4551.0045.71ANATOM101CZARGA2931.00213.3227.9011.0050.53ACATOM102NH1ARGA2930.53412.4398.7771.0052.47ANATOM103NH2ARGA2930.20814.2997.4721.0052.60ANATOM104CARGA2935.4029.93111.6801.0022.61ACATOM105OARGA2935.8919.07610.9441.0023.74AOATOM106NPROA3035.0949.66912.9591.0020.77ANATOM107CDPROA3034.65410.60714.0061.0019.85ACATOM108CAPROA3035.3348.34013.5231.0019.49ACATOM109CBPROA3034.7988.47114.9511.0018.27ACATOM110CGPROA3035.0819.89515.2761.0018.94ACATOM111CPROA3034.6557.20612.7571.0019.01ACATOM112OPROA3033.5527.36712.2361.0018.19AOATOM113NLYSA3135.3326.06312.6891.0019.05ANATOM114CALYSA3134.7904.88012.0331.0019.18ACATOM115CBLYSA3135.9193.89111.7031.0018.74ACATOM116CGLYSA3136.8814.39210.6301.0018.49ACATOM117CDLYSA3138.0483.44210.4091.0016.87ACATOM118CELYSA3139.0073.9829.3591.0016.16ACATOM119NZLYSA3140.2383.1619.2541.0017.03ANATOM120CLYSA3133.7774.26013.0091.0019.76ACATOM121OLYSA3133.8624.46514.2211.0019.24AOATOM122NPROA3232.8163.48012.4921.0020.78ANATOM123CDPROA3232.7722.97111.1061.0020.08ACATOM124CAPROA3231.7782.84013.3111.0020.65ACATOM125CBPROA3231.3761.64012.4651.0018.59ACATOM126CGPROA3231.4602.19711.0791.0019.84ACATOM127CPROA3232.1082.46014.7611.0021.61ACATOM128OPROA3231.4122.87715.6951.0020.03AOATOM129NLEUA3333.1641.67914.9551.0022.55ANATOM130CALEUA3333.5221.23716.2961.0023.06ACATOM131CBLEUA3334.6770.23616.2231.0023.79ACATOM132CGLEUA3334.537−0.99217.1351.0024.29ACATOM133CD1LEUA3333.136−1.59717.0201.0022.52ACATOM134CD2LEUA3335.597−2.01516.7471.0023.61ACATOM135CLEUA3333.8502.37017.2601.0023.64ACATOM136OLEUA3333.3482.38518.3821.0025.22AOATOM137NLEUA3434.6843.31916.8381.0023.73ANATOM138CALEUA3435.0334.44517.7071.0023.80ACATOM139CBLEUA3436.1735.28117.1081.0022.45ACATOM140CGLEUA3436.4596.60317.8421.0021.72ACATOM141CD1LEUA3436.7226.32419.3101.0020.49ACATOM142CD2LEUA3437.6477.32417.2091.0020.12ACATOM143CLEUA3433.8295.35117.9491.0024.92ACATOM144OLEUA3433.6415.86719.0581.0025.03AOATOM145NLEUA3533.0195.54916.9111.0024.02ANATOM146CALEUA3531.8416.39417.0271.0024.15ACATOM147CBLEUA3531.1136.47015.6901.0021.76ACATOM148CGLEUA3530.4157.78715.3411.0020.69ACATOM149CD1LEUA3529.1767.48914.5221.0017.66ACATOM150CD2LEUA3530.0268.52616.5891.0020.82ACATOM151CLEUA3530.8895.84918.1011.0026.94ACATOM152OLEUA3530.3026.61718.8701.0027.88AOATOM153NLYSA3630.7354.52718.1521.0027.77ANATOM154CALYSA3629.8593.91319.1401.0028.78ACATOM155CBLYSA3629.7782.39818.9391.0031.12ACATOM156CGLYSA3629.0621.68720.0811.0035.08ACATOM157CDLYSA3629.4720.22020.2231.0038.33ACATOM158CELYSA3628.711−0.68119.2681.0041.52ACATOM159NZLYSA3629.044−2.12019.4871.0043.62ANATOM160CLYSA3630.3974.20020.5301.0028.98ACATOM161OLYSA3629.6324.46321.4591.0029.52AOATOM162NLEUA3731.7194.13720.6641.0028.82ANATOM163CALEUA3732.3964.39521.9361.0028.09ACATOM164CBLEUA3733.9084.24421.7511.0028.11ACATOM165CGLEUA3734.8884.33022.9291.0027.55ACATOM166CD1LEUA3734.6555.59223.7361.0027.78ACATOM167CD2LEUA3734.7303.10923.7881.0027.77ACATOM168CLEUA3732.0795.81422.4021.0028.36ACATOM169OLEUA3731.7306.03423.5591.0027.57AOATOM170NLEUA3832.2096.77221.4861.0028.83ANATOM171CALEUA3831.9518.17521.7851.0027.42ACATOM172CBLEUA3832.3249.04520.5811.0025.41ACATOM173CGLEUA3833.7878.97320.1411.0025.18ACATOM174CD1LEUA3834.0159.98019.0421.0024.55ACATOM175CD2LEUA3834.7159.25121.3151.0025.40ACATOM176CLEUA3830.5048.44922.1861.0027.27ACATOM177OLEUA3830.2398.98923.2591.0027.56AOATOM178NLYSA3929.5628.08321.3271.0026.08ANATOM179CALYSA3928.1638.32521.6381.0024.78ACATOM180CBLYSA3927.2947.88520.4611.0023.77ACATOM181CGLYSA3927.5938.69619.2151.0025.97ACATOM182CDLYSA3926.6578.40918.0511.0026.72ACATOM183CELYSA3926.9439.40116.9161.0029.24ACATOM184NZLYSA3926.1699.18315.6571.0031.08ANATOM185CLYSA3927.7087.65522.9401.0023.69ACATOM186OLYSA3926.8128.15623.6231.0024.40AOATOM187NSERA4028.3386.54523.3051.0021.60ANATOM188CASERA4027.9465.85024.5221.0018.78ACATOM189CBSERA4028.6024.46524.5931.0016.27ACATOM190OGSERA4029.9474.53825.0201.0013.26AOATOM191CSERA4028.2996.66325.7661.0018.97ACATOM192OSERA4027.8086.37626.8541.0018.43AOATOM193NVALA4129.1577.66725.6161.0018.55ANATOM194CAVALA4129.5158.49626.7581.0019.39ACATOM195CBVALA4131.0578.64526.9401.0020.54ACATOM196CG1VALA4131.6307.40227.6071.0018.57ACATOM197CG2VALA4131.7338.89125.6001.0021.46ACATOM198CVALA4128.8879.88126.6621.0020.20ACATOM199OVALA4129.21810.77127.4441.0019.90AOATOM200NGLYA4227.97510.06225.7071.0020.98ANATOM201CAGLYA4227.30611.34525.5711.0021.00ACATOM202CGLYA4227.54212.15524.3091.0022.06ACATOM203OGLYA4226.80913.10724.0601.0023.06AOATOM204NALAA4328.55711.80723.5221.0023.02ANATOM205CAALAA4328.84112.53022.2801.0023.42ACATOM206CBALAA4330.07511.94021.5931.0020.28ACATOM207CALAA4327.63212.42721.3541.0023.40ACATOM208OALAA4326.81611.51721.4951.0021.98AOATOM209NGLNA4427.50513.35220.4071.0025.42ANATOM210CAGLNA4426.36913.27919.5021.0027.06ACATOM211CBGLNA4425.13013.87220.1651.0027.82ACATOM212CGGLNA4425.31515.23220.7631.0028.96ACATOM213CDGLNA4424.57615.35722.0851.0032.56ACATOM214OE1GLNA4424.35716.46222.5851.0034.47AOATOM215NE2GLNA4424.20014.21522.6681.0031.28ANATOM216CGLNA4426.52013.85418.1061.0026.84ACATOM217OGLNA4425.53214.26817.5001.0026.83AOATOM218NLYSA4527.74513.88117.5921.0025.93ANATOM219CALYSA4527.98014.36316.2301.0025.65ACATOM220CBLYSA4528.96015.54416.1981.0025.47ACATOM221CGLYSA4528.54616.76716.9921.0024.64ACATOM222CDLYSA4529.61417.86016.9481.0021.21ACATOM223CELYSA4530.90717.41017.6151.0019.16ACATOM224NZLYSA4531.84918.54317.7851.0016.01ANATOM225CLYSA4528.62713.19915.5081.0024.50ACATOM226OLYSA4528.90412.16216.1121.0024.58AOATOM227NASPA4628.86113.35914.2191.0022.87ANATOM228CAASPA4629.53912.31413.4831.0023.75ACATOM229CBASPA4628.76511.93112.2191.0026.21ACATOM230CGASPA4627.45111.22212.5251.0028.44ACATOM231OD1ASPA4627.37910.48013.5301.0028.33AOATOM232OD2ASPA4626.48911.39611.7461.0030.59AOATOM233CASPA4630.91312.87213.1251.0023.42ACATOM234OASPA4631.82012.13412.7591.0024.56AOATOM235NTHRA4731.06214.18813.2451.0022.36ANATOM236CATHRA4732.32614.84712.9391.0020.77ACATOM237CBTHRA4732.15115.89611.8311.0021.07ACATOM238OG1THRA4731.57315.27610.6761.0022.41AOATOM239CG2THRA4733.49616.49811.4581.0019.56ACATOM240CTHRA4732.85915.53614.1871.0019.61ACATOM241OTHRA4732.11416.21314.8931.0019.20AOATOM242NTYRA4834.14715.36414.4611.0017.90ANATOM243CATYRA4834.74415.96615.6461.0017.29ACATOM244CBTYRA4834.90414.92416.7631.0017.51ACATOM245CGTYRA4833.64514.19517.1781.0018.47ACATOM246CD1TYRA4833.09413.19916.3761.0017.60ACATOM247CE1TYRA4831.92612.54916.7431.0019.18ACATOM248CD2TYRA4832.99314.51818.3681.0018.07ACATOM249CE2TYRA4831.82613.87718.7461.0018.21ACATOM250CZTYRA4831.29112.89317.9301.0019.97ACATOM251OHTYRA4830.11212.26418.2941.0020.10AOATOM252CTYRA4836.12316.52815.3561.0017.64ACATOM253OTYRA4836.65016.40114.2451.0019.08AOATOM254NTHRA4936.69517.17216.3641.0016.11ANATOM255CATHRA4938.05717.67716.2671.0016.21ACATOM256CBTHRA4938.21919.06116.8911.0015.01ACATOM257OG1THRA4938.02818.96918.3091.0014.67AOATOM258CG2THRA4937.21220.00616.3161.0014.41ACATOM259CTHRA4938.76616.67217.1641.0016.33ACATOM260OTHRA4938.14216.09118.0571.0016.33AOATOM261NMETA5040.05016.44816.9371.0016.12ANATOM262CAMETA5040.77015.50017.7651.0016.31ACATOM263CBMETA5042.25315.51517.4111.0016.08ACATOM264CGMETA5042.55014.80416.1001.0015.76ACATOM265SDMETA5042.00713.08816.1741.0015.40ASATOM266CEMETA5043.38312.36417.1081.0012.28ACATOM267CMETA5040.57015.82019.2361.0017.20ACATOM268OMETA5040.30014.93120.0341.0018.81AOATOM269NLYSA5140.67917.09919.5811.0016.94ANATOM270CALYSA5140.51517.55120.9521.0016.59ACATOM271CBLYSA5140.58819.08320.9931.0019.46ACATOM272CGLYSA5140.77319.66222.3821.0024.41ACATOM273CDLYSA5141.17721.13222.3331.0029.49ACATOM274CELYSA5141.63321.62323.7111.0030.87ACATOM275NZLYSA5142.11123.03923.6931.0032.84ANATOM276CLYSA5139.19517.05921.5551.0015.64ACATOM277OLYSA5139.13316.67722.7291.0014.01AOATOM278NGLUA5238.13917.06220.7501.0015.07ANATOM279CAGLUA5236.83716.61321.2341.0015.62ACATOM280CBGLUA5235.73817.01720.2541.0016.29ACATOM281CGGLUA5235.58618.52020.1271.0018.24ACATOM282CDGLUA5234.64918.92119.0181.0019.03ACATOM283OE1GLUA5234.76418.34117.9181.0022.90AOATOM284OE2GLUA5233.81219.82119.2361.0019.46AOATOM285CGLUA5236.80815.11021.4541.0015.03ACATOM286OGLUA5236.23214.63822.4351.0016.38AOATOM287NVALA5337.43214.36120.5461.0014.02ANATOM288CAVALA5337.47512.90820.6611.0012.12ACATOM289CBVALA5338.21612.27419.4781.0011.38ACATOM290CG1VALA5338.12910.76919.5661.0010.68ACATOM291CG2VALA5337.61212.75018.1711.0012.22ACATOM292CVALA5338.19112.54021.9551.0012.50ACATOM293OVALA5337.69111.74422.7611.0012.84AOATOM294NLEUA5439.36213.12922.1581.009.57ANATOM295CALEUA5440.10912.87123.3651.0010.63ACATOM296CBLEUA5441.36513.72623.4051.0011.63ACATOM297CGLEUA5442.52013.13122.6091.0011.73ACATOM298CD1LEUA5443.56314.19222.4181.0014.32ACATOM299CD2LEUA5443.09511.92223.3441.0012.23ACATOM300CLEUA5439.26013.15924.5811.0012.08ACATOM301OLEUA5439.28012.39825.5411.0013.29AOATOM302NPHEA5538.50814.25624.5451.0013.96ANATOM303CAPHEA5537.65314.61225.6751.0014.56ACATOM304CBPHEA5536.87415.90125.3911.0015.14ACATOM305CGPHEA5535.98416.33026.5301.0012.59ACATOM306CD1PHEA5536.47817.13527.5511.0012.50ACATOM307CD2PHEA5534.67415.87026.6141.0011.59ACATOM308CE1PHEA5535.67917.47328.6431.0012.57ACATOM309CE2PHEA5533.86916.19827.6961.0010.75ACATOM310CZPHEA5534.37317.00128.7141.0012.37ACATOM311CPHEA5536.65413.50325.9981.0015.87ACATOM312OPHEA5536.53713.07327.1491.0014.84AOATOM313NTYRA5635.91613.05924.9851.0015.22ANATOM314CATYRA5634.92812.01325.2011.0016.95ACATOM315CBTYRA5634.07011.83223.9521.0014.70ACATOM316CGTYRA5633.08412.95323.7371.0014.95ACATOM317CD1TYRA5632.01513.14824.6151.0015.85ACATOM318CE1TYRA5631.08614.16924.4061.0017.59ACATOM319CD2TYRA5633.20513.81022.6451.0015.37ACATOM320CE2TYRA5632.29014.83322.4231.0016.46ACATOM321CZTYRA5631.23115.00723.3031.0018.11ACATOM322OHTYRA5630.31116.00123.0591.0018.28AOATOM323CTYRA5635.59810.69825.5801.0017.45ACATOM324OTYRA5635.1179.95826.4401.0016.40AOATOM325NLEUA5736.71710.41124.9311.0018.36ANATOM326CALEUA5737.4499.19425.2171.0017.30ACATOM327CBLEUA5738.6219.08124.2451.0015.20ACATOM328CGLEUA5738.9037.70623.6441.0016.42ACATOM329CD1LEUA5737.6377.03723.1661.0016.54ACATOM330CD2LEUA5739.8607.88522.4991.0018.63ACATOM331CLEUA5737.9159.33226.6751.0017.78ACATOM332OLEUA5738.0748.35027.3981.0017.21AOATOM333NGLYA5838.09910.57627.1031.0017.15ANATOM334CAGLYA5838.51510.83228.4641.0016.26ACATOM335CGLYA5837.40610.51129.4381.0017.52ACATOM336OGLYA5837.6569.90930.4821.0018.49AOATOM337NGLNA5936.17910.90629.1141.0015.94ANATOM338CAGLNA5935.07110.61730.0101.0017.18ACATOM339CBGLNA5933.76111.19929.4811.0017.70ACATOM340CGGLNA5933.71312.72029.5001.0018.77ACATOM341CDGLNA5934.06413.28130.8591.0019.30ACATOM342OE1GLNA5933.43512.93931.8561.0020.86AOATOM343NE2GLNA5935.07814.14530.9091.0018.39ANATOM344CGLNA5934.9669.11530.1091.0017.93ACATOM345OGLNA5934.9038.55231.1991.0017.50AOATOM346NTYRA6034.9848.47328.9491.0019.35ANATOM347CATYRA6034.9067.02328.8541.0019.97ACATOM348CBTYRA6035.2706.58027.4501.0018.67ACATOM349CGTYRA6035.0615.12127.2581.0018.93ACATOM350CD1TYRA6033.7834.60827.1141.0019.95ACATOM351CE1TYRA6033.5733.25626.9451.0022.90ACATOM352CD2TYRA6036.1394.24327.2351.0021.13ACATOM353CE2TYRA6035.9462.88027.0681.0022.87ACATOM354CZTYRA6034.6562.39326.9201.0024.39ACATOM355OHTYRA6034.4391.05126.7221.0026.24AOATOM356CTYRA6035.8336.30929.8371.0020.15ACATOM357OTYRA6035.3845.52730.6821.0019.42AOATOM358NILEA6137.1306.56429.7011.0020.01ANATOM359CAILEA6138.1165.94930.5741.0021.24ACATOM360CBILEA6139.5086.55630.3461.0019.34ACATOM361CG2ILEA6140.4496.16931.4811.0017.74ACATOM362CG1ILEA6140.0506.09628.9931.0018.22ACATOM363CD1ILEA6141.3436.77428.6021.0017.99ACATOM364CILEA6137.7176.17532.0201.0022.76ACATOM365OILEA6137.7315.26132.8371.0019.91AOATOM366NMETA6237.3427.41432.3091.0026.52ANATOM367CAMETA6236.9517.82733.6451.0028.53ACATOM368CBMETA6236.7359.33833.6611.0028.55ACATOM369CGMETA6237.1539.97134.9481.0029.96ACATOM370SDMETA6238.8439.52735.3011.0032.30ASATOM371CEMETA6239.64411.11235.1681.0034.41ACATOM372CMETA6235.7097.12034.1801.0029.87ACATOM373OMETA6235.6896.69135.3361.0031.34AOATOM374NTHRA6334.6776.99233.3501.0030.81ANATOM375CATHRA6333.4506.34233.7921.0031.38ACATOM376CBTHRA6332.2656.62532.8341.0031.49ACATOM377OG1THRA6331.5055.42732.6491.0033.06AOATOM378CG2THRA6332.7477.12031.5011.0032.85ACATOM379CTHRA6333.5884.83634.0021.0031.82ACATOM380OTHRA6333.0454.30134.9751.0032.68AOATOM381NLYSA6434.3054.14933.1151.0031.19ANATOM382CALYSA6434.4912.70633.2791.0030.89ACATOM383CBLYSA6434.7192.03231.9221.0029.02ACATOM384CGLYSA6433.6002.29530.9311.0029.54ACATOM385CDLYSA6433.6571.38029.7231.0028.26ACATOM386CELYSA6433.1170.00530.0461.0029.17ACATOM387NZLYSA6432.990−0.82928.8251.0027.96ANATOM388CLYSA6435.6612.40834.2211.0031.59ACATOM389OLYSA6435.9261.25634.5591.0031.45AOATOM390NARGA6536.3453.46334.6531.0033.27ANATOM391CAARGA6537.4933.35235.5511.0034.34ACATOM392CBARGA6537.0432.89136.9351.0037.67ACATOM393CGARGA6536.0163.80037.5601.0043.08ACATOM394CDARGA6535.5853.28338.9091.0046.77ACATOM395NEARGA6534.4344.02539.4071.0051.51ANATOM396CZARGA6533.9273.88840.6281.0053.49ACATOM397NH1ARGA6534.4743.03241.4841.0054.10ANATOM398NH2ARGA6532.8724.60840.9931.0054.47ANATOM399CARGA6538.5572.39835.0211.0033.22ACATOM400OARGA6539.0861.57635.7701.0032.38AOATOM401NLEUA6638.8632.51833.7311.0031.04ANATOM402CALEUA6639.8681.68733.0891.0029.81ACATOM403CBLEUA6639.8211.87031.5641.0028.29ACATOM404CGLEUA6638.5571.47130.7951.0027.60ACATOM405CD1LEUA6638.8091.61129.3011.0025.14ACATOM406CD2LEUA6638.1700.03531.1211.0026.60ACATOM407CLEUA6641.2722.02033.5971.0030.22ACATOM408OLEUA6642.2511.41633.1621.0030.64AOATOM409NTYRA6741.3752.98034.5141.0030.84ANATOM410CATYRA6742.6773.36535.0551.0032.60ACATOM411CBTYRA6742.6884.84635.4381.0033.43ACATOM412CGTYRA6741.6425.22636.4631.0036.96ACATOM413CD1TYRA6741.8094.92237.8101.0037.60ACATOM414CE1TYRA6740.8335.25438.7451.0039.51ACATOM415CD2TYRA6740.4685.87536.0771.0038.20ACATOM416CE2TYRA6739.4886.21137.0041.0038.78ACATOM417CZTYRA6739.6755.89838.3341.0039.55ACATOM418OHTYRA6738.7036.22739.2541.0042.02AOATOM419CTYRA6743.0372.53436.2701.0033.52ACATOM420OTYRA6742.1671.96836.9291.0033.03AOATOM421NASPA6844.3272.45936.5671.0035.06ANATOM422CAASPA6844.7651.69937.7211.0036.88ACATOM423CBASPA6846.1461.10037.4761.0037.88ACATOM424CGASPA6846.6580.34038.6741.0038.95ACATOM425OD1ASPA6845.863−0.40839.2811.0039.74AOATOM426OD2ASPA6847.8500.48639.0061.0039.12AOATOM427CASPA6844.7952.59338.9521.0038.61ACATOM428OASPA6845.3913.67138.9391.0036.17AOATOM429NGLUA6944.1382.13840.0131.0041.45ANATOM430CAGLUA6944.0682.88941.2611.0044.18ACATOM431CBGLUA6943.3922.04242.3451.0047.21ACATOM432CGGLUA6941.8831.95342.2221.0050.20ACATOM433CDGLUA6941.2383.32242.2491.0052.69ACATOM434OE1GLUA6941.6194.13243.1261.0053.29AOATOM435OE2GLUA6940.3523.58641.4031.0054.11AOATOM436CGLUA6945.4213.36641.7741.0044.17ACATOM437OGLUA6945.6154.55342.0231.0043.71AOATOM438NLYSA7046.3492.43041.9331.0044.88ANATOM439CALYSA7047.6792.73342.4411.0045.87ACATOM440CBLYSA7048.2601.48243.1131.0047.39ACATOM441CGLYSA7048.0010.19442.3261.0050.82ACATOM442CDLYSA7048.491−1.06043.0521.0052.70ACATOM443CELYSA7048.068−2.33342.3071.0053.19ACATOM444NZLYSA7048.468−3.58643.0221.0053.35ANATOM445CLYSA7048.6393.25541.3761.0045.61ACATOM446OLYSA7049.6873.80341.7031.0046.82AOATOM447NGLNA7148.2843.07940.1071.0045.07ANATOM448CAGLNA7149.1233.53938.9951.0044.59ACATOM449CBGLNA7149.8522.35238.3571.0045.81ACATOM450CGGLNA7151.0482.75437.5251.0048.21ACATOM451CDGLNA7152.0853.50038.3431.0049.07ACATOM452OE1GLNA7153.0084.10337.7951.0049.90AOATOM453NE2GLNA7151.9403.45839.6651.0049.28ANATOM454CGLNA7148.1994.20737.9771.0042.82ACATOM455OGLNA7148.0233.73336.8511.0041.55AOATOM456NGLNA7247.6285.32738.4061.0040.92ANATOM457CAGLNA7246.6586.09637.6391.0038.61ACATOM458CBGLNA7246.1447.23238.5191.0039.65ACATOM459CGGLNA7245.1726.74139.5761.0041.28ACATOM460CDGLNA7244.8197.79940.5901.0041.51ACATOM461OE1GLNA7244.6718.97640.2531.0042.50AOATOM462NE2GLNA7244.6667.38541.8421.0041.01ANATOM463CGLNA7246.9486.63136.2471.0035.53ACATOM464OGLNA7246.0156.97335.5321.0034.95AOATOM465NHISA7348.2106.71235.8471.0033.43ANATOM466CAHISA7348.5087.21634.5121.0031.21ACATOM467CBHISA7349.8417.97534.5141.0032.43ACATOM468CGHISA7351.0397.11134.7531.0035.52ACATOM469CD2HISA7351.6156.68335.9011.0036.10ACATOM470ND1HISA7351.7966.58833.7251.0036.24ANATOM471CE1HISA7352.7885.87634.2301.0036.90ACATOM472NE2HISA7352.7015.91835.5481.0037.46ANATOM473CHISA7348.5186.07633.4871.0029.68ACATOM474OHISA7348.6816.29732.2781.0028.72AOATOM475NILEA7448.3154.85933.9871.0026.57ANATOM476CAILEA7448.2813.66333.1521.0025.03ACATOM477CBILEA7449.1672.53833.7451.0023.93ACATOM478CG2ILEA7448.9281.24433.0101.0023.04ACATOM479CG1ILEA7450.6432.93333.6691.0022.73ACATOM480CD1ILEA7451.1403.21032.2791.0021.40ACATOM481CILEA7446.8563.13533.0171.0024.39ACATOM482OILEA7446.1992.83334.0101.0025.39AOATOM483NVALA7546.3873.02531.7821.0023.12ANATOM484CAVALA7545.0482.52731.5061.0022.39ACATOM485CBVALA7544.4133.30630.3191.0021.87ACATOM486CG1VALA7543.0162.78430.0241.0019.40ACATOM487CG2VALA7544.3764.77730.6291.0021.46ACATOM488CVALA7545.1211.04431.1201.0023.43ACATOM489OVALA7546.0310.63130.3961.0024.66AOATOM490NTYRA7644.1740.24631.6041.0022.50ANATOM491CATYRA7644.115−1.17331.2561.0022.83ACATOM492CBTYRA7644.106−2.06332.5081.0022.60ACATOM493CGTYRA7645.435−2.13033.2371.0023.26ACATOM494CD1TYRA7645.728−1.25734.2841.0023.34ACATOM495CE1TYRA7646.964−1.29134.9281.0024.06ACATOM496CD2TYRA7646.414−3.04132.8551.0022.74ACATOM497CE2TYRA7647.654−3.08333.4931.0023.63ACATOM498CZTYRA7647.926−2.20734.5261.0023.89ACATOM499OHTYRA7649.159−2.23435.1501.0023.35AOATOM500CTYRA7642.825−1.36730.4651.0023.68ACATOM501OTYRA7641.727−1.24531.0031.0024.33AOATOM502NCYSA7742.953−1.66329.1811.0024.40ANATOM503CACYSA7741.780−1.82628.3421.0026.23ACATOM504CBCYSA7741.778−0.74427.2581.0024.90ACATOM505SGCYSA7743.313−0.60126.3251.0017.76ASATOM506CCYSA7741.681−3.19327.6921.0029.22ACATOM507OCYSA7741.001−3.35426.6761.0029.98AOATOM508NSERA7842.337−4.17628.3001.0032.27ANATOM509CASERA7842.366−5.53827.7751.0035.19ACATOM510CBSERA7843.016−6.46928.7981.0036.60ACATOM511OGSERA7843.133−7.78228.2791.0038.65AOATOM512CSERA7841.020−6.11927.3401.0036.61ACATOM513OSERA7840.777−6.30926.1441.0038.66AOATOM514NASNA7940.145−6.40228.2971.0036.16ANATOM515CAASNA7938.849−6.98227.9611.0037.19ACATOM516CBASNA7938.340−7.87129.1091.0040.14ACATOM517CGASNA7939.448−8.68229.7691.0042.98ACATOM518OD1ASNA7940.255−8.14630.5381.0044.77AOATOM519ND2ASNA7939.495−9.97829.4711.0042.57ANATOM520CASNA7937.805−5.90927.6691.0036.10ACATOM521OASNA7936.619−6.10527.9361.0036.61AOATOM522NASPA8038.227−4.78727.1011.0033.75ANATOM523CAASPA8037.283−3.71626.8361.0031.35ACATOM524CBASPA8037.630−2.51327.7081.0033.87ACATOM525CGASPA8036.563−1.44827.6721.0034.54ACATOM526OD1ASPA8035.832−1.31528.6791.0035.54AOATOM527OD2ASPA8036.453−0.75826.6311.0033.13AOATOM528CASPA8037.229−3.28025.3831.0029.65ACATOM529OASPA8038.182−3.47424.6341.0030.16AOATOM530NLEUA8136.109−2.67524.9951.0027.43ANATOM531CALEUA8135.932−2.20023.6291.0026.30ACATOM532CBLEUA8134.605−1.46123.4751.0025.12ACATOM533CGLEUA8134.437−0.77822.1111.0023.81ACATOM534CD1LEUA8134.714−1.77821.0131.0023.42ACATOM535CD2LEUA8133.040−0.21321.9711.0023.74ACATOM536CLEUA8137.064−1.27823.1941.0026.69ACATOM537OLEUA8137.416−1.23522.0101.0027.34AOATOM538NLEUA8237.621−0.52924.1441.0025.53ANATOM539CALEUA8238.7170.37523.8271.0024.07ACATOM540CBLEUA8239.0871.21725.0471.0020.46ACATOM541CGLEUA8240.2362.20224.8291.0018.75ACATOM542CD1LEUA8239.9133.16623.6891.0017.60ACATOM543CD2LEUA8240.4882.95526.1121.0018.82ACATOM544CLEUA8239.908−0.46823.3761.0025.11ACATOM545OLEUA8240.569−0.14922.3811.0026.18AOATOM546NGLYA8340.162−1.55324.1051.0024.69ANATOM547CAGLYA8341.249−2.45123.7601.0024.41ACATOM548CGLYA8341.170−2.92022.3181.0024.29ACATOM549OGLYA8342.196−3.13921.6811.0023.83AOATOM550NASPA8439.958−3.07621.7961.0024.91ANATOM551CAASPA8439.803−3.50320.4101.0027.77ACATOM552CBASPA8438.386−3.99620.1491.0028.89ACATOM553CGASPA8438.093−5.29520.8371.0031.01ACATOM554OD1ASPA8439.042−6.08521.0391.0032.12AOATOM555OD2ASPA8436.913−5.53221.1601.0031.66AOATOM556CASPA8440.119−2.39219.4101.0028.99ACATOM557OASPA8440.587−2.66418.2971.0029.29AOATOM558NLEUA8539.849−1.14619.7991.0028.12ANATOM559CALEUA8540.104−0.00918.9261.0026.68ACATOM560CBLEUA8539.3851.24119.4411.0027.62ACATOM561CGLEUA8537.8661.15519.5821.0029.80ACATOM562CD1LEUA8537.3252.47820.1041.0028.93ACATOM563CD2LEUA8537.2450.80718.2341.0030.79ACATOM564CLEUA8541.5920.26818.8661.0025.94ACATOM565OLEUA8542.1690.40017.7831.0025.60AOATOM566NPHEA8642.2080.35420.0421.0024.28ANATOM567CAPHEA8643.6360.63320.1431.0023.89ACATOM568CBPHEA8643.9801.11321.5631.0023.07ACATOM569CGPHEA8643.6012.54821.8371.0021.05ACATOM570CD1PHEA8642.8583.28420.9141.0019.37ACATOM571CD2PHEA8643.9923.16523.0211.0020.29ACATOM572CE1PHEA8642.5094.61221.1671.0018.94ACATOM573CE2PHEA8643.6494.49623.2851.0020.32ACATOM574CZPHEA8642.9035.22022.3521.0019.94ACATOM575CPHEA8644.498−0.57519.7811.0022.94ACATOM576OPHEA8645.550−0.43019.1561.0022.42AOATOM577NGLYA8744.049−1.76220.1781.0021.80ANATOM578CAGLYA8744.800−2.96919.8811.0020.71ACATOM579CGLYA8745.882−3.27020.9041.0018.88ACATOM580OGLYA8746.874−3.94020.6041.0017.62AOATOM581NVALA8845.703−2.76922.1191.0017.60ANATOM582CAVALA8846.685−3.01423.1581.0017.15ACATOM583CBVALA8847.642−1.81523.3561.0016.00ACATOM584CG1VALA8848.277−1.43022.0321.0013.25ACATOM585CG2VALA8846.901−0.65223.9751.0015.16ACATOM586CVALA8845.997−3.29024.4721.0017.59ACATOM587OVALA8844.841−2.92224.6671.0018.43AOATOM588NPROA8946.699−3.96625.3901.0018.50ANATOM589CDPROA8947.976−4.67325.1771.0017.26ACATOM590CAPROA8946.138−4.28726.7051.0017.37ACATOM591CBPROA8946.958−5.49627.1371.0016.69ACATOM592CGPROA8948.310−5.17026.5751.0017.70ACATOM593CPROA8946.271−3.11527.6771.0017.13ACATOM594OPROA8945.549−3.04228.6691.0018.98AOATOM595NSERA9047.196−2.20027.3971.0016.91ANATOM596CASERA9047.394−1.04428.2731.0016.57ACATOM597CBSERA9048.002−1.48529.6121.0015.12ACATOM598OGSERA9049.329−1.95629.4391.0013.05AOATOM599CSERA9048.2910.02327.6531.0016.15ACATOM600OSERA9049.090−0.26126.7641.0017.41AO

[0226]

5

TABLE 2

compound 876273 ([8-Chloro-3-(4-chloro-phenyl)-7-iodo-2,5-dioxo-1,2,3,5-

tetrahydro-benzo[e][1,4]diazepin-4-yl]-(4-chloro-phenyl)-acetic acid)

REMARK coordinates from restrained individual B-factor refinement

REMARK refinement resolution: 25 − 2.6 A

REMARK starting
r = 0.2563
free_r = 0.2787

REMARK final
r = 0.2553
free_r = 0.2761

REMARK B rmsd for bonded mainchain atoms = 1.483 target = 1.5

REMARK B rmsd for bonded sidechain atoms = 1.740 target = 2.0

REMARK B rmsd for angle mainchain atoms = 2.593 target = 2.0

REMARK B rmsd for angle sidechain atoms = 2.780 target = 2.5

REMARK rweight = 0.1000 (with wa = 3.71696)

REMARK target = mlf steps = 30

REMARK sg = P4(3)2(1)2 a = 54.3 b = 54.3 c = 83.3 alpha = 90 beta = 90 gamma = 90

REMARK parameter file 1: MSI_CNX_TOPPAR:protein_rep.param

REMARK parameter file 2: ../cid.par

REMARK molecular structure file: recycle.psf

REMARK input coordinates: anneal_9.pdb

REMARK reflection file = ../M876273_2_P43212.cv

REMARK ncs = none

REMARK B-correction resolution: 6.0 − 2.6

REMARK initial B-factor correction applied to fobs:

REMARK
B11 =
−1.189
B22 =
−1.189
B33 =
2.379

REMARK
B12 =
0.000
B13 =
0.000
B23 =
0.000

REMARK B-factor correction applied to coordinate array B: −0.119

REMARK bulk solvent: (Mask) density level = 0.341945 e/A{circumflex over ( )}3, B-factor = 22.3925 A{circumflex over ( )}2

REMARK reflections with |Fobs|/sigma_F < 0.0 rejected

REMARK reflections with |Fobs| > 10000 * rms (Fobs) rejected

REMARK theoretical total number of refl. in resol. range: 4173 (100.0%)

REMARK number of unobserved reflections (no entry or |F| = 0): 9 (0.2%)

REMARK number of reflections rejected: 0 (0.0%)

REMARK total number of reflections used: 4164 (99.8%)

REMARK number of reflections in working set: 3737 (89.6%)

REMARK number of reflections in test set: 427 (10.2%)

CRYST1 54.300 54.300 83.300 90.00 90.00 90.00 P 43 21 2

REMARK FILENAME = “bindividual.pdb”

REMARK Written by CNX VERSION: 2000.12

ATOM
1
C
GLY
A
16
50.842
45.566
39.472
1.00
68.15
A

C

ATOM
2
O
GLY
A
16
49.884
45.429
40.244
1.00
68.22
A

O

ATOM
3
N
GLY
A
16
51.272
44.956
37.085
1.00
67.11
A

N

ATOM
4
CA
GLY
A
16
51.225
44.463
38.498
1.00
67.90
A

C

ATOM
5
N
SER
A
17
51.601
46.662
39.435
1.00
67.05
A

N

ATOM
6
CA
SER
A
17
51.358
47.819
40.296
1.00
64.73
A

C

ATOM
7
CB
SER
A
17
52.359
47.851
41.458
1.00
65.01
A

C

ATOM
8
OG
SER
A
17
52.175
46.743
42.330
1.00
63.84
A

O

ATOM
9
C
SER
A
17
51.495
49.080
39.449
1.00
62.82
A

C

ATOM
10
O
SER
A
17
51.039
50.157
39.837
1.00
62.75
A

O

ATOM
11
N
GLN
A
18
52.130
48.925
38.289
1.00
60.52
A

N

ATOM
12
CA
GLN
A
18
52.323
50.023
37.346
1.00
57.89
A

C

ATOM
13
CB
GLN
A
18
53.377
49.652
36.306
1.00
57.50
A

C

ATOM
14
CG
GLN
A
18
54.800
49.725
36.791
1.00
57.38
A

C

ATOM
15
CD
GLN
A
18
55.786
49.390
35.687
1.00
58.16
A

C

ATOM
16
OE1
GLN
A
18
55.675
49.892
34.565
1.00
56.84
A

O

ATOM
17
NE2
GLN
A
18
56.761
48.543
36.002
1.00
58.44
A

N

ATOM
18
C
GLN
A
18
51.013
50.299
36.620
1.00
55.87
A

C

ATOM
19
O
GLN
A
18
50.763
51.414
36.157
1.00
55.83
A

O

ATOM
20
N
ILE
A
19
50.187
49.261
36.524
1.00
52.87
A

N

ATOM
21
CA
ILE
A
19
48.898
49.337
35.850
1.00
50.05
A

C

ATOM
22
CB
ILE
A
19
48.721
48.131
34.883
1.00
48.06
A

C

ATOM
23
CG2
ILE
A
19
47.404
48.239
34.138
1.00
48.17
A

C

ATOM
24
CG1
ILE
A
19
49.885
48.069
33.889
1.00
45.44
A

C

ATOM
25
CD1
ILE
A
19
49.939
49.218
32.921
1.00
43.26
A

C

ATOM
26
C
ILE
A
19
47.769
49.319
36.884
1.00
49.72
A

C

ATOM
27
O
ILE
A
19
47.863
48.631
37.902
1.00
49.03
A

O

ATOM
28
N
PRO
A
20
46.694
50.095
36.643
1.00
49.57
A

N

ATOM
29
CD
PRO
A
20
46.609
51.167
35.636
1.00
49.58
A

C

ATOM
30
CA
PRO
A
20
45.546
50.162
37.553
1.00
49.39
A

C

ATOM
31
CB
PRO
A
20
44.693
51.271
36.949
1.00
48.67
A

C

ATOM
32
CG
PRO
A
20
45.704
52.159
36.318
1.00
48.94
A

C

ATOM
33
C
PRO
A
20
44.784
48.836
37.628
1.00
49.97
A

C

ATOM
34
O
PRO
A
20
44.551
48.184
36.606
1.00
50.18
A

O

ATOM
35
N
ALA
A
21
44.399
48.446
38.840
1.00
49.45
A

N

ATOM
36
CA
ALA
A
21
43.660
47.207
39.057
1.00
49.81
A

C

ATOM
37
CB
ALA
A
21
43.252
47.094
40.528
1.00
49.85
A

C

ATOM
38
C
ALA
A
21
42.419
47.133
38.160
1.00
49.65
A

C

ATOM
39
O
ALA
A
21
42.160
46.112
37.517
1.00
49.33
A

O

ATOM
40
N
SER
A
22
41.650
48.217
38.125
1.00
48.76
A

N

ATOM
41
CA
SER
A
22
40.451
48.260
37.302
1.00
47.75
A

C

ATOM
42
CB
SER
A
22
39.873
49.678
37.296
1.00
47.15
A

C

ATOM
43
OG
SER
A
22
40.857
50.625
36.915
1.00
48.43
A

O

ATOM
44
C
SER
A
22
40.792
47.816
35.877
1.00
46.34
A

C

ATOM
45
O
SER
A
22
40.029
47.083
35.242
1.00
45.89
A

O

ATOM
46
N
GLU
A
23
41.947
48.251
35.384
1.00
44.68
A

N

ATOM
47
CA
GLU
A
23
42.375
47.887
34.040
1.00
43.25
A

C

ATOM
48
CB
GLU
A
23
43.526
48.771
33.588
1.00
42.16
A

C

ATOM
49
CG
GLU
A
23
43.939
48.525
32.164
1.00
40.86
A

C

ATOM
50
CD
GLU
A
23
44.747
49.671
31.612
1.00
40.82
A

C

ATOM
51
OE1
GLU
A
23
45.613
50.189
32.344
1.00
41.52
A

O

ATOM
52
OE2
GLU
A
23
44.523
50.054
30.448
1.00
41.56
A

O

ATOM
53
C
GLU
A
23
42.790
46.428
33.991
1.00
42.01
A

C

ATOM
54
O
GLU
A
23
42.419
45.701
33.076
1.00
42.32
A

O

ATOM
55
N
GLN
A
24
43.561
45.998
34.977
1.00
41.29
A

N

ATOM
56
CA
GLN
A
24
43.973
44.610
35.027
1.00
42.07
A

C

ATOM
57
CB
GLN
A
24
44.762
44.334
36.314
1.00
41.13
A

C

ATOM
58
CG
GLN
A
24
46.206
44.813
36.250
1.00
42.57
A

C

ATOM
59
CD
GLN
A
24
46.978
44.602
37.546
1.00
43.91
A

C

ATOM
60
OE1
GLN
A
24
46.823
43.580
38.225
1.00
44.84
A

O

ATOM
61
NE2
GLN
A
24
47.831
45.564
37.884
1.00
43.17
A

N

ATOM
62
C
GLN
A
24
42.714
43.747
34.984
1.00
43.32
A

C

ATOM
63
O
GLN
A
24
42.750
42.596
34.541
1.00
43.40
A

O

ATOM
64
N
GLU
A
25
41.596
44.326
35.423
1.00
44.62
A

N

ATOM
65
CA
GLU
A
25
40.314
43.618
35.464
1.00
44.92
A

C

ATOM
66
CB
GLU
A
25
39.471
44.123
36.642
1.00
48.33
A

C

ATOM
67
CG
GLU
A
25
40.216
44.254
37.972
1.00
53.04
A

C

ATOM
68
CD
GLU
A
25
40.899
42.969
38.423
1.00
55.79
A

C

ATOM
69
OE1
GLU
A
25
41.474
42.972
39.533
1.00
57.11
A

O

ATOM
70
OE2
GLU
A
25
40.869
41.961
37.681
1.00
57.84
A

O

ATOM
71
C
GLU
A
25
39.472
43.697
34.184
1.00
42.75
A

C

ATOM
72
O
GLU
A
25
38.563
42.887
33.992
1.00
42.62
A

O

ATOM
73
N
THR
A
26
39.760
44.666
33.319
1.00
40.18
A

N

ATOM
74
CA
THR
A
26
39.013
44.813
32.067
1.00
38.13
A

C

ATOM
75
CB
THR
A
26
39.714
45.803
31.100
1.00
37.92
A

C

ATOM
76
OG1
THR
A
26
40.061
47.002
31.803
1.00
37.02
A

O

ATOM
77
CG2
THR
A
26
38.798
46.161
29.945
1.00
36.76
A

C

ATOM
78
C
THR
A
26
38.897
43.456
31.367
1.00
36.79
A

C

ATOM
79
O
THR
A
26
39.859
42.693
31.321
1.00
36.47
A

O

ATOM
80
N
LEU
A
27
37.715
43.152
30.841
1.00
36.63
A

N

ATOM
81
CA
LEU
A
27
37.490
41.887
30.138
1.00
35.77
A

C

ATOM
82
CB
LEU
A
27
36.035
41.429
30.291
1.00
36.16
A

C

ATOM
83
CG
LEU
A
27
35.799
39.909
30.293
1.00
38.05
A

C

ATOM
84
CD1
LEU
A
27
36.293
39.313
31.617
1.00
36.12
A

C

ATOM
85
CD2
LEU
A
27
34.305
39.610
30.112
1.00
38.41
A

C

ATOM
86
C
LEU
A
27
37.808
42.130
28.665
1.00
34.52
A

C

ATOM
87
O
LEU
A
27
37.395
43.139
28.090
1.00
33.72
A

O

ATOM
88
N
VAL
A
28
38.540
41.204
28.054
1.00
33.53
A

N

ATOM
89
CA
VAL
A
28
38.941
41.364
26.662
1.00
32.88
A

C

ATOM
90
CB
VAL
A
28
40.420
41.848
26.589
1.00
32.86
A

C

ATOM
91
CG1
VAL
A
28
40.570
43.182
27.302
1.00
31.21
A

C

ATOM
92
CG2
VAL
A
28
41.340
40.821
27.242
1.00
33.40
A

C

ATOM
93
C
VAL
A
28
38.792
40.107
25.802
1.00
31.29
A

C

ATOM
94
O
VAL
A
28
38.708
38.992
26.314
1.00
30.99
A

O

ATOM
95
N
ARG
A
29
38.754
40.312
24.489
1.00
29.80
A

N

ATOM
96
CA
ARG
A
29
38.641
39.224
23.528
1.00
28.94
A

C

ATOM
97
CB
ARG
A
29
37.379
39.371
22.685
1.00
33.14
A

C

ATOM
98
CG
ARG
A
29
36.132
38.818
23.326
1.00
38.54
A

C

ATOM
99
CD
ARG
A
29
34.905
39.188
22.511
1.00
43.39
A

C

ATOM
100
NE
ARG
A
29
33.712
38.549
23.051
1.00
47.28
A

N

ATOM
101
CZ
ARG
A
29
33.397
37.276
22.843
1.00
49.30
A

C

ATOM
102
NH1
ARG
A
29
34.185
36.511
22.093
1.00
49.75
A

N

ATOM
103
nh2
ARG
A
29
32.309
36.763
23.405
1.00
50.29
A

N

ATOM
104
C
ARG
A
29
39.842
39.254
22.602
1.00
26.43
A

C

ATOM
105
O
ARG
A
29
39.935
40.121
21.727
1.00
25.41
A

O

ATOM
106
N
PRO
A
30
40.785
38.315
22.789
1.00
24.69
A

N

ATOM
107
CD
PRO
A
30
40.798
37.274
23.830
1.00
23.43
A

C

ATOM
108
CA
PRO
A
30
41.995
38.234
21.958
1.00
23.00
A

C

ATOM
109
CB
PRO
A
30
42.826
37.151
22.643
1.00
21.72
A

C

ATOM
110
CG
PRO
A
30
42.261
37.064
24.025
1.00
22.48
A

C

ATOM
111
C
PRO
A
30
41.620
37.801
20.544
1.00
22.20
A

C

ATOM
112
O
PRO
A
30
40.663
37.050
20.360
1.00
22.27
A

O

ATOM
113
N
LYS
A
31
42.365
38.273
19.551
1.00
21.65
A

N

ATOM
114
CA
LYS
A
31
42.118
37.880
18.166
1.00
19.51
A

C

ATOM
115
CB
LYS
A
31
42.825
38.839
17.210
1.00
19.68
A

C

ATOM
116
CG
LYS
A
31
42.364
40.279
17.348
1.00
20.82
A

C

ATOM
117
CD
LYS
A
31
43.115
41.174
16.376
1.00
22.74
A

C

ATOM
118
CE
LYS
A
31
42.641
42.630
16.435
1.00
20.68
A

C

ATOM
119
NZ
LYS
A
31
43.356
43.433
15.396
1.00
21.75
A

N

ATOM
120
C
LYS
A
31
42.666
36.454
18.011
1.00
18.36
A

C

ATOM
121
O
LYS
A
31
43.441
35.983
18.847
1.00
17.38
A

O

ATOM
122
N
PRO
A
32
42.291
35.760
16.930
1.00
17.15
A

N

ATOM
123
CD
PRO
A
32
41.612
36.293
15.736
1.00
16.30
A

C

ATOM
124
CA
PRO
A
32
42.737
34.387
16.684
1.00
16.70
A

C

ATOM
125
CB
PRO
A
32
42.392
34.182
15.213
1.00
16.53
A

C

ATOM
126
CG
PRO
A
32
41.180
35.032
15.044
1.00
16.35
A

C

ATOM
127
C
PRO
A
32
44.198
34.043
16.997
1.00
16.73
A

C

ATOM
128
O
PRO
A
32
44.470
33.062
17.695
1.00
17.12
A

O

ATOM
129
N
LEU
A
33
45.137
34.830
16.483
1.00
14.62
A

N

ATOM
130
CA
LEU
A
33
46.540
34.538
16.724
1.00
13.59
A

C

ATOM
131
CB
LEU
A
33
47.425
35.427
15.843
1.00
15.36
A

C

ATOM
132
CG
LEU
A
33
48.097
34.759
14.626
1.00
13.91
A

C

ATOM
133
CD1
LEU
A
33
47.597
33.319
14.406
1.00
13.51
A

C

ATOM
134
CD2
LEU
A
33
47.838
35.609
13.411
1.00
8.87
A

C

ATOM
135
C
LEU
A
33
46.936
34.641
18.189
1.00
13.14
A

C

ATOM
136
O
LEU
A
33
47.545
33.724
18.715
1.00
12.37
A

O

ATOM
137
N
LEU
A
34
46.610
35.744
18.856
1.00
14.58
A

N

ATOM
138
CA
LEU
A
34
46.930
35.859
20.279
1.00
13.84
A

C

ATOM
139
CB
LEU
A
34
46.540
37.236
20.826
1.00
13.73
A

C

ATOM
140
CG
LEU
A
34
46.613
37.449
22.347
1.00
10.65
A

C

ATOM
141
CD1
LEU
A
34
48.041
37.367
22.818
1.00
9.38
A

C

ATOM
142
CD2
LEU
A
34
46.029
38.795
22.701
1.00
11.47
A

C

ATOM
143
C
LEU
A
34
46.158
34.771
21.039
1.00
15.75
A

C

ATOM
144
O
LEU
A
34
46.678
34.176
21.975
1.00
16.50
A

O

ATOM
145
N
LEU
A
35
44.917
34.506
20.635
1.00
17.07
A

N

ATOM
146
CA
LEU
A
35
44.125
33.469
21.295
1.00
18.94
A

C

ATOM
147
CB
LEU
A
35
42.720
33.381
20.686
1.00
16.70
A

C

ATOM
148
CG
LEU
A
35
41.753
32.424
21.391
1.00
14.51
A

C

ATOM
149
CD1
LEU
A
35
41.542
32.888
22.825
1.00
13.73
A

C

ATOM
150
CD2
LEU
A
35
40.425
32.379
20.653
1.00
13.01
A

C

ATOM
151
C
LEU
A
35
44.815
32.094
21.218
1.00
20.66
A

C

ATOM
152
O
LEU
A
35
44.668
31.276
22.133
1.00
21.36
A

O

ATOM
153
N
LYS
A
36
45.563
31.845
20.140
1.00
20.77
A

N

ATOM
154
CA
LYS
A
36
46.279
30.581
19.979
1.00
22.28
A

C

ATOM
155
CB
LYS
A
36
46.792
30.398
18.547
1.00
23.62
A

C

ATOM
156
CG
LYS
A
36
45.782
29.781
17.586
1.00
28.23
A

C

ATOM
157
CD
LYS
A
36
46.444
28.754
16.647
1.00
30.56
A

C

ATOM
158
CE
LYS
A
36
47.556
29.366
15.789
1.00
32.43
A

C

ATOM
159
NZ
LYS
A
36
48.108
28.414
14.778
1.00
31.16
A

N

ATOM
160
C
LYS
A
36
47.461
30.504
20.937
1.00
23.86
A

C

ATOM
161
O
LYS
A
36
47.716
29.451
21.537
1.00
26.24
A

O

ATOM
162
N
LEU
A
37
48.196
31.603
21.076
1.00
23.16
A

N

ATOM
163
CA
LEU
A
37
49.332
31.612
21.994
1.00
24.32
A

C

ATOM
164
CB
LEU
A
37
49.920
33.019
22.134
1.00
25.18
A

C

ATOM
165
CG
LEU
A
37
50.647
33.606
20.934
1.00
27.89
A

C

ATOM
166
CD1
LEU
A
37
51.343
34.901
21.343
1.00
28.24
A

C

ATOM
167
CD2
LEU
A
37
51.659
32.597
20.431
1.00
28.07
A

C

ATOM
168
C
LEU
A
37
48.884
31.144
23.377
1.00
23.05
A

C

ATOM
169
O
LEU
A
37
49.526
30.304
24.003
1.00
20.34
A

O

ATOM
170
N
LEU
A
38
47.770
31.706
23.834
1.00
23.36
A

N

ATOM
171
CA
LEU
A
38
47.218
31.399
25.139
1.00
24.58
A

C

ATOM
172
CB
LEU
A
38
46.036
32.322
25.447
1.00
21.20
A

C

ATOM
173
CG
LEU
A
38
46.216
33.821
25.189
1.00
19.16
A

C

ATOM
174
CD1
LEU
A
38
44.954
34.538
25.619
1.00
16.77
A

C

ATOM
175
CD2
LEU
A
38
47.420
34.370
25.950
1.00
18.04
A

C

ATOM
176
C
LEU
A
38
46.772
29.950
25.241
1.00
27.20
A

C

ATOM
177
O
LEU
A
38
46.970
29.309
26.273
1.00
29.33
A

O

ATOM
178
N
LYS
A
39
46.175
29.419
24.182
1.00
28.13
A

N

ATOM
179
CA
LYS
A
39
45.720
28.041
24.241
1.00
29.30
A

C

ATOM
180
CB
LYS
A
39
44.782
27.741
23.071
1.00
28.63
A

C

ATOM
181
CG
LYS
A
39
43.532
28.596
23.123
1.00
28.78
A

C

ATOM
182
CD
LYS
A
39
42.451
28.113
22.184
1.00
27.98
A

C

ATOM
183
CE
LYS
A
39
41.239
29.021
22.270
1.00
26.89
A

C

ATOM
184
NZ
LYS
A
39
40.089
28.444
21.537
1.00
27.11
A

N

ATOM
185
C
LYS
A
39
46.884
27.062
24.270
1.00
30.33
A

C

ATOM
186
O
LYS
A
39
46.787
25.998
24.883
1.00
31.74
A

O

ATOM
187
N
SER
A
40
47.993
27.428
23.633
1.00
30.27
A

N

ATOM
188
CA
SER
A
40
49.169
26.559
23.607
1.00
29.62
A

C

ATOM
189
CB
SER
A
40
50.280
27.175
22.735
1.00
28.81
A

C

ATOM
190
OG
SER
A
40
50.904
28.292
23.357
1.00
26.68
A

O

ATOM
191
C
SER
A
40
49.701
26.301
25.020
1.00
29.48
A

C

ATOM
192
O
SER
A
40
50.396
25.316
25.254
1.00
29.59
A

O

ATOM
193
N
VAL
A
41
49.374
27.186
25.958
1.00
30.35
A

N

ATOM
194
CA
VAL
A
41
49.827
27.044
27.345
1.00
30.76
A

C

ATOM
195
CB
VAL
A
41
50.717
28.252
27.799
1.00
30.64
A

C

ATOM
196
CG1
VAL
A
41
52.087
28.184
27.125
1.00
29.00
A

C

ATOM
197
CG2
VAL
A
41
50.030
29.574
27.470
1.00
28.32
A

C

ATOM
198
C
VAL
A
41
48.678
26.891
28.345
1.00
32.02
A

C

ATOM
199
O
VAL
A
41
48.691
27.500
29.419
1.00
31.05
A

O

ATOM
200
N
GLY
A
42
47.675
26.092
27.983
1.00
33.77
A

N

ATOM
201
CA
GLY
A
42
46.563
25.862
28.889
1.00
36.14
A

C

ATOM
202
C
GLY
A
42
45.260
26.597
28.641
1.00
38.10
A

C

ATOM
203
O
GLY
A
42
44.201
25.971
28.653
1.00
40.02
A

O

ATOM
204
N
ALA
A
43
45.317
27.912
28.432
1.00
38.97
A

N

ATOM
205
CA
ALA
A
43
44.107
28.703
28.203
1.00
39.16
A

C

ATOM
206
CB
ALA
A
43
44.459
30.022
27.518
1.00
38.86
A

C

ATOM
207
C
ALA
A
43
43.080
27.938
27.375
1.00
39.94
A

C

ATOM
208
O
ALA
A
43
43.437
27.164
26.485
1.00
40.04
A

O

ATOM
209
N
GLN
A
44
41.802
28.155
27.675
1.00
41.54
A

N

ATOM
210
CA
GLN
A
44
40.733
27.475
26.955
1.00
42.78
A

C

ATOM
211
CB
GLN
A
44
40.609
26.037
27.466
1.00
45.11
A

C

ATOM
212
CG
GLN
A
44
40.573
25.913
28.984
1.00
47.61
A

C

ATOM
213
CD
GLN
A
44
40.868
24.493
29.456
1.00
49.56
A

C

ATOM
214
OE1
GLN
A
44
40.913
24.221
30.662
1.00
49.35
A

O

ATOM
215
NE2
GLN
A
44
41.075
23.581
28.506
1.00
49.08
A

N

ATOM
216
C
GLN
A
44
39.379
28.183
27.030
1.00
42.23
A

C

ATOM
217
O
GLN
A
44
38.355
27.557
27.322
1.00
42.70
A

O

ATOM
218
N
LYS
A
45
39.391
29.488
26.763
1.00
40.15
A

N

ATOM
219
CA
LYS
A
45
38.184
30.307
26.765
1.00
37.90
A

C

ATOM
220
CB
LYS
A
45
38.085
31.150
28.034
1.00
39.62
A

C

ATOM
221
CG
LYS
A
45
38.193
30.392
29.341
1.00
41.18
A

C

ATOM
222
CD
LYS
A
45
37.768
31.288
30.502
1.00
42.96
A

C

ATOM
223
CE
LYS
A
45
38.491
32.629
30.473
1.00
45.64
A

C

ATOM
224
NZ
LYS
A
45
38.045
33.556
31.559
1.00
48.08
A

N

ATOM
225
C
LYS
A
45
38.296
31.254
25.585
1.00
36.61
A

C

ATOM
226
O
LYS
A
45
39.258
31.183
24.822
1.00
36.82
A

O

ATOM
227
N
ASP
A
46
37.323
32.149
25.448
1.00
34.69
A

N

ATOM
228
CA
ASP
A
46
37.332
33.128
24.368
1.00
33.64
A

C

ATOM
229
CB
ASP
A
46
36.015
33.106
23.577
1.00
35.21
A

C

ATOM
230
CG
ASP
A
46
35.826
31.828
22.778
1.00
36.60
A

C

ATOM
231
OD1
ASP
A
46
36.819
31.326
22.204
1.00
35.63
A

O

ATOM
232
OD2
ASP
A
46
34.677
31.337
22.712
1.00
36.79
A

O

ATOM
233
C
ASP
A
46
37.529
34.526
24.935
1.00
32.32
A

C

ATOM
234
O
ASP
A
46
38.032
35.419
24.249
1.00
33.06
A

O

ATOM
235
N
THR
A
47
37.118
34.715
26.186
1.00
30.30
A

N

ATOM
236
CA
THR
A
47
37.233
36.012
26.850
1.00
27.52
A

C

ATOM
237
CB
THR
A
47
35.849
36.568
27.265
1.00
28.37
A

C

ATOM
238
OG1
THR
A
47
35.055
35.513
27.822
1.00
28.12
A

O

ATOM
239
CG2
THR
A
47
35.130
37.169
26.071
1.00
28.11
A

C

ATOM
240
C
THR
A
47
38.097
35.897
28.088
1.00
25.47
A

C

ATOM
241
O
THR
A
47
38.111
34.862
28.759
1.00
24.25
A

O

ATOM
242
N
TYR
A
48
38.820
36.973
28.382
1.00
24.41
A

N

ATOM
243
CA
TYR
A
48
39.716
37.010
29.526
1.00
24.02
A

C

ATOM
244
CB
TYR
A
48
41.142
36.566
29.126
1.00
23.01
A

C

ATOM
245
CG
TYR
A
48
41.265
35.192
28.492
1.00
22.29
A

C

ATOM
246
CD1
TYR
A
48
40.966
34.992
27.143
1.00
21.16
A

C

ATOM
247
CE1
TYR
A
48
41.035
33.713
26.568
1.00
20.20
A

C

ATOM
248
CD2
TYR
A
48
41.647
34.079
29.254
1.00
21.34
A

C

ATOM
249
CE2
TYR
A
48
41.721
32.806
28.688
1.00
20.29
A

C

ATOM
250
CZ
TYR
A
48
41.409
32.633
27.348
1.00
19.58
A

C

ATOM
251
OH
TYR
A
48
41.436
31.378
26.795
1.00
20.11
A

O

ATOM
252
C
TYR
A
48
39.829
38.419
30.085
1.00
24.38
A

C

ATOM
253
O
TYR
A
48
39.512
39.403
29.409
1.00
22.46
A

O

ATOM
254
N
THR
A
49
40.288
38.497
31.329
1.00
24.50
A

N

ATOM
255
CA
THR
A
49
40.554
39.774
31.974
1.00
25.25
A

C

ATOM
256
CB
THR
A
49
40.510
39.647
33.515
1.00
26.57
A

C

ATOM
257
OG1
THR
A
49
41.215
38.459
33.914
1.00
26.24
A

O

ATOM
258
CG2
THR
A
49
39.056
39.580
34.017
1.00
24.91
A

C

ATOM
259
C
THR
A
49
42.000
40.027
31.524
1.00
25.63
A

C

ATOM
260
O
THR
A
49
42.738
39.079
31.248
1.00
24.71
A

O

ATOM
261
N
MET
A
50
42.414
41.281
31.424
1.00
26.39
A

N

ATOM
262
CA
MET
A
50
43.776
41.545
30.986
1.00
26.62
A

C

ATOM
263
CB
MET
A
50
44.053
43.040
30.977
1.00
25.74
A

C

ATOM
264
CG
MET
A
50
43.446
43.740
29.780
1.00
25.74
A

C

ATOM
265
SD
MET
A
50
44.280
43.286
28.239
1.00
24.59
A

S

ATOM
266
CE
MET
A
50
45.652
44.433
28.225
1.00
22.52
A

C

ATOM
267
C
MET
A
50
44.797
40.832
31.855
1.00
28.23
A

C

ATOM
268
O
MET
A
50
45.890
40.518
31.396
1.00
29.67
A

O

ATOM
269
N
LYS
A
51
44.442
40.554
33.105
1.00
28.66
A

N

ATOM
270
CA
LYS
A
51
45.370
39.872
33.993
1.00
29.11
A

C

ATOM
271
CB
LYS
A
51
44.878
39.943
35.439
1.00
32.66
A

C

ATOM
272
CG
LYS
A
51
45.919
39.458
36.443
1.00
37.67
A

C

ATOM
273
CD
LYS
A
51
45.462
39.604
37.889
1.00
41.07
A

C

ATOM
274
CE
LYS
A
51
46.527
39.071
38.855
1.00
42.73
A

C

ATOM
275
NZ
LYS
A
51
46.109
39.129
40.295
1.00
45.66
A

N

ATOM
276
C
LYS
A
51
45.597
38.411
33.586
1.00
28.29
A

C

ATOM
277
O
LYS
A
51
46.723
37.908
33.669
1.00
28.36
A

O

ATOM
278
N
GLU
A
52
44.537
37.729
33.152
1.00
25.71
A

N

ATOM
279
CA
GLU
A
52
44.662
36.334
32.732
1.00
23.60
A

C

ATOM
280
CB
GLU
A
52
43.278
35.702
32.522
1.00
24.83
A

C

ATOM
281
CG
GLU
A
52
42.420
35.589
33.777
1.00
27.15
A

C

ATOM
282
CD
GLU
A
52
40.989
35.116
33.479
1.00
29.01
A

C

ATOM
283
OE1
GLU
A
52
40.281
35.785
32.691
1.00
29.80
A

O

ATOM
284
OE2
GLU
A
52
40.568
34.078
34.032
1.00
29.19
A

O

ATOM
285
C
GLU
A
52
45.476
36.230
31.432
1.00
21.67
A

C

ATOM
286
O
GLU
A
52
46.128
35.214
31.183
1.00
20.99
A

O

ATOM
287
N
VAL
A
53
45.425
37.266
30.598
1.00
18.55
A

N

ATOM
288
CA
VAL
A
53
46.181
37.255
29.351
1.00
16.46
A

C

ATOM
289
CB
VAL
A
53
45.807
38.454
28.423
1.00
17.02
A

C

ATOM
290
CG1
VAL
A
53
46.806
38.553
27.264
1.00
15.92
A

C

ATOM
291
CG2
VAL
A
53
44.402
38.261
27.853
1.00
14.61
A

C

ATOM
292
C
VAL
A
53
47.650
37.331
29.742
1.00
15.15
A

C

ATOM
293
O
VAL
A
53
48.436
36.443
29.403
1.00
13.10
A

O

ATOM
294
N
LEU
A
54
48.010
38.394
30.463
1.00
15.42
A

N

ATOM
295
CA
LEU
A
54
49.375
38.570
30.952
1.00
14.74
A

C

ATOM
296
CB
LEU
A
54
49.454
39.698
31.982
1.00
12.86
A

C

ATOM
297
CG
LEU
A
54
49.718
41.124
31.497
1.00
13.00
A

C

ATOM
298
CD1
LEU
A
54
50.874
41.100
30.500
1.00
14.60
A

C

ATOM
299
CD2
LEU
A
54
48.494
41.706
30.859
1.00
11.73
A

C

ATOM
300
C
LEU
A
54
49.846
37.281
31.619
1.00
15.13
A

C

ATOM
301
O
LEU
A
54
51.009
36.897
31.502
1.00
16.88
A

O

ATOM
302
N
PHE
A
55
48.942
36.605
32.312
1.00
14.69
A

N

ATOM
303
CA
PHE
A
55
49.305
35.371
32.991
1.00
16.41
A

C

ATOM
304
CB
PHE
A
55
48.137
34.831
33.819
1.00
18.34
A

C

ATOM
305
CG
PHE
A
55
48.428
33.500
34.429
1.00
20.72
A

C

ATOM
306
CD1
PHE
A
55
49.136
33.411
35.626
1.00
20.24
A

C

ATOM
307
CD2
PHE
A
55
48.101
32.324
33.749
1.00
20.52
A

C

ATOM
308
CE1
PHE
A
55
49.524
32.170
36.135
1.00
20.60
A

C

ATOM
309
CE2
PHE
A
55
48.485
31.079
34.248
1.00
21.73
A

C

ATOM
310
CZ
PHE
A
55
49.199
31.001
35.444
1.00
20.59
A

C

ATOM
311
C
PHE
A
55
49.779
34.268
32.058
1.00
16.04
A

C

ATOM
312
O
PHE
A
55
50.853
33.698
32.259
1.00
17.31
A

O

ATOM
313
N
TYR
A
56
48.960
33.949
31.060
1.00
16.71
A

N

ATOM
314
CA
TYR
A
56
49.283
32.904
30.087
1.00
17.61
A

C

ATOM
315
CB
TYR
A
56
48.079
32.620
29.189
1.00
18.45
A

C

ATOM
316
CG
TYR
A
56
46.996
31.859
29.902
1.00
21.48
A

C

ATOM
317
CD1
TYR
A
56
47.213
30.541
30.318
1.00
23.38
A

C

ATOM
318
CE1
TYR
A
56
46.237
29.832
31.013
1.00
25.16
A

C

ATOM
319
CD2
TYR
A
56
45.766
32.459
30.198
1.00
22.53
A

C

ATOM
320
CE2
TYR
A
56
44.773
31.761
30.898
1.00
23.90
A

C

ATOM
321
CZ
TYR
A
56
45.019
30.445
31.303
1.00
26.15
A

C

ATOM
322
OH
TYR
A
56
44.065
29.738
32.003
1.00
26.91
A

O

ATOM
323
C
TYR
A
56
50.450
33.345
29.243
1.00
16.78
A

C

ATOM
324
O
TYR
A
56
51.235
32.530
28.754
1.00
18.53
A

O

ATOM
325
N
LEU
A
57
50.543
34.656
29.065
1.00
15.78
A

N

ATOM
326
CA
LEU
A
57
51.619
35.252
28.300
1.00
13.13
A

C

ATOM
327
CB
LEU
A
57
51.348
36.749
28.171
1.00
11.95
A

C

ATOM
328
CG
LEU
A
57
51.232
37.364
26.771
1.00
13.21
A

C

ATOM
329
CD1
LEU
A
57
50.535
36.422
25.805
1.00
10.11
A

C

ATOM
330
CD2
LEU
A
57
50.491
38.694
26.888
1.00
10.01
A

C

ATOM
331
C
LEU
A
57
52.922
34.973
29.074
1.00
12.23
A

C

ATOM
332
O
LEU
A
57
53.974
34.734
28.477
1.00
9.19
A

O

ATOM
333
N
GLY
A
58
52.824
34.984
30.404
1.00
11.88
A

N

ATOM
334
CA
GLY
A
58
53.969
34.719
31.249
1.00
14.46
A

C

ATOM
335
C
GLY
A
58
54.403
33.278
31.089
1.00
17.50
A

C

ATOM
336
O
GLY
A
58
55.594
32.988
30.928
1.00
18.69
A

O

ATOM
337
N
GLN
A
59
53.435
32.368
31.132
1.00
18.46
A

N

ATOM
338
CA
GLN
A
59
53.728
30.958
30.975
1.00
19.45
A

C

ATOM
339
CB
GLN
A
59
52.463
30.128
31.161
1.00
22.28
A

C

ATOM
340
CG
GLN
A
59
51.877
30.260
32.549
1.00
24.82
A

C

ATOM
341
CD
GLN
A
59
52.956
30.214
33.619
1.00
25.90
A

C

ATOM
342
OE1
GLN
A
59
53.655
29.212
33.768
1.00
26.11
A

O

ATOM
343
NE2
GLN
A
59
53.104
31.312
34.361
1.00
26.90
A

N

ATOM
344
C
GLN
A
59
54.299
30.729
29.592
1.00
19.50
A

C

ATOM
345
O
GLN
A
59
55.218
29.927
29.410
1.00
20.93
A

O

ATOM
346
N
TYR
A
60
53.765
31.450
28.616
1.00
17.52
A

N

ATOM
347
CA
TYR
A
60
54.239
31.315
27.252
1.00
18.33
A

C

ATOM
348
CB
TYR
A
60
53.432
32.220
26.317
1.00
14.85
A

C

ATOM
349
CG
TYR
A
60
53.776
32.069
24.845
1.00
15.47
A

C

ATOM
350
CD1
TYR
A
60
53.279
31.001
24.089
1.00
14.63
A

C

ATOM
351
CE1
TYR
A
60
53.581
30.873
22.716
1.00
11.14
A

C

ATOM
352
CD2
TYR
A
60
54.594
33.007
24.196
1.00
15.88
A

C

ATOM
353
CE2
TYR
A
60
54.902
32.886
22.826
1.00
13.26
A

C

ATOM
354
CZ
TYR
A
60
54.391
31.818
22.096
1.00
12.81
A

C

ATOM
355
OH
TYR
A
60
54.678
31.716
20.748
1.00
10.53
A

O

ATOM
356
C
TYR
A
60
55.728
31.664
27.158
1.00
20.42
A

C

ATOM
357
O
TYR
A
60
56.557
30.793
26.871
1.00
19.39
A

O

ATOM
358
N
ILE
A
61
56.069
32.928
27.418
1.00
21.45
A

N

ATOM
359
CA
ILE
A
61
57.458
33.361
27.319
1.00
23.11
A

C

ATOM
360
CB
ILE
A
61
57.624
34.874
27.588
1.00
22.76
A

C

ATOM
361
CG2
ILE
A
61
56.939
35.682
26.499
1.00
23.31
A

C

ATOM
362
CG1
ILE
A
61
57.085
35.230
28.965
1.00
22.24
A

C

ATOM
363
CD1
ILE
A
61
57.384
36.655
29.349
1.00
23.32
A

C

ATOM
364
C
ILE
A
61
58.410
32.604
28.235
1.00
25.11
A

C

ATOM
365
O
ILE
A
61
59.573
32.396
27.899
1.00
25.25
A

O

ATOM
366
N
MET
A
62
57.931
32.186
29.393
1.00
27.56
A

N

ATOM
367
CA
MET
A
62
58.797
31.452
30.293
1.00
30.23
A

C

ATOM
368
CB
MET
A
62
58.158
31.371
31.680
1.00
32.88
A

C

ATOM
369
CG
MET
A
62
59.042
30.734
32.738
1.00
34.56
A

C

ATOM
370
SD
MET
A
62
58.113
29.481
33.637
1.00
39.80
A

S

ATOM
371
CE
MET
A
62
58.272
28.115
32.471
1.00
35.55
A

C

ATOM
372
C
MET
A
62
59.064
30.043
29.737
1.00
31.22
A

C

ATOM
373
O
MET
A
62
60.218
29.656
29.513
1.00
30.54
A

O

ATOM
374
N
THR
A
63
57.997
29.291
29.483
1.00
31.07
A

N

ATOM
375
CA
THR
A
63
58.150
27.931
28.976
1.00
31.77
A

C

ATOM
376
CB
THR
A
63
56.775
27.264
28.687
1.00
30.74
A

C

ATOM
377
OG1
THR
A
63
56.009
28.092
27.808
1.00
31.02
A

O

ATOM
378
CG2
THR
A
63
56.004
27.044
29.982
1.00
31.19
A

C

ATOM
379
C
THR
A
63
59.023
27.823
27.724
1.00
32.00
A

C

ATOM
380
O
THR
A
63
59.890
26.947
27.645
1.00
33.74
A

O

ATOM
381
N
LYS
A
64
58.797
28.697
26.747
1.00
30.45
A

N

ATOM
382
CA
LYS
A
64
59.578
28.655
25.522
1.00
29.14
A

C

ATOM
383
CB
LYS
A
64
58.783
29.262
24.363
1.00
28.22
A

C

ATOM
384
CG
LYS
A
64
57.581
28.437
23.947
1.00
26.54
A

C

ATOM
385
CD
LYS
A
64
56.870
29.029
22.738
1.00
26.08
A

C

ATOM
386
CE
LYS
A
64
57.757
29.029
21.514
1.00
26.73
A

C

ATOM
387
NZ
LYS
A
64
57.043
29.526
20.308
1.00
26.87
A

N

ATOM
388
C
LYS
A
64
60.926
29.358
25.674
1.00
29.64
A

C

ATOM
389
O
LYS
A
64
61.640
29.574
24.695
1.00
28.68
A

O

ATOM
390
N
ARG
A
65
61.264
29.716
26.909
1.00
31.08
A

N

ATOM
391
CA
ARG
A
65
62.541
30.359
27.206
1.00
31.77
A

C

ATOM
392
CB
ARG
A
65
63.624
29.278
27.281
1.00
32.61
A

C

ATOM
393
CG
ARG
A
65
63.422
28.319
28.456
1.00
36.27
A

C

ATOM
394
CD
ARG
A
65
64.128
26.980
28.268
1.00
38.75
A

C

ATOM
395
NE
ARG
A
65
63.951
26.108
29.433
1.00
41.50
A

N

ATOM
396
CZ
ARG
A
65
64.107
24.782
29.425
1.00
43.14
A

C

ATOM
397
NH1
ARG
A
65
64.444
24.144
28.308
1.00
43.25
A

N

ATOM
398
NH2
ARG
A
65
63.923
24.087
30.540
1.00
41.34
A

N

ATOM
399
C
ARG
A
65
62.931
31.442
26.193
1.00
30.62
A

C

ATOM
400
O
ARG
A
65
63.990
31.365
25.562
1.00
31.11
A

O

ATOM
401
N
LEU
A
66
62.069
32.447
26.043
1.00
27.85
A

N

ATOM
402
CA
LEU
A
66
62.315
33.554
25.117
1.00
24.57
A

C

ATOM
403
CB
LEU
A
66
60.996
34.080
24.535
1.00
21.73
A

C

ATOM
404
CG
LEU
A
66
60.195
33.192
23.588
1.00
18.58
A

C

ATOM
405
CD1
LEU
A
66
58.917
33.893
23.171
1.00
16.38
A

C

ATOM
406
CD2
LEU
A
66
61.039
32.882
22.373
1.00
16.78
A

C

ATOM
407
C
LEU
A
66
63.023
34.696
25.829
1.00
24.06
A

C

ATOM
408
O
LEU
A
66
63.334
35.715
25.221
1.00
22.74
A

O

ATOM
409
N
TYR
A
67
63.255
34.535
27.127
1.00
25.28
A

N

ATOM
410
CA
TYR
A
67
63.931
35.569
27.900
1.00
26.02
A

C

ATOM
411
CB
TYR
A
67
63.406
35.580
29.344
1.00
26.69
A

C

ATOM
412
CG
TYR
A
67
63.546
34.267
30.069
1.00
26.95
A

C

ATOM
413
CD1
TYR
A
67
64.668
34.000
30.850
1.00
27.52
A

C

ATOM
414
CE1
TYR
A
67
64.836
32.770
31.469
1.00
27.15
A

C

ATOM
415
CD2
TYR
A
67
62.587
33.269
29.928
1.00
26.57
A

C

ATOM
416
CE2
TYR
A
67
62.742
32.031
30.544
1.00
27.84
A

C

ATOM
417
CZ
TYR
A
67
63.875
31.787
31.312
1.00
27.23
A

C

ATOM
418
OH
TYR
A
67
64.068
30.554
31.888
1.00
24.32
A

O

ATOM
419
C
TYR
A
67
65.443
35.347
27.857
1.00
26.40
A

C

ATOM
420
O
TYR
A
67
65.917
34.216
27.828
1.00
25.07
A

O

ATOM
421
N
ASP
A
68
66.194
36.440
27.837
1.00
28.69
A

N

ATOM
422
CA
ASP
A
68
67.645
36.365
27.764
1.00
31.43
A

C

ATOM
423
CB
ASP
A
68
68.222
37.737
27.411
1.00
31.86
A

C

ATOM
424
CG
ASP
A
68
69.688
37.666
27.043
1.00
31.50
A

C

ATOM
425
OD1
ASP
A
68
69.997
37.105
25.972
1.00
29.47
A

O

ATOM
426
OD2
ASP
A
68
70.526
38.154
27.833
1.00
33.11
A

O

ATOM
427
C
ASP
A
68
68.313
35.848
29.035
1.00
33.44
A

C

ATOM
428
O
ASP
A
68
67.871
36.128
30.152
1.00
33.12
A

O

ATOM
429
N
GLU
A
69
69.399
35.105
28.845
1.00
36.37
A

N

ATOM
430
CA
GLU
A
69
70.152
34.529
29.950
1.00
39.07
A

C

ATOM
431
CB
GLU
A
69
71.214
33.558
29.420
1.00
42.56
A

C

ATOM
432
CG
GLU
A
69
70.627
32.277
28.851
1.00
48.37
A

C

ATOM
433
CD
GLU
A
69
69.565
31.677
29.766
1.00
51.95
A

C

ATOM
434
OE1
GLU
A
69
69.848
31.514
30.974
1.00
54.24
A

O

ATOM
435
OE2
GLU
A
69
68.449
31.370
29.281
1.00
54.25
A

O

ATOM
436
C
GLU
A
69
70.810
35.566
30.837
1.00
38.35
A

C

ATOM
437
O
GLU
A
69
70.695
35.506
32.057
1.00
38.84
A

O

ATOM
438
N
LYS
A
70
71.504
36.519
30.235
1.00
38.42
A

N

ATOM
439
CA
LYS
A
70
72.162
37.542
31.030
1.00
38.82
A

C

ATOM
440
CB
LYS
A
70
73.285
38.187
30.210
1.00
41.21
A

C

ATOM
441
CG
LYS
A
70
74.320
37.148
29.776
1.00
43.81
A

C

ATOM
442
CD
LYS
A
70
75.539
37.743
29.092
1.00
46.99
A

C

ATOM
443
CE
LYS
A
70
76.504
36.632
28.674
1.00
47.44
A

C

ATOM
444
NZ
LYS
A
70
77.794
37.156
28.143
1.00
48.71
A

N

ATOM
445
C
LYS
A
70
71.121
38.554
31.494
1.00
37.27
A

C

ATOM
446
O
LYS
A
70
70.854
38.673
32.690
1.00
36.92
A

O

ATOM
447
N
GLN
A
71
70.512
39.262
30.551
1.00
35.72
A

N

ATOM
448
CA
GLN
A
71
69.476
40.228
30.893
1.00
33.41
A

C

ATOM
449
CB
GLN
A
71
69.478
41.365
29.878
1.00
34.05
A

C

ATOM
450
CG
GLN
A
71
70.781
42.116
29.818
1.00
35.15
A

C

ATOM
451
CD
GLN
A
71
70.728
43.264
28.839
1.00
36.85
A

C

ATOM
452
OE1
GLN
A
71
70.697
43.062
27.621
1.00
37.63
A

O

ATOM
453
NE2
GLN
A
71
70.701
44.482
29.364
1.00
38.20
A

N

ATOM
454
C
GLN
A
71
68.115
39.512
30.898
1.00
31.00
A

C

ATOM
455
O
GLN
A
71
67.412
39.466
29.883
1.00
31.06
A

O

ATOM
456
N
GLN
A
72
67.754
38.957
32.051
1.00
27.04
A

N

ATOM
457
CA
GLN
A
72
66.505
38.216
32.200
1.00
23.77
A

C

ATOM
458
CB
GLN
A
72
66.437
37.583
33.592
1.00
21.94
A

C

ATOM
459
CG
GLN
A
72
65.172
36.783
33.877
1.00
19.04
A

C

ATOM
460
CD
GLN
A
72
65.343
35.849
35.066
1.00
18.27
A

C

ATOM
461
OE1
GLN
A
72
66.141
34.917
35.018
1.00
16.43
A

O

ATOM
462
NE2
GLN
A
72
64.600
36.098
36.137
1.00
19.03
A

N

ATOM
463
C
GLN
A
72
65.231
39.003
31.936
1.00
21.79
A

C

ATOM
464
O
GLN
A
72
64.255
38.438
31.464
1.00
20.39
A

O

ATOM
465
N
HIS
A
73
65.234
40.300
32.226
1.00
21.17
A

N

ATOM
466
CA
HIS
A
73
64.039
41.103
32.004
1.00
19.46
A

C

ATOM
467
CB
HIS
A
73
64.143
42.440
32.738
1.00
19.40
A

C

ATOM
468
CG
HIS
A
73
65.242
43.328
32.244
1.00
21.41
A

C

ATOM
469
CD2
HIS
A
73
66.560
43.376
32.556
1.00
21.24
A

C

ATOM
470
ND1
HIS
A
73
65.029
44.339
31.331
1.00
22.42
A

N

ATOM
471
CE1
HIS
A
73
66.167
44.972
31.104
1.00
21.05
A

C

ATOM
472
NE2
HIS
A
73
67.111
44.406
31.836
1.00
21.25
A

N

ATOM
473
C
HIS
A
73
63.772
41.338
30.526
1.00
20.37
A

C

ATOM
474
O
HIS
A
73
62.667
41.747
30.156
1.00
19.89
A

O

ATOM
475
N
ILE
A
74
64.774
41.083
29.681
1.00
19.94
A

N

ATOM
476
CA
ILE
A
74
64.607
41.259
28.239
1.00
19.76
A

C

ATOM
477
CB
ILE
A
74
65.942
41.605
27.523
1.00
20.27
A

C

ATOM
478
CG2
ILE
A
74
65.699
41.745
26.022
1.00
18.27
A

C

ATOM
479
CG1
ILE
A
74
66.536
42.906
28.072
1.00
22.09
A

C

ATOM
480
CD1
ILE
A
74
65.704
44.127
27.810
1.00
22.98
A

C

ATOM
481
C
ILE
A
74
64.060
39.970
27.611
1.00
19.56
A

C

ATOM
482
O
ILE
A
74
64.555
38.875
27.885
1.00
19.09
A

O

ATOM
483
N
VAL
A
75
63.045
40.115
26.764
1.00
17.84
A

N

ATOM
484
CA
VAL
A
75
62.429
38.982
26.087
1.00
16.49
A

C

ATOM
485
CB
VAL
A
75
60.918
38.928
26.388
1.00
14.74
A

C

ATOM
486
CG1
VAL
A
75
60.245
37.892
25.529
1.00
13.12
A

C

ATOM
487
CG2
VAL
A
75
60.707
38.602
27.852
1.00
15.39
A

C

ATOM
488
C
VAL
A
75
62.650
39.136
24.588
1.00
17.78
A

C

ATOM
489
O
VAL
A
75
62.249
40.140
23.995
1.00
17.51
A

O

ATOM
490
N
TYR
A
76
63.302
38.150
23.977
1.00
17.97
A

N

ATOM
491
CA
TYR
A
76
63.570
38.201
22.544
1.00
18.96
A

C

ATOM
492
CB
TYR
A
76
64.958
37.622
22.229
1.00
20.36
A

C

ATOM
493
CG
TYR
A
76
66.085
38.507
22.713
1.00
22.91
A

C

ATOM
494
CD1
TYR
A
76
66.677
38.306
23.966
1.00
22.46
A

C

ATOM
495
CE1
TYR
A
76
67.685
39.168
24.438
1.00
24.23
A

C

ATOM
496
CD2
TYR
A
76
66.525
39.587
21.942
1.00
23.56
A

C

ATOM
497
CE2
TYR
A
76
67.532
40.457
22.408
1.00
23.98
A

C

ATOM
498
CZ
TYR
A
76
68.102
40.242
23.653
1.00
23.95
A

C

ATOM
499
OH
TYR
A
76
69.065
41.112
24.120
1.00
24.89
A

O

ATOM
500
C
TYR
A
76
62.499
37.438
21.801
1.00
17.43
A

C

ATOM
501
O
TYR
A
76
62.277
36.273
22.074
1.00
18.57
A

O

ATOM
502
N
CYS
A
77
61.841
38.094
20.850
1.00
19.17
A

N

ATOM
503
CA
CYS
A
77
60.755
37.458
20.100
1.00
20.17
A

C

ATOM
504
CB
CYS
A
77
59.410
37.978
20.628
1.00
18.05
A

C

ATOM
505
SG
CYS
A
77
59.288
39.802
20.678
1.00
17.89
A

S

ATOM
506
C
CYS
A
77
60.792
37.612
18.575
1.00
20.92
A

C

ATOM
507
O
CYS
A
77
59.817
37.293
17.902
1.00
22.93
A

O

ATOM
508
N
SER
A
78
61.904
38.083
18.027
1.00
21.73
A

N

ATOM
509
CA
SER
A
78
62.002
38.261
16.582
1.00
23.67
A

C

ATOM
510
CB
SER
A
78
63.369
38.828
16.209
1.00
23.31
A

C

ATOM
511
OG
SER
A
78
64.394
38.058
16.804
1.00
24.57
A

O

ATOM
512
C
SER
A
78
61.754
36.978
15.791
1.00
24.32
A

C

ATOM
513
O
SER
A
78
61.341
37.039
14.632
1.00
24.57
A

O

ATOM
514
N
ASN
A
79
62.003
35.824
16.403
1.00
23.65
A

N

ATOM
515
CA
ASN
A
79
61.794
34.553
15.709
1.00
24.00
A

C

ATOM
516
CB
ASN
A
79
63.081
33.709
15.694
1.00
24.75
A

C

ATOM
517
CG
ASN
A
79
64.160
34.293
14.792
1.00
25.05
A

C

ATOM
518
OD1
ASN
A
79
65.059
34.994
15.254
1.00
25.04
A

O

ATOM
519
ND2
ASN
A
79
64.064
34.015
13.495
1.00
25.70
A

N

ATOM
520
C
ASN
A
79
60.668
33.742
16.343
1.00
23.53
A

C

ATOM
521
O
ASN
A
79
60.753
32.512
16.451
1.00
23.89
A

O

ATOM
522
N
ASP
A
80
59.612
34.437
16.747
1.00
21.43
A

N

ATOM
523
CA
ASP
A
80
58.472
33.797
17.381
1.00
20.47
A

C

ATOM
524
CB
ASP
A
80
58.658
33.789
18.907
1.00
20.36
A

C

ATOM
525
CG
ASP
A
80
57.567
33.022
19.626
1.00
20.02
A

C

ATOM
526
OD1
ASP
A
80
57.870
31.966
20.215
1.00
20.17
A

O

ATOM
527
OD2
ASP
A
80
56.404
33.469
19.597
1.00
20.97
A

O

ATOM
528
C
ASP
A
80
57.193
34.542
17.024
1.00
20.46
A

C

ATOM
529
O
ASP
A
80
57.218
35.752
16.742
1.00
20.32
A

O

ATOM
530
N
LEU
A
81
56.078
33.812
17.034
1.00
19.74
A

N

ATOM
531
CA
LEU
A
81
54.766
34.379
16.725
1.00
19.05
A

C

ATOM
532
CB
LEU
A
81
53.685
33.351
17.047
1.00
20.17
A

C

ATOM
533
CG
LEU
A
81
52.228
33.802
17.023
1.00
23.86
A

C

ATOM
534
CD1
LEU
A
81
51.870
34.357
15.650
1.00
24.25
A

C

ATOM
535
CD2
LEU
A
81
51.339
32.608
17.378
1.00
24.57
A

C

ATOM
536
C
LEU
A
81
54.537
35.657
17.539
1.00
17.50
A

C

ATOM
537
O
LEU
A
81
54.022
36.656
17.027
1.00
15.88
A

O

ATOM
538
N
LEU
A
82
54.948
35.604
18.805
1.00
14.87
A

N

ATOM
539
CA
LEU
A
82
54.821
36.718
19.734
1.00
12.91
A

C

ATOM
540
CB
LEU
A
82
55.545
36.376
21.049
1.00
11.35
A

C

ATOM
541
CG
LEU
A
82
55.603
37.457
22.138
1.00
10.75
A

C

ATOM
542
CD1
LEU
A
82
54.187
37.899
22.505
1.00
10.31
A

C

ATOM
543
CD2
LEU
A
82
56.344
36.922
23.354
1.00
9.38
A

C

ATOM
544
C
LEU
A
82
55.374
38.023
19.157
1.00
12.97
A

C

ATOM
545
O
LEU
A
82
54.738
39.083
19.263
1.00
9.83
A

O

ATOM
546
N
GLY
A
83
56.561
37.944
18.557
1.00
12.95
A

N

ATOM
547
CA
GLY
A
83
57.163
39.129
17.980
1.00
15.06
A

C

ATOM
548
C
GLY
A
83
56.238
39.761
16.951
1.00
16.77
A

C

ATOM
549
O
GLY
A
83
56.060
40.980
16.919
1.00
15.55
A

O

ATOM
550
N
ASP
A
84
55.635
38.924
16.112
1.00
18.65
A

N

ATOM
551
CA
ASP
A
84
54.742
39.412
15.078
1.00
21.41
A

C

ATOM
552
CB
ASP
A
84
54.347
38.272
14.141
1.00
25.41
A

C

ATOM
553
CG
ASP
A
84
55.547
37.604
13.507
1.00
28.55
A

C

ATOM
554
OD1
ASP
A
84
56.489
38.335
13.100
1.00
27.94
A

O

ATOM
555
OD2
ASP
A
84
55.539
36.354
13.412
1.00
30.30
A

O

ATOM
556
C
ASP
A
84
53.491
40.055
15.650
1.00
21.92
A

C

ATOM
557
O
ASP
A
84
53.065
41.104
15.173
1.00
22.99
A

O

ATOM
558
N
LEU
A
85
52.906
39.428
16.666
1.00
21.04
A

N

ATOM
559
CA
LEU
A
85
51.697
39.955
17.288
1.00
22.00
A

C

ATOM
560
CB
LEU
A
85
51.092
38.915
18.240
1.00
21.98
A

C

ATOM
561
CG
LEU
A
85
50.821
37.544
17.609
1.00
23.19
A

C

ATOM
562
CD1
LEU
A
85
50.177
36.593
18.628
1.00
20.96
A

C

ATOM
563
CD2
LEU
A
85
49.923
37.734
16.390
1.00
22.60
A

C

ATOM
564
C
LEU
A
85
51.979
41.258
18.039
1.00
21.67
A

C

ATOM
565
O
LEU
A
85
51.122
42.143
18.102
1.00
20.70
A

O

ATOM
566
N
PHE
A
86
53.182
41.376
18.597
1.00
21.86
A

N

ATOM
567
CA
PHE
A
86
53.565
42.579
19.338
1.00
20.91
A

C

ATOM
568
CB
PHE
A
86
54.531
42.224
20.470
1.00
19.44
A

C

ATOM
569
CG
PHE
A
86
53.852
41.763
21.741
1.00
16.86
A

C

ATOM
570
CD1
PHE
A
86
52.508
41.381
21.742
1.00
15.83
A

C

ATOM
571
CD2
PHE
A
86
54.564
41.710
22.936
1.00
14.83
A

C

ATOM
572
CE1
PHE
A
86
51.878
40.952
22.914
1.00
14.04
A

C

ATOM
573
CE2
PHE
A
86
53.949
41.281
24.119
1.00
18.00
A

C

ATOM
574
CZ
PHE
A
86
52.596
40.902
24.105
1.00
16.08
A

C

ATOM
575
C
PHE
A
86
54.211
43.604
18.416
1.00
22.21
A

C

ATOM
576
O
PHE
A
86
54.233
44.797
18.714
1.00
23.98
A

O

ATOM
577
N
GLY
A
87
54.728
43.140
17.284
1.00
22.25
A

N

ATOM
578
CA
GLY
A
87
55.360
44.055
16.356
1.00
20.93
A

C

ATOM
579
C
GLY
A
87
56.711
44.578
16.820
1.00
20.93
A

C

ATOM
580
O
GLY
A
87
57.055
45.731
16.534
1.00
22.00
A

O

ATOM
581
N
VAL
A
88
57.471
43.752
17.542
1.00
18.42
A

N

ATOM
582
CA
VAL
A
88
58.802
44.136
18.014
1.00
16.75
A

C

ATOM
583
CB
VAL
A
88
58.791
44.793
19.420
1.00
16.55
A

C

ATOM
584
CG1
VAL
A
88
57.951
46.054
19.405
1.00
15.93
A

C

ATOM
585
CG2
VAL
A
88
58.312
43.795
20.462
1.00
13.35
A

C

ATOM
586
C
VAL
A
88
59.695
42.911
18.100
1.00
16.74
A

C

ATOM
587
O
VAL
A
88
59.215
41.792
18.273
1.00
16.22
A

O

ATOM
588
N
PRO
A
89
61.013
43.114
17.978
1.00
16.36
A

N

ATOM
589
CD
PRO
A
89
61.636
44.398
17.606
1.00
17.10
A

C

ATOM
590
CA
PRO
A
89
62.013
42.042
18.040
1.00
16.05
A

C

ATOM
591
CB
PRO
A
89
63.221
42.659
17.344
1.00
15.83
A

C

ATOM
592
CG
PRO
A
89
63.124
44.096
17.747
1.00
18.07
A

C

ATOM
593
C
PRO
A
89
62.322
41.623
19.476
1.00
16.21
A

C

ATOM
594
O
PRO
A
89
62.832
40.522
19.715
1.00
15.73
A

O

ATOM
595
N
SER
A
90
62.009
42.505
20.425
1.00
15.13
A

N

ATOM
596
CA
SER
A
90
62.243
42.232
21.843
1.00
14.02
A

C

ATOM
597
CB
SER
A
90
63.738
42.128
22.130
1.00
12.56
A

C

ATOM
598
OG
SER
A
90
64.336
43.403
21.986
1.00
13.74
A

O

ATOM
599
C
SER
A
90
61.652
43.350
22.702
1.00
12.89
A

C

ATOM
600
O
SER
A
90
61.331
44.422
22.192
1.00
12.05
A

O

ATOM
601
N
PHE
A
91
61.517
43.091
24.001
1.00
11.19
A

N

ATOM
602
CA
PHE
A
91
60.972
44.069
24.926
1.00
11.45
A

C

ATOM
603
CB
PHE
A
91
59.439
44.173
24.759
1.00
10.33
A

C

ATOM
604
CG
PHE
A
91
58.705
42.895
25.039
1.00
8.05
A

C

ATOM
605
CD1
PHE
A
91
58.263
42.598
26.325
1.00
7.52
A

C

ATOM
606
CD2
PHE
A
91
58.496
41.961
24.024
1.00
7.09
A

C

ATOM
607
CE1
PHE
A
91
57.620
41.373
26.605
1.00
7.90
A

C

ATOM
608
CE2
PHE
A
91
57.859
40.739
24.287
1.00
7.31
A

C

ATOM
609
CZ
PHE
A
91
57.419
40.445
25.588
1.00
7.15
A

C

ATOM
610
C
PHE
A
91
61.327
43.737
26.373
1.00
13.35
A

C

ATOM
611
O
PHE
A
91
61.795
42.632
26.685
1.00
12.34
A

O

ATOM
612
N
SER
A
92
61.102
44.708
27.254
1.00
14.78
A

N

ATOM
613
CA
SER
A
92
61.398
44.547
28.667
1.00
16.74
A

C

ATOM
614
CB
SER
A
92
62.086
45.809
29.203
1.00
15.00
A

C

ATOM
615
OG
SER
A
92
62.293
45.719
30.607
1.00
15.51
A

O

ATOM
616
C
SER
A
92
60.148
44.254
29.499
1.00
18.09
A

C

ATOM
617
O
SER
A
92
59.156
44.978
29.422
1.00
17.05
A

O

ATOM
618
N
VAL
A
93
60.206
43.189
30.295
1.00
19.76
A

N

ATOM
619
CA
VAL
A
93
59.094
42.822
31.163
1.00
21.70
A

C

ATOM
620
CB
VAL
A
93
59.322
41.442
31.866
1.00
22.34
A

C

ATOM
621
CG1
VAL
A
93
59.380
40.329
30.828
1.00
22.82
A

C

ATOM
622
CG2
VAL
A
93
60.606
41.462
32.683
1.00
20.47
A

C

ATOM
623
C
VAL
A
93
58.891
43.884
32.239
1.00
22.48
A

C

ATOM
624
O
VAL
A
93
58.089
43.702
33.140
1.00
24.56
A

O

ATOM
625
N
LYS
A
94
59.618
44.991
32.146
1.00
24.37
A

N

ATOM
626
CA
LYS
A
94
59.494
46.078
33.121
1.00
26.51
A

C

ATOM
627
CB
LYS
A
94
60.873
46.623
33.515
1.00
27.71
A

C

ATOM
628
CG
LYS
A
94
61.581
45.888
34.659
1.00
30.96
A

C

ATOM
629
CD
LYS
A
94
62.965
46.516
34.914
1.00
33.87
A

C

ATOM
630
CE
LYS
A
94
63.695
45.915
36.127
1.00
35.49
A

C

ATOM
631
NZ
LYS
A
94
65.052
46.534
36.343
1.00
35.43
A

N

ATOM
632
C
LYS
A
94
58.655
47.232
32.579
1.00
26.44
A

C

ATOM
633
O
LYS
A
94
58.156
48.054
33.342
1.00
27.30
A

O

ATOM
634
N
GLU
A
95
58.522
47.305
31.259
1.00
25.84
A

N

ATOM
635
CA
GLU
A
95
57.747
48.361
30.620
1.00
25.31
A

C

ATOM
636
CB
GLU
A
95
58.317
48.651
29.231
1.00
26.45
A

C

ATOM
637
CG
GLU
A
95
59.798
49.016
29.200
1.00
28.64
A

C

ATOM
638
CD
GLU
A
95
60.081
50.452
29.615
1.00
30.17
A

C

ATOM
639
OE1
GLU
A
95
59.138
51.277
29.622
1.00
31.51
A

O

ATOM
640
OE2
GLU
A
95
61.257
50.759
29.917
1.00
28.42
A

O

ATOM
641
C
GLU
A
95
56.286
47.904
30.500
1.00
24.66
A

C

ATOM
642
O
GLU
A
95
55.776
47.667
29.398
1.00
22.08
A

O

ATOM
643
N
HIS
A
96
55.619
47.799
31.647
1.00
24.62
A

N

ATOM
644
CA
HIS
A
96
54.234
47.348
31.702
1.00
26.26
A

C

ATOM
645
CB
HIS
A
96
53.694
47.452
33.132
1.00
27.90
A

C

ATOM
646
CG
HIS
A
96
54.457
46.635
34.128
1.00
30.90
A

C

ATOM
647
CD2
HIS
A
96
55.784
46.395
34.257
1.00
31.52
A

C

ATOM
648
ND1
HIS
A
96
53.844
45.963
35.164
1.00
32.30
A

N

ATOM
649
CE1
HIS
A
96
54.761
45.345
35.887
1.00
32.43
A

C

ATOM
650
NE2
HIS
A
96
55.947
45.591
35.358
1.00
32.16
A

N

ATOM
651
C
HIS
A
96
53.279
48.052
30.747
1.00
26.13
A

C

ATOM
652
O
HIS
A
96
52.436
47.400
30.136
1.00
26.36
A

O

ATOM
653
N
ARG
A
97
53.403
49.370
30.618
1.00
25.66
A

N

ATOM
654
CA
ARG
A
97
52.522
50.123
29.728
1.00
25.19
A

C

ATOM
655
CB
ARG
A
97
52.708
51.639
29.953
1.00
25.74
A

C

ATOM
656
CG
ARG
A
97
51.909
52.562
29.031
1.00
24.90
A

C

ATOM
657
CD
ARG
A
97
50.440
52.148
28.919
1.00
27.96
A

C

ATOM
658
NE
ARG
A
97
49.677
52.294
30.157
1.00
29.51
A

N

ATOM
659
CZ
ARG
A
97
48.450
51.804
30.337
1.00
29.81
A

C

ATOM
660
NH1
ARG
A
97
47.849
51.133
29.359
1.00
31.04
A

N

ATOM
661
NH2
ARG
A
97
47.817
51.986
31.489
1.00
27.76
A

N

ATOM
662
C
ARG
A
97
52.758
49.745
28.262
1.00
24.39
A

C

ATOM
663
O
ARG
A
97
51.805
49.623
27.497
1.00
25.23
A

O

ATOM
664
N
LYS
A
98
54.010
49.547
27.865
1.00
23.55
A

N

ATOM
665
CA
LYS
A
98
54.288
49.166
26.480
1.00
23.84
A

C

ATOM
666
CB
LYS
A
98
55.800
49.167
26.195
1.00
25.86
A

C

ATOM
667
CG
LYS
A
98
56.406
50.558
26.039
1.00
29.53
A

C

ATOM
668
CD
LYS
A
98
57.892
50.512
25.693
1.00
31.47
A

C

ATOM
669
CE
LYS
A
98
58.519
51.909
25.794
1.00
33.99
A

C

ATOM
670
NZ
LYS
A
98
59.989
51.918
25.509
1.00
34.37
A

N

ATOM
671
C
LYS
A
98
53.708
47.779
26.170
1.00
23.22
A

C

ATOM
672
O
LYS
A
98
53.150
47.563
25.091
1.00
21.35
A

O

ATOM
673
N
ILE
A
99
53.844
46.846
27.115
1.00
21.20
A

N

ATOM
674
CA
ILE
A
99
53.323
45.496
26.938
1.00
20.16
A

C

ATOM
675
CB
ILE
A
99
53.723
44.584
28.130
1.00
18.26
A

C

ATOM
676
CG2
ILE
A
99
52.911
43.290
28.108
1.00
16.58
A

C

ATOM
677
CG1
ILE
A
99
55.227
44.283
28.063
1.00
16.19
A

C

ATOM
678
CD1
ILE
A
99
55.764
43.539
29.255
1.00
12.79
A

C

ATOM
679
C
ILE
A
99
51.799
45.545
26.802
1.00
21.79
A

C

ATOM
.680
O
ILE
A
99
51.217
44.909
25.919
1.00
21.34
A

O

ATOM
681
N
TYR
A
100
51.156
46.316
27.672
1.00
23.34
A

N

ATOM
682
CA
TYR
A
100
49.706
46.457
27.639
1.00
24.14
A

C

ATOM
683
CB
TYR
A
100
49.243
47.387
28.763
1.00
25.12
A

C

ATOM
684
CG
TYR
A
100
48.602
46.651
29.911
1.00
28.22
A

C

ATOM
685
CD1
TYR
A
100
49.336
45.739
30.681
1.00
28.65
A

C

ATOM
686
CE1
TYR
A
100
48.734
45.008
31.700
1.00
28.51
A

C

ATOM
687
CD2
TYR
A
100
47.248
46.817
30.196
1.00
28.65
A

C

ATOM
688
CE2
TYR
A
100
46.632
46.088
31.215
1.00
29.38
A

C

ATOM
689
CZ
TYR
A
100
47.380
45.187
31.957
1.00
29.62
A

C

ATOM
690
OH
TYR
A
100
46.766
44.450
32.938
1.00
31.04
A

O

ATOM
691
C
TYR
A
100
49.154
46.960
26.299
1.00
25.10
A

C

ATOM
692
O
TYR
A
100
48.138
46.446
25.812
1.00
25.32
A

O

ATOM
693
N
THR
A
101
49.798
47.956
25.693
1.00
23.58
A

N

ATOM
694
CA
THR
A
101
49.269
48.447
24.434
1.00
24.54
A

C

ATOM
695
CB
THR
A
101
49.683
49.926
24.162
1.00
25.48
A

C

ATOM
696
OG1
THR
A
101
51.085
50.021
23.920
1.00
26.87
A

O

ATOM
697
CG2
THR
A
101
49.330
50.786
25.361
1.00
27.33
A

C

ATOM
698
C
THR
A
101
49.627
47.539
23.259
1.00
23.52
A

C

ATOM
699
O
THR
A
101
49.034
47.642
22.188
1.00
24.28
A

O

ATOM
700
N
MET
A
102
50.585
46.636
23.450
1.00
22.80
A

N

ATOM
701
CA
MET
A
102
50.921
45.697
22.377
1.00
20.40
A

C

ATOM
702
CB
MET
A
102
52.321
45.109
22.567
1.00
15.37
A

C

ATOM
703
CG
MET
A
102
53.403
46.131
22.321
1.00
14.03
A

C

ATOM
704
SD
MET
A
102
55.075
45.483
22.349
1.00
11.93
A

S

ATOM
705
CE
MET
A
102
55.294
45.184
24.125
1.00
10.87
A

C

ATOM
706
C
MET
A
102
49.863
44.592
22.392
1.00
19.65
A

C

ATOM
707
O
MET
A
102
49.528
44.017
21.356
1.00
19.47
A

O

ATOM
708
N
ILE
A
103
49.338
44.319
23.580
1.00
18.90
A

N

ATOM
709
CA
ILE
A
103
48.300
43.321
23.764
1.00
21.34
A

C

ATOM
710
CB
ILE
A
103
48.131
42.966
25.273
1.00
20.40
A

C

ATOM
711
CG2
ILE
A
103
46.835
42.185
25.497
1.00
19.03
A

C

ATOM
712
CG1
ILE
A
103
49.339
42.156
25.750
1.00
19.84
A

C

ATOM
713
CD1
ILE
A
103
49.457
42.046
27.259
1.00
18.82
A

C

ATOM
714
C
ILE
A
103
46.985
43.896
23.228
1.00
24.13
A

C

ATOM
715
O
ILE
A
103
46.189
43.185
22.612
1.00
24.18
A

O

ATOM
716
N
TYR
A
104
46.775
45.192
23.461
1.00
27.06
A

N

ATOM
717
CA
TYR
A
104
45.566
45.886
23.016
1.00
29.10
A

C

ATOM
718
CB
TYR
A
104
45.608
47.344
23.491
1.00
30.33
A

C

ATOM
719
CG
TYR
A
104
45.205
47.494
24.940
1.00
30.58
A

C

ATOM
720
CD1
TYR
A
104
45.775
48.469
25.754
1.00
29.56
A

C

ATOM
721
CE1
TYR
A
104
45.415
48.584
27.095
1.00
29.30
A

C

ATOM
722
CD2
TYR
A
104
44.259
46.638
25.502
1.00
31.51
A

C

ATOM
723
CE2
TYR
A
104
43.894
46.746
26.836
1.00
31.90
A

C

ATOM
724
CZ
TYR
A
104
44.476
47.718
27.625
1.00
30.22
A

C

ATOM
725
OH
TYR
A
104
44.113
47.801
28.947
1.00
32.03
A

O

ATOM
726
C
TYR
A
104
45.321
45.824
21.510
1.00
29.49
A

C

ATOM
727
O
TYR
A
104
44.173
45.769
21.067
1.00
30.07
A

O

ATOM
728
N
ARG
A
105
46.397
45.831
20.731
1.00
30.44
A

N

ATOM
729
CA
ARG
A
105
46.291
45.757
19.281
1.00
31.09
A

C

ATOM
730
CB
ARG
A
105
47.561
46.288
18.614
1.00
32.59
A

C

ATOM
731
CG
ARG
A
105
47.624
47.803
18.491
1.00
35.48
A

C

ATOM
732
CD
ARG
A
105
48.761
48.212
17.567
1.00
38.68
A

C

ATOM
733
NE
ARG
A
105
50.069
47.877
18.129
1.00
41.14
A

N

ATOM
734
CZ
ARG
A
105
50.806
48.712
18.859
1.00
42.11
A

C

ATOM
735
NH1
ARG
A
105
50.368
49.942
19.117
1.00
41.27
A

N

ATOM
736
NH2
ARG
A
105
51.984
48.317
19.333
1.00
42.61
A

N

ATOM
737
C
ARG
A
105
46.059
44.317
18.845
1.00
31.15
A

C

ATOM
738
O
ARG
A
105
45.919
44.040
17.649
1.00
30.58
A

O

ATOM
739
N
ASN
A
106
46.029
43.403
19.814
1.00
30.35
A

N

ATOM
740
CA
ASN
A
106
45.797
41.992
19.523
1.00
31.38
A

C

ATOM
741
CB
ASN
A
106
46.927
41.120
20.069
1.00
30.13
A

C

ATOM
742
CG
ASN
A
106
48.164
41.186
19.219
1.00
30.74
A

C

ATOM
743
OD1
ASN
A
106
48.957
42.126
19.327
1.00
30.89
A

O

ATOM
744
ND2
ASN
A
106
48.335
40.193
18.346
1.00
30.12
A

N

ATOM
745
C
ASN
A
106
44.480
41.497
20.087
1.00
32.04
A

C

ATOM
746
O
ASN
A
106
44.309
40.303
20.324
1.00
30.99
A

O

ATOM
747
N
LEU
A
107
43.543
42.409
20.297
1.00
34.74
A

N

ATOM
748
CA
LEU
A
107
42.257
42.009
20.834
1.00
39.45
A

C

ATOM
749
CB
LEU
A
107
42.392
41.716
22.335
1.00
39.46
A

C

ATOM
750
CG
LEU
A
107
43.091
42.738
23.238
1.00
38.61
A

C

ATOM
751
CD1
LEU
A
107
42.333
44.055
23.242
1.00
38.52
A

C

ATOM
752
CD2
LEU
A
107
43.181
42.176
24.647
1.00
37.16
A

C

ATOM
753
C
LEU
A
107
41.157
43.025
20.604
1.00
42.25
A

C

ATOM
754
O
LEU
A
107
41.327
43.993
19.859
1.00
42.75
A

O

ATOM
755
N
VAL
A
108
40.021
42.778
21.245
1.00
46.00
A

N

ATOM
756
CA
VAL
A
108
38.859
43.653
21.163
1.00
49.43
A

C

ATOM
757
CB
VAL
A
108
37.823
43.129
20.149
1.00
48.08
A

C

ATOM
758
CG1
VAL
A
108
37.030
44.290
19.594
1.00
48.02
A

C

ATOM
759
CG2
VAL
A
108
38.509
42.343
19.040
1.00
46.78
A

C

ATOM
760
C
VAL
A
108
38.216
43.671
22.555
1.00
53.19
A

C

ATOM
761
O
VAL
A
108
37.589
42.690
22.966
1.00
52.78
A

O

ATOM
762
N
VAL
A
109
38.386
44.778
23.280
1.00
57.34
A

N

ATOM
763
CA
VAL
A
109
37.829
44.921
24.630
1.00
61.10
A

C

ATOM
764
CB
VAL
A
109
38.035
46.351
25.191
1.00
61.46
A

C

ATOM
765
CG
VAL
A
109
37.715
46.367
26.683
1.00
61.63
A

C

ATOM
766
CG2
VAL
A
109
39.458
46.830
24.928
1.00
62.28
A

C

ATOM
767
C
VAL
A
109
36.326
44.631
24.662
1.00
63.47
A

C

ATOM
768
O
VAL
A
109
35.527
45.410
24.131
1.00
63.73
A

O

ATOM
769
N
VAL
A
110
35.947
43.518
25.293
1.00
65.46
A

N

ATOM
770
CA
VAL
A
110
34.542
43.127
25.392
1.00
67.21
A

C

ATOM
771
CB
VAL
A
110
34.366
41.919
26.365
1.00
66.97
A

C

ATOM
772
CG1
VAL
A
110
32.939
41.374
26.283
1.00
67.04
A

C

ATOM
773
CG2
VAL
A
110
35.371
40.825
26.033
1.00
66.24
A

C

ATOM
774
C
VAL
A
110
33.697
44.309
25.898
1.00
69.20
A

C

ATOM
775
O
VAL
A
110
34.287
45.249
26.488
1.00
69.94
A

O

ATOM
776
OXT
VAL
A
110
32.456
44.284
25.705
1.00
70.58
A

O

ATOM
777
C1
CID
A
1
55.200
42.184
33.980
1.00
21.13

INH1 C

ATOM
778
C2
CID
A
1
54.610
43.160
33.125
1.00
21.31

INH1 C

ATOM
779
C3
CID
A
1
53.194
43.197
32.974
1.00
21.72

INH1 C

ATOM
780
C4
CID
A
1
52.372
42.284
33.667
1.00
21.74

INH1 C

ATOM
781
C5
CID
A
1
52.953
41.311
34.515
1.00
21.42

INH1 C

ATOM
782
C6
CID
A
1
54.387
41.238
34.692
1.00
22.49

INH1 C

ATOM
783
C7
CID
A
1
55.092
40.168
35.590
1.00
23.66

INH1 C

ATOM
784
C8
CID
A
1
54.267
39.594
36.800
1.00
25.69

INH1 C

ATOM
785
O1
CID
A
1
54.677
38.706
37.544
1.00
29.01

INH1 O

ATOM
786
O2
CID
A
1
53.229
40.347
37.224
1.00
30.64

INH1 O

ATOM
787
N1
CID
A
1
55.591
39.038
34.674
1.00
19.99

INH1 N

ATOM
788
C9
CID
A
1
54.593
38.352
33.801
1.00
18.95

INH1 C

ATOM
789
C10
CID
A
1
54.631
38.684
32.289
1.00
18.04

INH1 C

ATOM
790
C11
CID
A
1
55.647
39.488
31.665
1.00
17.01

INH1 C

ATOM
791
C12
CID
A
1
55.614
39.775
30.286
1.00
16.97

INH1 C

ATOM
792
C13
CID
A
1
54.563
39.261
29.507
1.00
17.64

INH1 C

ATOM
793
CL1
CID
A
1
54.498
39.606
27.865
1.00
14.96

INH1CL

ATOM
794
C14
CID
A
1
53.550
38.464
30.083
1.00
18.96

INH1 C

ATOM
795
C15
CID
A
1
53.586
38.180
31.458
1.00
17.55

INH1 C

ATOM
796
C16
CID
A
1
54.559
36.817
34.087
1.00
18.08

INH1 C

ATOM
797
O3
CID
A
1
53.499
36.278
34.423
1.00
18.82

INH1 O

ATOM
798
N2
CID
A
1
55.695
36.036
33.977
1.00
16.78

INH1 N

ATOM
799
C17
CID
A
1
57.002
36.408
33.618
1.00
17.03

INH1 C

ATOM
800
C18
CID
A
1
57.616
37.644
33.943
1.00
16.70

INH1 C

ATOM
801
C19
CID
A
1
56.972
38.734
34.754
1.00
19.45

INH1 C

ATOM
802
O4
CID
A
1
57.728
39.367
35.532
1.00
18.52

INH1 O

ATOM
803
C20
CID
A
1
58.948
37.897
33.495
1.00
17.26

INH1 C

ATOM
804
C21
CID
A
1
59.660
36.940
32.750
1.00
18.91

INH1 C

ATOM
805
I1
CID
A
1
61.599
37.431
32.161
1.00
19.64

INH1 I

ATOM
806
C22
CID
A
1
59.069
35.711
32.436
1.00
17.86

INH1 C

ATOM
807
C23
CID
A
1
57.742
35.435
32.859
1.00
17.23

INH1 C

ATOM
808
CL2
CID
A
1
52.462
44.354
31.946
1.00
20.99

INH1CL

ATOM
809
CL3
CID
A
1
59.915
34.517
31.548
1.00
20.31

INH1CL

END

[0227]

6

TABLE 3

Superimposed: trigonal and tetragonal crystal forms

REMARK Superimposed on /xray1/hmdm2/PDB/M338437.pdb

REMARK The 19 atoms have an RMS distance of 0.249 A

REMARK RMS delta B = 6.724 A2

REMARK Estimated RMSD for 2 random proteins
= 5.398 A

REMARK Relative RMSD
= 0.04621

REMARK Normalised RMSD (100) = 1.471 A

REMARK coordinates from restrained individual B-factor refinement

REMARK refinement resolution: 25 − 2.6 A

REMARK starting
r = 0.2563
free_r = 0.2787

REMARK final
r = 0.2553
free_r = 0.2761

REMARK B rmsd for bonded mainchain atoms = 1.483 target = 1.5

REMARK B rmsd for bonded sidechain atoms = 1.740 target = 2.0

REMARK B rmsd for angle mainchain atoms = 2.593 target = 2.0

REMARK B rmsd for angle sidechain atoms = 2.780 target = 2.5

REMARK rweight = 0.1000 (with wa = 3.71696)

REMARK target = mlf steps = 30

REMARK sg = P4(3)2(1)2 a = 54.3 b = 54.3 c = 83.3 alpha = 90 beta = 90 gamma = 90

REMARK parameter file 1: MSI_CNX_TOPPAR: protein_rep.param

REMARK parameter file 2: ../cid.par

REMARK molecular structure file: recycle.psf

REMARK input coordinates: anneal_9.pdb

REMARK reflection file = ../M876273_2_P43212.cv

REMARK ncs = none

REMARK B-correction resolution: 6.0 − 2.6

REMARK initial B-factor correction applied to fobs:

REMARK
B11 =
−1.189
B22 =
−1.189
B33 =
2.379

REMARK
B12 =
0.000
B13 =
0.000
B23 =
0.000

REMARK B-factor correction applied to coordinate array B: −0.119

REMARK bulk solvent: (Mask) density level = 0.341945 e/A{circumflex over ( )}3, B-factor = 22.3925 A{circumflex over ( )}2

REMARK reflections with |Fobs|/sigma_F < 0.0 rejected

REMARK reflections with |Fobs| > 10000 * rms(Fobs) rejected

REMARK theoretical total number of refl.in resol.range: 4173 (100.0%)

REMARK number of unobserved reflections (no entry or |F| = 0): 9 (0.2%)

REMARK number of reflections rejected: 0 (0.0%)

REMARK total number of reflections used: 4164 (99.8%)

REMARK number of reflections in working set: 3737 (89.6%)

REMARK number of reflections in test set: 427 (10.2%)

REMARK FILENAME = “bindividual.pdb”

REMARK Written by CNX VERSION: 2000.12

ATOM
1
C
GLY
A
16
48.607
19.990
25.187
1.00
68.15
A

ATOM
2
O
GLY
A
16
48.239
21.106
24.797
1.00
68.22
A

ATOM
3
N
GLY
A
16
47.838
17.646
24.774
1.00
67.11
A

ATOM
4
CA
GLY
A
16
47.594
18.911
25.537
1.00
67.90
A

ATOM
5
N
SER
A
17
49.889
19.652
25.332
1.00
67.05
A

ATOM
6
CA
SER
A
17
50.986
20.568
25.025
1.00
64.73
A

ATOM
7
CB
SER
A
17
51.581
21.155
26.312
1.00
65.01
A

ATOM
8
OG
SER
A
17
50.639
21.978
26.989
1.00
63.84
A

ATOM
9
C
SER
A
17
52.053
19.794
24.258
1.00
62.82
A

ATOM
10
O
SER
A
17
52.921
20.382
23.611
1.00
62.75
A

ATOM
11
N
GLN
A
18
51.970
18.468
24.343
1.00
60.52
A

ATOM
12
CA
GLN
A
18
52.895
17.577
23.647
1.00
57.89
A

ATOM
13
CB
GLN
A
18
52.794
16.161
24.210
1.00
57.50
A

ATOM
14
CG
GLN
A
18
53.480
15.955
25.534
1.00
57.38
A

ATOM
15
CD
GLN
A
18
53.377
14.514
25.999
1.00
58.16
A

ATOM
16
OE1
GLN
A
18
53.614
13.581
25.228
1.00
56.84
A

ATOM
17
NE2
GLN
A
18
53.027
14.327
27.268
1.00
58.44
A

ATOM
18
C
GLN
A
18
52.532
17.529
22.169
1.00
55.87
A

ATOM
19
O
GLN
A
18
53.378
17.267
21.312
1.00
55.83
A

ATOM
20
N
ILE
A
19
51.256
17.781
21.889
1.00
52.87
A

ATOM
21
CA
ILE
A
19
50.727
17.763
20.532
1.00
50.05
A

ATOM
22
CB
ILE
A
19
49.408
16.940
20.476
1.00
48.06
A

ATOM
23
CG2
ILE
A
19
48.886
16.873
19.053
1.00
48.17
A

ATOM
24
CG1
ILE
A
19
49.638
15.526
21.020
1.00
45.44
A

ATOM
25
CD1
ILE
A
19
50.552
14.677
20.180
1.00
43.26
A

ATOM
26
C
ILE
A
19
50.443
19.194
20.066
1.00
49.72
A

ATOM
27
O
ILE
A
19
50.014
20.036
20.856
1.00
49.03
A

ATOM
28
N
PRO
A
20
50.702
19.490
18.777
1.00
49.57
A

ATOM
29
CD
PRO
A
20
51.486
18.667
17.841
1.00
49.58
A

ATOM
30
CA
PRO
A
20
50.469
20.822
18.209
1.00
49.39
A

ATOM
31
CB
PRO
A
20
51.058
20.705
16.808
1.00
48.67
A

ATOM
32
CG
PRO
A
20
52.153
19.717
16.991
1.00
48.94
A

ATOM
33
C
PRO
A
20
48.982
21.187
18.171
1.00
49.97
A

ATOM
34
O
PRO
A
20
48.138
20.358
17.819
1.00
50.18
A

ATOM
35
N
ALA
A
21
48.672
22.429
18.534
1.00
49.45
A

ATOM
36
CA
ALA
A
21
47.296
22.913
18.540
1.00
49.81
A

ATOM
37
CB
ALA
A
21
47.270
24.405
18.880
1.00
49.85
A

ATOM
38
C
ALA
A
21
46.613
22.670
17.189
1.00
49.65
A

ATOM
39
O
ALA
A
21
45.483
22.179
17.128
1.00
49.33
A

ATOM
40
N
SER
A
22
47.302
23.022
16.107
1.00
48.76
A

ATOM
41
CA
SER
A
22
46.753
22.830
14.774
1.00
47.75
A

ATOM
42
CB
SER
A
22
47.823
23.134
13.721
1.00
47.15
A

ATOM
43
OG
SER
A
22
49.001
22.382
13.964
1.00
48.43
A

ATOM
44
C
SER
A
22
46.254
21.391
14.628
1.00
46.34
A

ATOM
45
O
SER
A
22
45.195
21.143
14.045
1.00
45.89
A

ATOM
46
N
GLU
A
23
47.012
20.445
15.172
1.00
44.68
A

ATOM
47
CA
GLU
A
23
46.632
19.041
15.098
1.00
43.25
A

ATOM
48
CB
GLU
A
23
47.804
18.149
15.472
1.00
42.16
A

ATOM
49
CG
GLU
A
23
47.513
16.684
15.303
1.00
40.86
A

ATOM
50
CD
GLU
A
23
48.777
15.866
15.250
1.00
40.82
A

ATOM
51
OE1
GLU
A
23
49.695
16.146
16.045
1.00
41.52
A

ATOM
52
OE2
GLU
A
23
48.856
14.942
14.418
1.00
41.56
A

ATOM
53
C
GLU
A
23
45.453
18.760
16.013
1.00
42.01
A

ATOM
54
O
GLU
A
23
44.505
18.087
15.625
1.00
42.32
A

ATOM
55
N
GLN
A
24
45.512
19.278
17.229
1.00
41.29
A

ATOM
56
CA
GLN
A
24
44.413
19.089
18.154
1.00
42.07
A

ATOM
57
CB
GLN
A
24
44.666
19.872
19.450
1.00
41.13
A

ATOM
58
CG
GLN
A
24
45.643
19.180
20.391
1.00
42.57
A

ATOM
59
CD
GLN
A
24
45.950
19.981
21.650
1.00
43.91
A

ATOM
60
OE1
GLN
A
24
45.068
20.622
22.233
1.00
44.84
A

ATOM
61
NE2
GLN
A
24
47.205
19.931
22.085
1.00
43.17
A

ATOM
62
C
GLN
A
24
43.140
19.589
17.475
1.00
43.32
A

ATOM
63
O
GLN
A
24
42.035
19.139
17.790
1.00
43.40
A

ATOM
64
N
GLU
A
25
43.310
20.505
16.521
1.00
44.62
A

ATOM
65
CA
GLU
A
25
42.183
21.095
15.795
1.00
44.92
A

ATOM
66
CB
GLU
A
25
42.507
22.543
15.406
1.00
48.33
A

ATOM
67
CG
GLU
A
25
43.121
23.398
16.516
1.00
53.04
A

ATOM
68
CD
GLU
A
25
42.283
23.449
17.787
1.00
55.79
A

ATOM
69
OE1
GLU
A
25
42.680
24.180
18.720
1.00
57.11
A

ATOM
70
OE2
GLU
A
25
41.236
22.766
17.864
1.00
57.84
A

ATOM
71
C
GLU
A
25
41.731
20.336
14.541
1.00
42.75
A

ATOM
72
O
GLU
A
25
40.616
20.547
14.059
1.00
42.62
A

ATOM
73
N
THR
A
26
42.587
19.467
14.008
1.00
40.18
A

ATOM
74
CA
THR
A
26
42.237
18.692
12.814
1.00
38.13
A

ATOM
75
CB
THR
A
26
43.254
17.547
12.563
1.00
37.92
A

ATOM
76
OG1
THR
A
26
44.589
18.059
12.647
1.00
37.02
A

ATOM
77
CG2
THR
A
26
43.047
16.942
11.187
1.00
36.76
A

ATOM
78
C
THR
A
26
40.847
18.074
12.983
1.00
36.79
A

ATOM
79
O
THR
A
26
40.511
17.574
14.054
1.00
36.47
A

ATOM
80
N
LEU
A
27
40.036
18.128
11.931
1.00
36.63
A

ATOM
81
CA
LEU
A
27
38.686
17.559
11.973
1.00
35.77
A

ATOM
82
CB
LEU
A
27
37.739
18.336
11.052
1.00
36.16
A

ATOM
83
CG
LEU
A
27
36.264
18.393
11.488
1.00
38.05
A

ATOM
84
CD1
LEU
A
27
36.120
19.331
12.692
1.00
36.12
A

ATOM
85
CD2
LEU
A
27
35.394
18.895
10.328
1.00
38.41
A

ATOM
86
C
LEU
A
27
38.796
16.110
11.505
1.00
34.52
A

ATOM
87
O
LEU
A
27
39.467
15.818
10.513
1.00
33.72
A

ATOM
88
N
VAL
A
28
38.135
15.204
12.218
1.00
33.53
A

ATOM
89
CA
VAL
A
28
38.214
13.787
11.886
1.00
32.88
A

ATOM
90
CB
VAL
A
28
39.207
13.071
12.850
1.00
32.86
A

ATOM
91
CG1
VAL
A
28
40.592
13.685
12.724
1.00
31.21
A

ATOM
92
CG2
VAL
A
28
38.726
13.204
14.292
1.00
33.40
A

ATOM
93
C
VAL
A
28
36.876
13.044
11.919
1.00
31.29
A

ATOM
94
O
VAL
A
28
35.910
13.501
12.527
1.00
30.99
A

ATOM
95
N
ARG
A
29
36.841
11.897
11.248
1.00
29.80
A

ATOM
96
CA
ARG
A
29
35.655
11.054
11.198
1.00
28.94
A

ATOM
97
CB
ARG
A
29
35.174
10.876
9.762
1.00
33.14
A

ATOM
98
CG
ARG
A
29
34.296
11.991
9.254
1.00
38.54
A

ATOM
99
CD
ARG
A
29
34.036
11.830
7.767
1.00
43.39
A

ATOM
100
NE
ARG
A
29
33.084
12.828
7.296
1.00
47.28
A

ATOM
101
CZ
ARG
A
29
31.772
12.741
7.477
1.00
49.30
A

ATOM
102
NH1
ARG
A
29
31.257
11.691
8.110
1.00
49.75
A

ATOM
103
NH2
ARG
A
29
30.978
13.716
7.049
1.00
50.29
A

ATOM
104
C
ARG
A
29
35.994
9.688
11.762
1.00
26.43
A

ATOM
105
O
ARG
A
29
36.680
8.895
11.110
1.00
25.41
A

ATOM
106
N
PRO
A
30
35.528
9.397
12.989
1.00
24.69
A

ATOM
107
CD
PRO
A
30
34.749
10.285
13.869
1.00
23.43
A

ATOM
108
CA
PRO
A
30
35.784
8.108
13.647
1.00
23.00
A

ATOM
109
CB
PRO
A
30
35.223
8.308
15.053
1.00
21.72
A

ATOM
110
CG
PRO
A
30
35.147
9.792
15.218
1.00
22.48
A

ATOM
111
C
PRO
A
30
35.023
7.001
12.923
1.00
22.20
A

ATOM
112
O
PRO
A
30
33.945
7.243
12.382
1.00
22.27
A

ATOM
113
N
LYS
A
31
35.580
5.796
12.910
1.00
21.65
A

ATOM
114
CA
LYS
A
31
34.909
4.658
12.286
1.00
19.51
A

ATOM
115
CB
LYS
A
31
35.901
3.519
12.056
1.00
19.68
A

ATOM
116
CG
LYS
A
31
37.058
3.899
11.150
1.00
20.82
A

ATOM
117
CD
LYS
A
31
38.006
2.724
10.976
1.00
22.74
A

ATOM
118
CE
LYS
A
31
39.161
3.040
10.019
1.00
20.68
A

ATOM
119
NZ
LYS
A
31
40.000
1.818
9.826
1.00
21.75
A

ATOM
120
C
LYS
A
31
33.795
4.225
13.249
1.00
18.36
A

ATOM
121
O
LYS
A
31
33.793
4.605
14.422
1.00
17.38
A

ATOM
122
N
PRO
A
32
32.848
3.406
12.774
1.00
17.15
A

ATOM
123
CD
PRO
A
32
32.886
2.665
11.501
1.00
16.30
A

ATOM
124
CA
PRO
A
32
31.729
2.939
13.595
1.00
16.70
A

ATOM
125
CB
PRO
A
32
31.178
1.775
12.778
1.00
16.53
A

ATOM
126
CG
PRO
A
32
31.463
2.200
11.378
1.00
16.35
A

ATOM
127
C
PRO
A
32
32.023
2.548
15.048
1.00
16.73
A

ATOM
128
O
PRO
A
32
31.343
3.014
15.967
1.00
17.12
A

ATOM
129
N
LEU
A
33
33.016
1.692
15.264
1.00
14.62
A

ATOM
130
CA
LEU
A
33
33.324
1.265
16.619
1.00
13.59
A

ATOM
131
CB
LEU
A
33
34.332
0.110
16.594
1.00
15.36
A

ATOM
132
CG
LEU
A
33
33.787
−1.301
16.896
1.00
13.91
A

ATOM
133
CD1
LEU
A
33
32.250
−1.320
16.992
1.00
13.51
A

ATOM
134
CD2
LEU
A
33
34.270
−2.239
15.822
1.00
8.87
A

ATOM
135
C
LEU
A
33
33.800
2.397
17.516
1.00
13.14
A

ATOM
136
O
LEU
A
33
33.281
2.560
18.608
1.00
12.37
A

ATOM
137
N
LEU
A
34
34.786
3.176
17.082
1.00
14.58
A

ATOM
138
CA
LEU
A
34
35.238
4.305
17.895
1.00
13.84
A

ATOM
139
CB
LEU
A
34
36.430
5.015
17.246
1.00
13.73
A

ATOM
140
CG
LEU
A
34
36.892
6.346
17.861
1.00
10.65
A

ATOM
141
CD1
LEU
A
34
37.437
6.120
19.247
1.00
9.38
A

ATOM
142
CD2
LEU
A
34
37.951
6.971
16.986
1.00
11.47
A

ATOM
143
C
LEU
A
34
34.073
5.294
18.042
1.00
15.75
A

ATOM
144
O
LEU
A
34
33.877
5.874
19.103
1.00
16.50
A

ATOM
145
N
LEU
A
35
33.294
5.484
16.979
1.00
17.07
A

ATOM
146
CA
LEU
A
35
32.152
6.395
17.046
1.00
18.94
A

ATOM
147
CB
LEU
A
35
31.440
6.482
15.690
1.00
16.70
A

ATOM
148
CG
LEU
A
35
30.311
7.514
15.602
1.00
14.51
A

ATOM
149
CD1
LEU
A
35
30.880
8.904
15.849
1.00
13.73
A

ATOM
150
CD2
LEU
A
35
29.646
7.453
14.237
1.00
13.01
A

ATOM
151
C
LEU
A
35
31.151
5.968
18.136
1.00
20.66
A

ATOM
152
O
LEU
A
35
30.494
6.823
18.742
1.00
21.36
A

ATOM
153
N
LYS
A
36
31.039
4.661
18.385
1.00
20.77
A

ATOM
154
CA
LYS
A
36
30.135
4.152
19.415
1.00
22.28
A

ATOM
155
CB
LYS
A
36
29.938
2.637
19.298
1.00
23.62
A

ATOM
156
CG
LYS
A
36
28.839
2.214
18.330
1.00
28.23
A

ATOM
157
CD
LYS
A
36
28.007
1.043
18.889
1.00
30.56
A

ATOM
158
CE
LYS
A
36
28.853
−0.202
19.171
1.00
32.43
A

ATOM
159
NZ
LYS
A
36
28.037
−1.385
19.580
1.00
31.16
A

ATOM
160
C
LYS
A
36
30.668
4.471
20.807
1.00
23.86
A

ATOM
161
O
LYS
A
36
29.901
4.855
21.700
1.00
26.24
A

ATOM
162
N
LEU
A
37
31.971
4.301
21.006
1.00
23.16
A

ATOM
163
CA
LEU
A
37
32.558
4.608
22.308
1.00
24.32
A

ATOM
164
CB
LEU
A
37
34.085
4.515
22.263
1.00
25.18
A

ATOM
165
CG
LEU
A
37
34.708
3.137
22.100
1.00
27.89
A

ATOM
166
CD1
LEU
A
37
36.217
3.232
22.302
1.00
28.24
A

ATOM
167
CD2
LEU
A
37
34.095
2.198
23.119
1.00
28.07
A

ATOM
168
C
LEU
A
37
32.179
6.027
22.725
1.00
23.05
A

ATOM
169
O
LEU
A
37
31.758
6.268
23.854
1.00
20.34
A

ATOM
170
N
LEU
A
38
32.338
6.956
21.788
1.00
23.36
A

ATOM
171
CA
LEU
A
38
32.055
8.359
22.022
1.00
24.58
A

ATOM
172
CB
LEU
A
38
32.493
9.198
20.819
1.00
21.20
A

ATOM
173
CG
LEU
A
38
33.886
8.937
20.238
1.00
19.16
A

ATOM
174
CD1
LEU
A
38
34.126
9.914
19.106
1.00
16.77
A

ATOM
175
CD2
LEU
A
38
34.966
9.092
21.306
1.00
18.04
A

ATOM
176
C
LEU
A
38
30.581
8.602
22.302
1.00
27.20
A

ATOM
177
O
LEU
A
38
30.236
9.411
23.162
1.00
29.33
A

ATOM
178
N
LYS
A
39
29.702
7.908
21.590
1.00
28.13
A

ATOM
179
CA
LYS
A
39
28.283
8.119
21.815
1.00
29.30
A

ATOM
180
CB
LYS
A
39
27.467
7.488
20.686
1.00
28.63
A

ATOM
181
CG
LYS
A
39
27.777
8.127
19.347
1.00
28.78
A

ATOM
182
CD
LYS
A
39
26.776
7.761
18.276
1.00
27.98
A

ATOM
183
CE
LYS
A
39
27.154
8.415
16.960
1.00
26.89
A

ATOM
184
NZ
LYS
A
39
26.074
8.260
15.959
1.00
27.11
A

ATOM
185
C
LYS
A
39
27.840
7.587
23.169
1.00
30.33
A

ATOM
186
O
LYS
A
39
26.931
8.141
23.789
1.00
31.74
A

ATOM
187
N
SER
A
40
28.495
6.531
23.644
1.00
30.27
A

ATOM
188
CA
SER
A
40
28.148
5.948
24.939
1.00
29.62
A

ATOM
189
CB
SER
A
40
28.995
4.691
25.213
1.00
28.81
A

ATOM
190
OG
SER
A
40
30.349
5.002
25.520
1.00
26.68
A

ATOM
191
C
SER
A
40
28.340
6.960
26.073
1.00
29.48
A

ATOM
192
O
SER
A
40
27.745
6.822
27.139
1.00
29.59
A

ATOM
193
N
VAL
A
41
29.170
7.974
25.843
1.00
30.35
A

ATOM
194
CA
VAL
A
41
29.432
9.002
26.854
1.00
30.76
A

ATOM
195
CB
VAL
A
41
30.944
9.047
27.267
1.00
30.64
A

ATOM
196
CG1
VAL
A
41
31.298
7.826
28.115
1.00
29.00
A

ATOM
197
CG2
VAL
A
41
31.834
9.108
26.030
1.00
28.32
A

ATOM
198
C
VAL
A
41
29.013
10.407
26.413
1.00
32.02
A

ATOM
199
O
VAL
A
41
29.742
11.380
26.628
1.00
31.05
A

ATOM
200
N
GLY
A
42
27.845
10.509
25.779
1.00
33.77
A

ATOM
201
CA
GLY
A
42
27.355
11.811
25.360
1.00
36.14
A

ATOM
202
C
GLY
A
42
27.488
12.202
23.901
1.00
38.10
A

ATOM
203
O
GLY
A
42
26.516
12.669
23.310
1.00
40.02
A

ATOM
204
N
ALA
A
43
28.675
12.035
23.318
1.00
38.97
A

ATOM
205
CA
ALA
A
43
28.897
12.403
21.919
1.00
39.16
A

ATOM
206
CB
ALA
A
43
30.124
11.678
21.370
1.00
38.86
A

ATOM
207
C
ALA
A
43
27.678
12.101
21.054
1.00
39.94
A

ATOM
208
O
ALA
A
43
26.968
11.120
21.284
1.00
40.04
A

ATOM
209
N
GLN
A
44
27.435
12.952
20.061
1.00
41.54
A

ATOM
210
CA
GLN
A
44
26.294
12.769
19.173
1.00
42.78
A

ATOM
211
CB
GLN
A
44
25.018
13.232
19.881
1.00
45.11
A

ATOM
212
CG
GLN
A
44
25.132
14.598
20.546
1.00
47.61
A

ATOM
213
CD
GLN
A
44
24.026
14.838
21.568
1.00
49.56
A

ATOM
214
OE1
GLN
A
44
23.986
15.884
22.227
1.00
49.35
A

ATOM
215
NE2
GLN
A
44
23.124
13.866
21.708
1.00
49.08
A

ATOM
216
C
GLN
A
44
26.434
13.470
17.821
1.00
42.23
A

ATOM
217
O
GLN
A
44
25.520
14.171
17.375
1.00
42.70
A

ATOM
218
N
LYS
A
45
27.585
13.271
17.180
1.00
40.15
A

ATOM
219
CA
LYS
A
45
27.871
13.845
15.870
1.00
37.90
A

ATOM
220
CB
LYS
A
45
28.802
15.050
15.980
1.00
39.62
A

ATOM
221
CG
LYS
A
45
28.359
16.141
16.933
1.00
41.18
A

ATOM
222
CD
LYS
A
45
29.197
17.399
16.713
1.00
42.96
A

ATOM
223
CE
LYS
A
45
30.690
17.093
16.732
1.00
45.64
A

ATOM
224
NZ
LYS
A
45
31.535
18.294
16.451
1.00
48.08
A

ATOM
225
C
LYS
A
45
28.590
12.774
15.071
1.00
36.61
A

ATOM
226
O
LYS
A
45
28.771
11.657
15.553
1.00
36.82
A

ATOM
227
N
ASP
A
46
29.012
13.121
13.859
1.00
34.69
A

ATOM
228
CA
ASP
A
46
29.736
12.187
13.006
1.00
33.64
A

ATOM
229
CB
ASP
A
46
29.089
12.074
11.617
1.00
35.21
A

ATOM
230
CG
ASP
A
46
27.726
11.403
11.652
1.00
36.60
A

ATOM
231
OD1
ASP
A
46
27.557
10.427
12.417
1.00
35.63
A

ATOM
232
OD2
ASP
A
46
26.830
11.846
10.899
1.00
36.79
A

ATOM
233
C
ASP
A
46
31.174
12.651
12.830
1.00
32.32
A

ATOM
234
O
ASP
A
46
32.071
11.843
12.578
1.00
33.06
A

ATOM
235
N
THR
A
47
31.388
13.959
12.950
1.00
30.30
A

ATOM
236
CA
THR
A
47
32.718
14.543
12.790
1.00
27.52
A

ATOM
237
CB
THR
A
47
32.762
15.556
11.620
1.00
28.37
A

ATOM
238
OG1
THR
A
47
31.586
16.375
11.650
1.00
28.12
A

ATOM
239
CG2
THR
A
47
32.846
14.836
10.287
1.00
28.11
A

ATOM
240
C
THR
A
47
33.138
15.254
14.059
1.00
25.47
A

ATOM
241
O
THR
A
47
32.307
15.811
14.781
1.00
24.25
A

ATOM
242
N
TYR
A
48
34.441
15.227
14.324
1.00
24.41
A

ATOM
243
CA
TYR
A
48
34.997
15.844
15.517
1.00
24.02
A

ATOM
244
CB
TYR
A
48
35.073
14.830
16.681
1.00
23.01
A

ATOM
245
CG
TYR
A
48
33.769
14.162
17.077
1.00
22.29
A

ATOM
246
CD1
TYR
A
48
33.259
13.087
16.347
1.00
21.16
A

ATOM
247
CE1
TYR
A
48
32.030
12.499
16.685
1.00
20.20
A

ATOM
248
CD2
TYR
A
48
33.021
14.632
18.166
1.00
21.34
A

ATOM
249
CE2
TYR
A
48
31.801
14.050
18.510
1.00
20.29
A

ATOM
250
CZ
TYR
A
48
31.312
12.990
17.762
1.00
19.58
A

ATOM
251
OH
TYR
A
48
30.092
12.442
18.066
1.00
20.11
A

ATOM
252
C
TYR
A
48
36.412
16.340
15.265
1.00
24.38
A

ATOM
253
O
TYR
A
48
37.080
15.913
14.318
1.00
22.46
A

ATOM
254
N
THR
A
49
36.855
17.245
16.130
1.00
24.50
A

ATOM
255
CA
THR
A
49
38.221
17.744
16.092
1.00
25.25
A

ATOM
256
CB
THR
A
49
38.333
19.134
16.762
1.00
26.57
A

ATOM
257
OG1
THR
A
49
37.583
19.131
17.989
1.00
26.24
A

ATOM
258
CG2
THR
A
49
37.796
20.235
15.829
1.00
24.91
A

ATOM
259
C
THR
A
49
38.932
16.699
16.965
1.00
25.63
A

ATOM
260
O
THR
A
49
38.307
16.088
17.833
1.00
24.71
A

ATOM
261
N
MET
A
50
40.216
16.466
16.740
1.00
26.39
A

ATOM
262
CA
MET
A
50
40.907
15.470
17.545
1.00
26.62
A

ATOM
263
CB
MET
A
50
42.373
15.388
17.150
1.00
25.74
A

ATOM
264
CG
MET
A
50
42.589
14.617
15.865
1.00
25.74
A

ATOM
265
SD
MET
A
50
42.250
12.852
16.072
1.00
24.59
A

ATOM
266
CE
MET
A
50
43.816
12.259
16.701
1.00
22.52
A

ATOM
267
C
MET
A
50
40.785
15.760
19.031
1.00
28.23
A

ATOM
268
O
MET
A
50
40.843
14.848
19.847
1.00
29.67
A

ATOM
269
N
LYS
A
51
40.594
17.026
19.388
1.00
28.66
A

ATOM
270
CA
LYS
A
51
40.467
17.377
20.794
1.00
29.11
A

ATOM
271
CB
LYS
A
51
40.573
18.891
20.980
1.00
32.66
A

ATOM
272
CG
LYS
A
51
40.687
19.300
22.445
1.00
37.67
A

ATOM
273
CD
LYS
A
51
40.874
20.801
22.628
1.00
41.07
A

ATOM
274
CE
LYS
A
51
40.948
21.164
24.116
1.00
42.73
A

ATOM
275
NZ
LYS
A
51
41.069
22.639
24.365
1.00
45.66
A

ATOM
276
C
LYS
A
51
39.159
16.862
21.406
1.00
28.29
A

ATOM
277
O
LYS
A
51
39.143
16.411
22.557
1.00
28.36
A

ATOM
278
N
GLU
A
52
38.064
16.929
20.647
1.00
25.71
A

ATOM
279
CA
GLU
A
52
36.775
16.451
21.144
1.00
23.60
A

ATOM
280
CB
GLU
A
52
35.638
16.866
20.199
1.00
24.83
A

ATOM
281
CG
GLU
A
52
35.407
18.369
20.084
1.00
27.15
A

ATOM
282
CD
GLU
A
52
34.383
18.732
18.998
1.00
29.01
A

ATOM
283
OE1
GLU
A
52
34.598
18.371
17.818
1.00
29.80
A

ATOM
284
OE2
GLU
A
52
33.364
19.380
19.320
1.00
29.19
A

ATOM
285
C
GLU
A
52
36.785
14.921
21.293
1.00
21.67
A

ATOM
286
O
GLU
A
52
36.069
14.370
22.132
1.00
20.99
A

ATOM
287
N
VAL
A
53
37.578
14.235
20.473
1.00
18.55
A

ATOM
288
CA
VAL
A
53
37.659
12.782
20.559
1.00
16.46
A

ATOM
289
CB
VAL
A
53
38.461
12.163
19.371
1.00
17.02
A

ATOM
290
CG1
VAL
A
53
38.749
10.682
19.645
1.00
15.92
A

ATOM
291
CG2
VAL
A
53
37.659
12.282
18.075
1.00
14.61
A

ATOM
292
C
VAL
A
53
38.350
12.471
21.879
1.00
15.15
A

ATOM
293
O
VAL
A
53
37.788
11.784
22.735
1.00
13.10
A

ATOM
294
N
LEU
A
54
39.570
12.988
22.037
1.00
15.42
A

ATOM
295
CA
LEU
A
54
40.328
12.814
23.273
1.00
14.74
A

ATOM
296
CB
LEU
A
54
41.548
13.736
23.309
1.00
12.86
A

ATOM
297
CG
LEU
A
54
42.871
13.232
22.730
1.00
13.00
A

ATOM
298
CD1
LEU
A
54
43.132
11.821
23.250
1.00
14.60
A

ATOM
299
CD2
LEU
A
54
42.833
13.235
21.232
1.00
11.73
A

ATOM
300
C
LEU
A
54
39.439
13.153
24.467
1.00
15.13
A

ATOM
301
O
LEU
A
54
39.515
12.511
25.514
1.00
16.88
A

ATOM
302
N
PHE
A
55
38.588
14.156
24.309
1.00
14.69
A

ATOM
303
CA
PHE
A
55
37.710
14.556
25.397
1.00
16.41
A

ATOM
304
CB
PHE
A
55
36.904
15.803
25.028
1.00
18.34
A

ATOM
305
CG
PHE
A
55
35.899
16.171
26.069
1.00
20.72
A

ATOM
306
CD1
PHE
A
55
36.278
16.916
27.184
1.00
20.24
A

ATOM
307
CD2
PHE
A
55
34.596
15.672
26.001
1.00
20.52
A

ATOM
308
CE1
PHE
A
55
35.376
17.153
28.223
1.00
20.60
A

ATOM
309
CE2
PHE
A
55
33.687
15.901
27.034
1.00
21.73
A

ATOM
310
CZ
PHE
A
55
34.078
16.644
28.149
1.00
20.59
A

ATOM
311
C
PHE
A
55
36.739
13.473
25.838
1.00
16.04
A

ATOM
312
O
PHE
A
55
36.661
13.148
27.025
1.00
17.31
A

ATOM
313
N
TYR
A
56
35.978
12.941
24.886
1.00
16.71
A

ATOM
314
CA
TYR
A
56
34.996
11.892
25.165
1.00
17.61
A

ATOM
315
CB
TYR
A
56
34.136
11.624
23.930
1.00
18.45
A

ATOM
316
CG
TYR
A
56
33.142
12.723
23.671
1.00
21.48
A

ATOM
317
CD1
TYR
A
56
32.090
12.951
24.565
1.00
23.38
A

ATOM
318
CE1
TYR
A
56
31.182
13.987
24.363
1.00
25.16
A

ATOM
319
CD2
TYR
A
56
33.266
13.562
22.557
1.00
22.53
A

ATOM
320
CE2
TYR
A
56
32.363
14.610
22.339
1.00
23.90
A

ATOM
321
CZ
TYR
A
56
31.322
14.816
23.251
1.00
26.15
A

ATOM
322
OH
TYR
A
56
30.425
15.846
23.068
1.00
26.91
A

ATOM
323
C
TYR
A
56
35.709
10.628
25.567
1.00
16.78
A

ATOM
324
O
TYR
A
56
35.189
9.810
26.329
1.00
18.53
A

ATOM
325
N
LEU
A
57
36.910
10.472
25.028
1.00
15.78
A

ATOM
326
CA
LEU
A
57
37.743
9.325
25.327
1.00
13.13
A

ATOM
327
CB
LEU
A
57
38.982
9.382
24.437
1.00
11.95
A

ATOM
328
CG
LEU
A
57
39.277
8.207
23.497
1.00
13.21
A

ATOM
329
CD1
LEU
A
57
38.000
7.628
22.913
1.00
10.11
A

ATOM
330
CD2
LEU
A
57
40.224
8.690
22.402
1.00
10.01
A

ATOM
331
C
LEU
A
57
38.108
9.418
26.821
1.00
12.23
A

ATOM
332
O
LEU
A
57
38.197
8.403
27.515
1.00
9.19
A

ATOM
333
N
GLY
A
58
38.291
10.649
27.300
1.00
11.88
A

ATOM
334
CA
GLY
A
58
38.620
10.877
28.691
1.00
14.46
A

ATOM
335
C
GLY
A
58
37.448
10.490
29.567
1.00
17.50
A

ATOM
336
O
GLY
A
58
37.613
9.800
30.579
1.00
18.69
A

ATOM
337
N
GLN
A
59
36.257
10.934
29.178
1.00
18.46
A

ATOM
338
CA
GLN
A
59
35.059
10.614
29.929
1.00
19.45
A

ATOM
339
CB
GLN
A
59
33.850
11.322
29.328
1.00
22.28
A

ATOM
340
CG
GLN
A
59
33.967
12.829
29.389
1.00
24.82
A

ATOM
341
CD
GLN
A
59
34.506
13.295
30.732
1.00
25.90
A

ATOM
342
OE1
GLN
A
59
33.883
13.079
31.771
1.00
26.11
A

ATOM
343
NE2
GLN
A
59
35.679
13.928
30.714
1.00
26.90
A

ATOM
344
C
GLN
A
59
34.850
9.115
29.898
1.00
19.50
A

ATOM
345
O
GLN
A
59
34.441
8.511
30.893
1.00
20.93
A

ATOM
346
N
TYR
A
60
35.148
8.510
28.757
1.00
17.52
A

ATOM
347
CA
TYR
A
60
34.991
7.075
28.617
1.00
18.33
A

ATOM
348
CB
TYR
A
60
35.359
6.636
27.198
1.00
14.85
A

ATOM
349
CG
TYR
A
60
35.120
5.162
26.914
1.00
15.47
A

ATOM
350
CD1
TYR
A
60
33.838
4.676
26.632
1.00
14.63
A

ATOM
351
CE1
TYR
A
60
33.620
3.311
26.347
1.00
11.14
A

ATOM
352
CD2
TYR
A
60
36.184
4.247
26.913
1.00
15.88
A

ATOM
353
CE2
TYR
A
60
35.974
2.882
26.631
1.00
13.26
A

ATOM
354
CZ
TYR
A
60
34.691
2.425
26.349
1.00
12.81
A

ATOM
355
OH
TYR
A
60
34.494
1.089
26.052
1.00
10.53
A

ATOM
356
C
TYR
A
60
35.862
6.332
29.635
1.00
20.42
A

ATOM
357
O
TYR
A
60
35.339
5.672
30.541
1.00
19.39
A

ATOM
358
N
ILE
A
61
37.184
6.453
29.501
1.00
21.45
A

ATOM
359
CA
ILE
A
61
38.092
5.753
30.401
1.00
23.11
A

ATOM
360
CB
ILE
A
61
39.576
5.969
30.026
1.00
22.76
A

ATOM
361
CG2
ILE
A
61
39.879
5.334
28.680
1.00
23.31
A

ATOM
362
CG1
ILE
A
61
39.913
7.453
30.028
1.00
22.24
A

ATOM
363
CD1
ILE
A
61
41.385
7.709
29.846
1.00
23.32
A

ATOM
364
C
ILE
A
61
37.911
6.115
31.869
1.00
25.11
A

ATOM
365
O
ILE
A
61
38.112
5.284
32.751
1.00
25.25
A

ATOM
366
N
MET
A
62
37.531
7.350
32.145
1.00
27.56
A

ATOM
367
CA
MET
A
62
37.335
7.737
33.527
1.00
30.23
A

ATOM
368
CB
MET
A
62
37.237
9.260
33.632
1.00
32.88
A

ATOM
369
CG
MET
A
62
37.161
9.783
35.056
1.00
34.56
A

ATOM
370
SD
MET
A
62
35.808
10.961
35.203
1.00
39.80
A

ATOM
371
CE
MET
A
62
34.440
9.803
35.399
1.00
35.55
A

ATOM
372
C
MET
A
62
36.066
7.073
34.087
1.00
31.22
A

ATOM
373
O
MET
A
62
36.118
6.340
35.083
1.00
30.54
A

ATOM
374
N
THR
A
63
34.934
7.302
33.428
1.00
31.07
A

ATOM
375
CA
THR
A
63
33.673
6.735
33.896
1.00
31.77
A

ATOM
376
CB
THR
A
63
32.495
7.074
32.939
1.00
30.74
A

ATOM
377
OG1
THR
A
63
32.818
6.664
31.608
1.00
31.02
A

ATOM
378
CG2
THR
A
63
32.206
8.569
32.956
1.00
31.19
A

ATOM
379
C
THR
A
63
33.710
5.221
34.115
1.00
32.00
A

ATOM
380
O
THR
A
63
33.230
4.730
35.142
1.00
33.74
A

ATOM
381
N
LYS
A
64
34.265
4.481
33.159
1.00
30.45
A

ATOM
382
CA
LYS
A
64
34.331
3.035
33.288
1.00
29.14
A

ATOM
383
CB
LYS
A
64
34.397
2.380
31.905
1.00
28.22
A

ATOM
384
CG
LYS
A
64
33.121
2.523
31.099
1.00
26.54
A

ATOM
385
CD
LYS
A
64
33.198
1.785
29.769
1.00
26.08
A

ATOM
386
CE
LYS
A
64
33.343
0.293
29.967
1.00
26.73
A

ATOM
387
NZ
LYS
A
64
33.332
−0.444
28.675
1.00
26.87
A

ATOM
388
C
LYS
A
64
35.509
2.586
34.151
1.00
29.64
A

ATOM
389
O
LYS
A
64
35.824
1.398
34.223
1.00
28.68
A

ATOM
390
N
ARG
A
65
36.160
3.548
34.799
1.00
31.08
A

ATOM
391
CA
ARG
A
65
37.279
3.259
35.691
1.00
31.77
A

ATOM
392
CB
ARG
A
65
36.720
2.800
37.041
1.00
32.61
A

ATOM
393
CG
ARG
A
65
35.955
3.907
37.771
1.00
36.27
A

ATOM
394
CD
ARG
A
65
34.975
3.376
38.812
1.00
38.75
A

ATOM
395
NE
ARG
A
65
34.298
4.465
39.521
1.00
41.50
A

ATOM
396
CZ
ARG
A
65
33.149
4.343
40.190
1.00
43.14
A

ATOM
397
NH1
ARG
A
65
32.519
3.173
40.251
1.00
43.25
A

ATOM
398
NH2
ARG
A
65
32.622
5.396
40.799
1.00
41.34
A

ATOM
399
C
ARG
A
65
38.254
2.216
35.131
1.00
30.62
A

ATOM
400
O
ARG
A
65
38.488
1.173
35.750
1.00
31.11
A

ATOM
401
N
LEU
A
66
38.817
2.505
33.958
1.00
27.85
A

ATOM
402
CA
LEU
A
66
39.773
1.606
33.309
1.00
24.57
A

ATOM
403
CB
LEU
A
66
39.657
1.699
31.781
1.00
21.73
A

ATOM
404
CG
LEU
A
66
38.392
1.185
31.099
1.00
18.58
A

ATOM
405
CD1
LEU
A
66
38.477
1.413
29.603
1.00
16.38
A

ATOM
406
CD2
LEU
A
66
38.240
−0.289
31.393
1.00
16.78
A

ATOM
407
C
LEU
A
66
41.195
1.960
33.712
1.00
24.06
A

ATOM
408
O
LEU
A
66
42.146
1.312
33.286
1.00
22.74
A

ATOM
409
N
TYR
A
67
41.343
3.008
34.515
1.00
25.28
A

ATOM
410
CA
TYR
A
67
42.665
3.428
34.962
1.00
26.02
A

ATOM
411
CB
TYR
A
67
42.703
4.953
35.146
1.00
26.69
A

ATOM
412
CG
TYR
A
67
41.675
5.492
36.106
1.00
26.95
A

ATOM
413
CD1
TYR
A
67
41.983
5.673
37.452
1.00
27.52
A

ATOM
414
CE1
TYR
A
67
41.025
6.108
38.356
1.00
27.15
A

ATOM
415
CD2
TYR
A
67
40.378
5.764
35.683
1.00
26.57
A

ATOM
416
CE2
TYR
A
67
39.407
6.202
36.579
1.00
27.84
A

ATOM
417
CZ
TYR
A
67
39.738
6.368
37.919
1.00
27.23
A

ATOM
418
OH
TYR
A
67
38.780
6.753
38.826
1.00
24.32
A

ATOM
419
C
TYR
A
67
43.032
2.700
36.256
1.00
26.40
A

ATOM
420
O
TYR
A
67
42.178
2.422
37.091
1.00
25.07
A

ATOM
421
N
ASP
A
68
44.311
2.381
36.403
1.00
28.69
A

ATOM
422
CA
ASP
A
68
44.785
1.659
37.574
1.00
31.43
A

ATOM
423
CB
ASP
A
68
46.199
1.130
37.326
1.00
31.86
A

ATOM
424
CG
ASP
A
68
46.635
0.139
38.382
1.00
31.50
A

ATOM
425
OD1
ASP
A
68
46.072
−0.975
38.409
1.00
29.47
A

ATOM
426
OD2
ASP
A
68
47.524
0.482
39.192
1.00
33.11
A

ATOM
427
C
ASP
A
68
44.770
2.474
38.864
1.00
33.44
A

ATOM
428
O
ASP
A
68
45.033
3.679
38.866
1.00
33.12
A

ATOM
429
N
GLU
A
69
44.477
1.789
39.966
1.00
36.37
A

ATOM
430
CA
GLU
A
69
44.415
2.416
41.279
1.00
39.07
A

ATOM
431
CB
GLU
A
69
43.852
1.432
42.311
1.00
42.56
A

ATOM
432
CG
GLU
A
69
42.371
1.145
42.123
1.00
48.37
A

ATOM
433
CD
GLU
A
69
41.564
2.420
41.901
1.00
51.95
A

ATOM
434
OE1
GLU
A
69
41.715
3.364
42.708
1.00
54.24
A

ATOM
435
OE2
GLU
A
69
40.782
2.480
40.921
1.00
54.25
A

ATOM
436
C
GLU
A
69
45.750
2.946
41.759
1.00
38.35
A

ATOM
437
O
GLU
A
69
45.845
4.084
42.207
1.00
38.84
A

ATOM
438
N
LYS
A
70
46.788
2.128
41.672
1.00
38.42
A

ATOM
439
CA
LYS
A
70
48.096
2.575
42.118
1.00
38.82
A

ATOM
440
CB
LYS
A
70
48.982
1.360
42.412
1.00
41.21
A

ATOM
441
CG
LYS
A
70
48.362
0.471
43.491
1.00
43.81
A

ATOM
442
CD
LYS
A
70
49.261
−0.669
43.940
1.00
46.99
A

ATOM
443
CE
LYS
A
70
48.551
−1.515
44.999
1.00
47.44
A

ATOM
444
NZ
LYS
A
70
49.436
−2.552
45.599
1.00
48.71
A

ATOM
445
C
LYS
A
70
48.694
3.493
41.058
1.00
37.27
A

ATOM
446
O
LYS
A
70
48.890
4.684
41.300
1.00
36.92
A

ATOM
447
N
GLN
A
71
48.958
2.950
39.876
1.00
35.72
A

ATOM
448
CA
GLN
A
71
49.496
3.755
38.787
1.00
33.41
A

ATOM
449
CB
GLN
A
71
50.372
2.888
37.891
1.00
34.05
A

ATOM
450
CG
GLN
A
71
51.544
2.272
38.608
1.00
35.15
A

ATOM
451
CD
GLN
A
71
52.414
1.462
37.678
1.00
36.85
A

ATOM
452
OE1
GLN
A
71
52.026
0.382
37.220
1.00
37.63
A

ATOM
453
NE2
GLN
A
71
53.596
1.983
37.377
1.00
38.20
A

ATOM
454
C
GLN
A
71
48.326
4.349
37.986
1.00
31.00
A

ATOM
455
O
GLN
A
71
47.855
3.759
37.007
1.00
31.06
A

ATOM
456
N
GLN
A
72
47.865
5.521
38.411
1.00
27.04
A

ATOM
457
CA
GLN
A
72
46.737
6.192
37.771
1.00
23.77
A

ATOM
458
CB
GLN
A
72
46.355
7.443
38.567
1.00
21.94
A

ATOM
459
CG
GLN
A
72
45.189
8.240
37.996
1.00
19.04
A

ATOM
460
CD
GLN
A
72
44.592
9.192
39.022
1.00
18.27
A

ATOM
461
OE1
GLN
A
72
44.040
8.758
40.029
1.00
16.43
A

ATOM
462
NE2
GLN
A
72
44.704
10.491
38.773
1.00
19.03
A

ATOM
463
C
GLN
A
72
46.926
6.558
36.307
1.00
21.79
A

ATOM
464
O
GLN
A
72
45.965
6.558
35.552
1.00
20.39
A

ATOM
465
N
HIS
A
73
48.155
6.859
35.899
1.00
21.17
A

ATOM
466
CA
HIS
A
73
48.395
7.227
34.510
1.00
19.46
A

ATOM
467
CB
HIS
A
73
49.768
7.880
34.355
1.00
19.40
A

ATOM
468
CG
HIS
A
73
50.918
6.974
34.667
1.00
21.41
A

ATOM
469
CD2
HIS
A
73
51.514
6.660
35.843
1.00
21.24
A

ATOM
470
ND1
HIS
A
73
51.613
6.290
33.692
1.00
22.42
A

ATOM
471
CE1
HIS
A
73
52.588
5.596
34.254
1.00
21.05
A

ATOM
472
NE2
HIS
A
73
52.548
5.804
35.559
1.00
21.25
A

ATOM
473
C
HIS
A
73
48.273
6.037
33.572
1.00
20.37
A

ATOM
474
O
HIS
A
73
48.166
6.219
32.355
1.00
19.89
A

ATOM
475
N
ILE
A
74
48.290
4.823
34.128
1.00
19.94
A

ATOM
476
CA
ILE
A
74
48.158
3.618
33.310
1.00
19.76
A

ATOM
477
CB
ILE
A
74
48.869
2.389
33.941
1.00
20.27
A

ATOM
478
CG2
ILE
A
74
48.667
1.165
33.052
1.00
18.27
A

ATOM
479
CG1
ILE
A
74
50.368
2.655
34.118
1.00
22.09
A

ATOM
480
CD1
ILE
A
74
51.121
2.838
32.833
1.00
22.98
A

ATOM
481
C
ILE
A
74
46.676
3.261
33.133
1.00
19.56
A

ATOM
482
O
ILE
A
74
45.911
3.245
34.099
1.00
19.09
A

ATOM
483
N
VAL
A
75
46.287
2.968
31.895
1.00
17.84
A

ATOM
484
CA
VAL
A
75
44.913
2.603
31.578
1.00
16.49
A

ATOM
485
CB
VAL
A
75
44.335
3.551
30.508
1.00
14.74
A

ATOM
486
CG1
VAL
A
75
42.999
3.053
30.027
1.00
13.12
A

ATOM
487
CG2
VAL
A
75
44.189
4.941
31.092
1.00
15.39
A

ATOM
488
C
VAL
A
75
44.901
1.172
31.058
1.00
17.78
A

ATOM
489
O
VAL
A
75
45.568
0.858
30.070
1.00
17.51
A

ATOM
490
N
TYR
A
76
44.155
0.300
31.731
1.00
17.97
A

ATOM
491
CA
TYR
A
76
44.077
−1.098
31.319
1.00
18.96
A

ATOM
492
CB
TYR
A
76
44.029
−2.024
32.544
1.00
20.36
A

ATOM
493
CG
TYR
A
76
45.341
−2.070
33.294
1.00
22.91
A

ATOM
494
CD1
TYR
A
76
45.582
−1.227
34.385
1.00
22.46
A

ATOM
495
CE1
TYR
A
76
46.827
−1.231
35.044
1.00
24.23
A

ATOM
496
CD2
TYR
A
76
46.371
−2.920
32.878
1.00
23.56
A

ATOM
497
CE2
TYR
A
76
47.621
−2.929
33.530
1.00
23.98
A

ATOM
498
CZ
TYR
A
76
47.840
−2.083
34.606
1.00
23.95
A

ATOM
499
OH
TYR
A
76
49.073
−2.071
35.223
1.00
24.89
A

ATOM
500
C
TYR
A
76
42.856
−1.303
30.454
1.00
17.43
A

ATOM
501
O
TYR
A
76
41.753
−0.999
30.870
1.00
18.57
A

ATOM
502
N
CYS
A
77
43.052
−1.833
29.250
1.00
19.17
A

ATOM
503
CA
CYS
A
77
41.940
−2.034
28.318
1.00
20.17
A

ATOM
504
CB
CYS
A
77
41.984
−0.939
27.242
1.00
18.05
A

ATOM
505
SG
CYS
A
77
43.606
−0.777
26.414
1.00
17.89
A

ATOM
506
C
CYS
A
77
41.853
−3.405
27.639
1.00
20.92
A

ATOM
507
O
CYS
A
77
41.084
−3.577
26.698
1.00
22.93
A

ATOM
508
N
SER
A
78
42.619
−4.379
28.110
1.00
21.73
A

ATOM
509
CA
SER
A
78
42.590
−5.706
27.504
1.00
23.67
A

ATOM
510
CB
SER
A
78
43.569
−6.636
28.216
1.00
23.31
A

ATOM
511
OG
SER
A
78
43.353
−6.594
29.612
1.00
24.57
A

ATOM
512
C
SER
A
78
41.202
−6.344
27.497
1.00
24.32
A

ATOM
513
O
SER
A
78
40.917
−7.189
26.647
1.00
24.57
A

ATOM
514
N
ASN
A
79
40.343
−5.949
28.432
1.00
23.65
A

ATOM
515
CA
ASN
A
79
38.996
−6.517
28.492
1.00
24.00
A

ATOM
516
CB
ASN
A
79
38.716
−7.139
29.872
1.00
24.75
A

ATOM
517
CG
ASN
A
79
39.516
−8.411
30.120
1.00
25.05
A

ATOM
518
OD1
ASN
A
79
40.571
−8.380
30.753
1.00
25.04
A

ATOM
519
ND2
ASN
A
79
39.021
−9.534
29.608
1.00
25.70
A

ATOM
520
C
ASN
A
79
37.928
−5.472
28.186
1.00
23.53
A

ATOM
521
O
ASN
A
79
36.857
−5.455
28.806
1.00
23.89
A

ATOM
522
N
ASP
A
80
38.222
−4.611
27.219
1.00
21.43
A

ATOM
523
CA
ASP
A
80
37.304
−3.554
26.831
1.00
20.47
A

ATOM
524
CB
ASP
A
80
37.609
−2.277
27.631
1.00
20.36
A

ATOM
525
CG
ASP
A
80
36.608
−1.170
27.370
1.00
20.02
A

ATOM
526
OD1
ASP
A
80
35.855
−0.817
28.299
1.00
20.17
A

ATOM
527
OD2
ASP
A
80
36.567
−0.656
26.236
1.00
20.97
A

ATOM
528
C
ASP
A
80
37.439
−3.270
25.341
1.00
20.46
A

ATOM
529
O
ASP
A
80
38.505
−3.492
24.744
1.00
20.32
A

ATOM
530
N
LEU
A
81
36.350
−2.783
24.746
1.00
19.74
A

ATOM
531
CA
LEU
A
81
36.317
−2.448
23.323
1.00
19.05
A

ATOM
532
CB
LEU
A
81
35.019
−1.709
23.010
1.00
20.17
A

ATOM
533
CG
LEU
A
81
34.870
−1.058
21.638
1.00
23.86
A

ATOM
534
CD1
LEU
A
81
35.022
−2.102
20.539
1.00
24.25
A

ATOM
535
CD2
LEU
A
81
33.500
−0.381
21.563
1.00
24.57
A

ATOM
536
C
LEU
A
81
37.522
−1.576
22.957
1.00
17.50
A

ATOM
537
O
LEU
A
81
38.155
−1.766
21.913
1.00
15.88
A

ATOM
538
N
LEU
A
82
37.831
−0.633
23.846
1.00
14.87
A

ATOM
539
CA
LEU
A
82
38.944
0.290
23.679
1.00
12.91
A

ATOM
540
CB
LEU
A
82
39.117
1.125
24.961
1.00
11.35
A

ATOM
541
CG
LEU
A
82
40.296
2.107
25.024
1.00
10.75
A

ATOM
542
CD1
LEU
A
82
40.216
3.088
23.855
1.00
10.31
A

ATOM
543
CD2
LEU
A
82
40.284
2.839
26.357
1.00
9.38
A

ATOM
544
C
LEU
A
82
40.252
−0.430
23.344
1.00
12.97
A

ATOM
545
O
LEU
A
82
40.992
−0.012
22.439
1.00
9.83
A

ATOM
546
N
GLY
A
83
40.538
−1.503
24.080
1.00
12.95
A

ATOM
547
CA
GLY
A
83
41.756
−2.248
23.834
1.00
15.06
A

ATOM
548
C
GLY
A
83
41.816
−2.728
22.391
1.00
16.77
A

ATOM
549
O
GLY
A
83
42.853
−2.635
21.732
1.00
15.55
A

ATOM
550
N
ASP
A
84
40.691
−3.233
21.894
1.00
18.65
A

ATOM
551
CA
ASP
A
84
40.631
−3.736
20.534
1.00
21.41
A

ATOM
552
CB
ASP
A
84
39.294
−4.432
20.288
1.00
25.41
A

ATOM
553
CG
ASP
A
84
39.043
−5.561
21.263
1.00
28.55
A

ATOM
554
OD1
ASP
A
84
40.004
−6.324
21.550
1.00
27.94
A

ATOM
555
OD2
ASP
A
84
37.887
−5.685
21.730
1.00
30.30
A

ATOM
556
C
ASP
A
84
40.830
−2.640
19.503
1.00
21.92
A

ATOM
557
O
ASP
A
84
41.547
−2.838
18.525
1.00
22.99
A

ATOM
558
N
LEU
A
85
40.197
−1.491
19.719
1.00
21.04
A

ATOM
559
CA
LEU
A
85
40.314
−0.373
18.790
1.00
22.00
A

ATOM
560
CB
LEU
A
85
39.286
0.713
19.133
1.00
21.98
A

ATOM
561
CG
LEU
A
85
37.835
0.226
19.211
1.00
23.19
A

ATOM
562
CD1
LEU
A
85
36.884
1.393
19.514
1.00
20.96
A

ATOM
563
CD2
LEU
A
85
37.472
−0.450
17.892
1.00
22.60
A

ATOM
564
C
LEU
A
85
41.727
0.214
18.799
1.00
21.67
A

ATOM
565
O
LEU
A
85
42.216
0.686
17.770
1.00
20.70
A

ATOM
566
N
PHE
A
86
42.381
0.173
19.958
1.00
21.86
A

ATOM
567
CA
PHE
A
86
43.740
0.702
20.086
1.00
20.91
A

ATOM
568
CB
PHE
A
86
43.965
1.264
21.491
1.00
19.44
A

ATOM
569
CG
PHE
A
86
43.487
2.688
21.671
1.00
16.86
A

ATOM
570
CD1
PHE
A
86
42.626
3.282
20.744
1.00
15.83
A

ATOM
571
CD2
PHE
A
86
43.899
3.431
22.773
1.00
14.83
A

ATOM
572
CE1
PHE
A
86
42.181
4.597
20.908
1.00
14.04
A

ATOM
573
CE2
PHE
A
86
43.461
4.749
22.955
1.00
18.00
A

ATOM
574
CZ
PHE
A
86
42.597
5.334
22.013
1.00
16.08
A

ATOM
575
C
PHE
A
86
44.774
−0.377
19.794
1.00
22.21
A

ATOM
576
O
PHE
A
86
45.917
−0.080
19.447
1.00
23.98
A

ATOM
577
N
GLY
A
87
44.370
−1.635
19.923
1.00
22.25
A

ATOM
578
CA
GLY
A
87
45.298
−2.717
19.664
1.00
20.93
A

ATOM
579
C
GLY
A
87
46.363
−2.894
20.735
1.00
20.93
A

ATOM
580
O
GLY
A
87
47.499
−3.266
20.417
1.00
22.00
A

ATOM
581
N
VAL
A
88
46.015
−2.621
21.994
1.00
18.42
A

ATOM
582
CA
VAL
A
88
46.947
−2.787
23.110
1.00
16.75
A

ATOM
583
CB
VAL
A
88
47.763
−1.506
23.426
1.00
16.55
A

ATOM
584
CG1
VAL
A
88
48.589
−1.098
22.223
1.00
15.93
A

ATOM
585
CG2
VAL
A
88
46.836
−0.394
23.892
1.00
13.35
A

ATOM
586
C
VAL
A
88
46.185
−3.155
24.371
1.00
16.74
A

ATOM
587
O
VAL
A
88
45.010
−2.822
24.518
1.00
16.22
A

ATOM
588
N
PRO
A
89
46.854
−3.851
25.300
1.00
16.36
A

ATOM
589
CD
PRO
A
89
48.202
−4.420
25.116
1.00
17.10
A

ATOM
590
CA
PRO
A
89
46.269
−4.283
26.574
1.00
16.05
A

ATOM
591
CB
PRO
A
89
47.181
−5.427
27.000
1.00
15.83
A

ATOM
592
CG
PRO
A
89
48.517
−4.975
26.501
1.00
18.07
A

ATOM
593
C
PRO
A
89
46.232
−3.155
27.604
1.00
16.21
A

ATOM
594
O
PRO
A
89
45.462
−3.210
28.570
1.00
15.73
A

ATOM
595
N
SER
A
90
47.066
−2.138
27.391
1.00
15.13
A

ATOM
596
CA
SER
A
90
47.131
−0.988
28.292
1.00
14.02
A

ATOM
597
CB
SER
A
90
47.652
−1.409
29.663
1.00
12.56
A

ATOM
598
OG
SER
A
90
49.018
−1.764
29.560
1.00
13.74
A

ATOM
599
C
SER
A
90
48.060
0.083
27.719
1.00
12.89
A

ATOM
600
O
SER
A
90
48.833
−0.191
26.803
1.00
12.05
A

ATOM
601
N
PHE
A
91
47.978
1.293
28.267
1.00
11.19
A

ATOM
602
CA
PHE
A
91
48.807
2.397
27.816
1.00
11.45
A

ATOM
603
CB
PHE
A
91
48.290
2.943
26.466
1.00
10.33
A

ATOM
604
CG
PHE
A
91
46.891
3.480
26.518
1.00
8.05
A

ATOM
605
CD1
PHE
A
91
46.655
4.817
26.828
1.00
7.52
A

ATOM
606
CD2
PHE
A
91
45.800
2.638
26.304
1.00
7.09
A

ATOM
607
CE1
PHE
A
91
45.338
5.315
26.932
1.00
7.90
A

ATOM
608
CE2
PHE
A
91
44.485
3.118
26.404
1.00
7.31
A

ATOM
609
CZ
PHE
A
91
44.256
4.467
26.721
1.00
7.15
A

ATOM
610
C
PHE
A
91
48.869
3.517
28.852
1.00
13.35
A

ATOM
611
O
PHE
A
91
48.090
3.547
29.817
1.00
12.34
A

ATOM
612
N
SER
A
92
49.807
4.437
28.644
1.00
14.78
A

ATOM
613
CA
SER
A
92
49.996
5.558
29.548
1.00
16.74
A

ATOM
614
CB
SER
A
92
51.493
5.769
29.811
1.00
15.00
A

ATOM
615
OG
SER
A
92
51.712
6.925
30.610
1.00
15.51
A

ATOM
616
C
SER
A
92
49.384
6.854
29.012
1.00
18.09
A

ATOM
617
O
SER
A
92
49.653
7.257
27.881
1.00
17.05
A

ATOM
618
N
VAL
A
93
48.562
7.502
29.835
1.00
19.76
A

ATOM
619
CA
VAL
A
93
47.941
8.765
29.456
1.00
21.70
A

ATOM
620
CB
VAL
A
93
46.883
9.242
30.506
1.00
22.34
A

ATOM
621
CG1
VAL
A
93
45.727
8.253
30.571
1.00
22.82
A

ATOM
622
CG2
VAL
A
93
47.520
9.393
31.880
1.00
20.47
A

ATOM
623
C
VAL
A
93
49.001
9.852
29.311
1.00
22.48
A

ATOM
624
O
VAL
A
93
48.672
11.011
29.120
1.00
24.56
A

ATOM
625
N
LYS
A
94
50.272
9.479
29.402
1.00
24.37
A

ATOM
626
CA
LYS
A
94
51.369
10.441
29.268
1.00
26.51
A

ATOM
627
CB
LYS
A
94
52.454
10.190
30.323
1.00
27.71
A

ATOM
628
CG
LYS
A
94
52.235
10.866
31.682
1.00
30.96
A

ATOM
629
CD
LYS
A
94
53.375
10.491
32.648
1.00
33.87
A

ATOM
630
CE
LYS
A
94
53.298
11.223
33.998
1.00
35.49
A

ATOM
631
NZ
LYS
A
94
54.414
10.825
34.930
1.00
35.43
A

ATOM
632
C
LYS
A
94
52.014
10.375
27.886
1.00
26.44
A

ATOM
633
O
LYS
A
94
52.693
11.309
27.469
1.00
27.30
A

ATOM
634
N
GLU
A
95
51.821
9.260
27.190
1.00
25.84
A

ATOM
635
CA
GLU
A
95
52.386
9.076
25.859
1.00
25.31
A

ATOM
636
CB
GLU
A
95
52.648
7.590
25.612
1.00
26.45
A

ATOM
637
CG
GLU
A
95
53.540
6.907
26.643
1.00
28.64
A

ATOM
638
CD
GLU
A
95
55.022
7.198
26.457
1.00
30.17
A

ATOM
639
OE1
GLU
A
95
55.415
7.657
25.359
1.00
31.51
A

ATOM
640
OE2
GLU
A
95
55.798
6.948
27.407
1.00
28.42
A

ATOM
641
C
GLU
A
95
51.394
9.612
24.818
1.00
24.66
A

ATOM
642
O
GLU
A
95
50.809
8.851
24.037
1.00
22.08
A

ATOM
643
N
HIS
A
96
51.225
10.932
24.808
1.00
24.62
A

ATOM
644
CA
HIS
A
96
50.295
11.590
23.900
1.00
26.26
A

ATOM
645
CB
HIS
A
96
50.410
13.113
24.027
1.00
27.90
A

ATOM
646
CG
HIS
A
96
50.114
13.629
25.400
1.00
30.90
A

ATOM
647
CD2
HIS
A
96
50.422
13.138
26.625
1.00
31.52
A

ATOM
648
ND1
HIS
A
96
49.432
14.807
25.621
1.00
32.30
A

ATOM
649
CE1
HIS
A
96
49.333
15.018
26.922
1.00
32.43
A

ATOM
650
NE2
HIS
A
96
49.926
14.019
27.554
1.00
32.16
A

ATOM
651
C
HIS
A
96
50.420
11.193
22.435
1.00
26.13
A

ATOM
652
O
HIS
A
96
49.408
11.006
21.764
1.00
26.36
A

ATOM
653
N
ARG
A
97
51.648
11.067
21.938
1.00
25.66
A

ATOM
654
CA
ARG
A
97
51.857
10.696
20.540
1.00
25.19
A

ATOM
655
CB
ARG
A
97
53.344
10.864
20.161
1.00
25.74
A

ATOM
656
CG
ARG
A
97
53.734
10.433
18.746
1.00
24.90
A

ATOM
657
CD
ARG
A
97
52.779
10.981
17.684
1.00
27.96
A

ATOM
658
NE
ARG
A
97
52.817
12.435
17.532
1.00
29.51
A

ATOM
659
CZ
ARG
A
97
51.931
13.132
16.820
1.00
29.81
A

ATOM
660
NH1
ARG
A
97
50.936
12.508
16.197
1.00
31.04
A

ATOM
661
NH2
ARG
A
97
52.037
14.451
16.722
1.00
27.76
A

ATOM
662
C
ARG
A
97
51.371
9.269
20.265
1.00
24.39
A

ATOM
663
O
ARG
A
97
50.775
9.012
19.222
1.00
25.23
A

ATOM
664
N
LYS
A
98
51.605
8.344
21.189
1.00
23.55
A

ATOM
665
CA
LYS
A
98
51.145
6.970
20.983
1.00
23.84
A

ATOM
666
CB
LYS
A
98
51.678
6.034
22.082
1.00
25.86
A

ATOM
667
CG
LYS
A
98
53.151
5.669
21.933
1.00
29.53
A

ATOM
668
CD
LYS
A
98
53.621
4.689
23.004
1.00
31.47
A

ATOM
669
CE
LYS
A
98
55.149
4.543
22.978
1.00
33.99
A

ATOM
670
NZ
LYS
A
98
55.672
3.627
24.040
1.00
34.37
A

ATOM
671
C
LYS
A
98
49.611
6.908
20.955
1.00
23.22
A

ATOM
672
O
LYS
A
98
49.031
6.190
20.136
1.00
21.35
A

ATOM
673
N
ILE
A
99
48.963
7.658
21.849
1.00
21.20
A

ATOM
674
CA
ILE
A
99
47.507
7.689
21.909
1.00
20.16
A

ATOM
675
CB
ILE
A
99
47.017
8.541
23.112
1.00
18.26
A

ATOM
676
CG2
ILE
A
99
45.526
8.843
22.980
1.00
16.58
A

ATOM
677
CG1
ILE
A
99
47.306
7.793
24.421
1.00
16.19
A

ATOM
678
CD1
ILE
A
99
47.022
8.589
25.665
1.00
12.79
A

ATOM
679
C
ILE
A
99
46.949
8.256
20.601
1.00
21.79
A

ATOM
680
O
ILE
A
99
46.008
7.710
20.019
1.00
21.34
A

ATOM
681
N
TYR
A
100
47.543
9.348
20.133
1.00
23.34
A

ATOM
682
CA
TYR
A
100
47.113
9.978
18.891
1.00
24.14
A

ATOM
683
CB
TYR
A
100
47.961
11.220
18.611
1.00
25.12
A

ATOM
684
CG
TYR
A
100
47.228
12.508
18.883
1.00
28.22
A

ATOM
685
CD1
TYR
A
100
46.799
12.833
20.177
1.00
28.65
A

ATOM
686
CE1
TYR
A
100
46.065
13.989
20.423
1.00
28.51
A

ATOM
687
CD2
TYR
A
100
46.908
13.379
17.843
1.00
28.65
A

ATOM
688
CE2
TYR
A
100
46.170
14.541
18.077
1.00
29.38
A

ATOM
689
CZ
TYR
A
100
45.752
14.835
19.366
1.00
29.62
A

ATOM
690
OH
TYR
A
100
45.002
15.961
19.589
1.00
31.04
A

ATOM
691
C
TYR
A
100
47.149
9.048
17.671
1.00
25.10
A

ATOM
692
O
TYR
A
100
46.216
9.055
16.857
1.00
25.32
A

ATOM
693
N
THR
A
101
48.206
8.251
17.524
1.00
23.58
A

ATOM
694
CA
THR
A
101
48.252
7.383
16.362
1.00
24.54
A

ATOM
695
CB
THR
A
101
49.714
7.004
15.972
1.00
25.48
A

ATOM
696
OG1
THR
A
101
50.297
6.160
16.962
1.00
26.87
A

ATOM
697
CG2
THR
A
101
50.552
8.262
15.841
1.00
27.33
A

ATOM
698
C
THR
A
101
47.376
6.143
16.527
1.00
23.52
A

ATOM
699
O
THR
A
101
47.074
5.459
15.553
1.00
24.28
A

ATOM
700
N
MET
A
102
46.949
5.851
17.753
1.00
22.80
A

ATOM
701
CA
MET
A
102
46.052
4.711
17.956
1.00
20.40
A

ATOM
702
CB
MET
A
102
46.081
4.229
19.408
1.00
15.37
A

ATOM
703
CG
MET
A
102
47.385
3.556
19.756
1.00
14.03
A

ATOM
704
SD
MET
A
102
47.437
2.805
21.384
1.00
11.93
A

ATOM
705
CE
MET
A
102
47.530
4.281
22.436
1.00
10.87
A

ATOM
706
C
MET
A
102
44.645
5.163
17.563
1.00
19.65
A

ATOM
707
O
MET
A
102
43.829
4.371
17.091
1.00
19.47
A

ATOM
708
N
ILE
A
103
44.384
6.451
17.755
1.00
18.90
A

ATOM
709
CA
ILE
A
103
43.108
7.049
17.406
1.00
21.34
A

ATOM
710
CB
ILE
A
103
42.959
8.459
18.055
1.00
20.40
A

ATOM
711
CG2
ILE
A
103
41.789
9.217
17.425
1.00
19.03
A

ATOM
712
CG1
ILE
A
103
42.757
8.312
19.565
1.00
19.84
A

ATOM
713
CD1
ILE
A
103
42.941
9.601
20.345
1.00
18.82
A

ATOM
714
C
ILE
A
103
43.045
7.183
15.881
1.00
24.13
A

ATOM
715
O
ILE
A
103
41.996
6.968
15.271
1.00
24.18
A

ATOM
716
N
TYR
A
104
44.182
7.530
15.277
1.00
27.06
A

ATOM
717
CA
TYR
A
104
44.283
7.701
13.827
1.00
29.10
A

ATOM
718
CB
TYR
A
104
45.702
8.155
13.462
1.00
30.33
A

ATOM
719
CG
TYR
A
104
45.914
9.635
13.689
1.00
30.58
A

ATOM
720
CD1
TYR
A
104
47.148
10.137
14.093
1.00
29.56
A

ATOM
721
CE1
TYR
A
104
47.328
11.499
14.323
1.00
29.30
A

ATOM
722
CD2
TYR
A
104
44.862
10.533
13.516
1.00
31.51
A

ATOM
723
CE2
TYR
A
104
45.032
11.892
13.742
1.00
31.90
A

ATOM
724
CZ
TYR
A
104
46.264
12.366
14.146
1.00
30.22
A

ATOM
725
OH
TYR
A
104
46.411
13.711
14.379
1.00
32.03
A

ATOM
726
C
TYR
A
104
43.895
6.466
13.017
1.00
29.49
A

ATOM
727
O
TYR
A
104
43.336
6.587
11.926
1.00
30.07
A

ATOM
728
N
ARG
A
105
44.188
5.287
13.553
1.00
30.44
A

ATOM
729
CA
ARG
A
105
43.851
4.039
12.883
1.00
31.09
A

ATOM
730
CB
ARG
A
105
44.714
2.889
13.407
1.00
32.59
A

ATOM
731
CG
ARG
A
105
46.098
2.802
12.783
1.00
35.48
A

ATOM
732
CD
ARG
A
105
46.758
1.479
13.140
1.00
38.68
A

ATOM
733
NE
ARG
A
105
47.041
1.380
14.572
1.00
41.14
A

ATOM
734
CZ
ARG
A
105
48.198
1.727
15.132
1.00
42.11
A

ATOM
735
NH1
ARG
A
105
49.192
2.196
14.382
1.00
41.27
A

ATOM
736
NH2
ARG
A
105
48.362
1.605
16.446
1.00
42.61
A

ATOM
737
C
ARG
A
105
42.382
3.705
13.104
1.00
31.15
A

ATOM
738
O
ARG
A
105
41.887
2.692
12.599
1.00
30.58
A

ATOM
739
N
ASN
A
106
41.691
4.552
13.867
1.00
30.35
A

ATOM
740
CA
ASN
A
106
40.272
4.349
14.137
1.00
31.38
A

ATOM
741
CB
ASN
A
106
39.995
4.297
15.639
1.00
30.13
A

ATOM
742
CG
ASN
A
106
40.393
2.984
16.250
1.00
30.74
A

ATOM
743
OD1
ASN
A
106
41.568
2.754
16.549
1.00
30.89
A

ATOM
744
ND2
ASN
A
106
39.415
2.094
16.427
1.00
30.12
A

ATOM
745
C
ASN
A
106
39.408
5.429
13.517
1.00
32.04
A

ATOM
746
O
ASN
A
106
38.293
5.677
13.970
1.00
30.99
A

ATOM
747
N
LEU
A
107
39.914
6.070
12.474
1.00
34.74
A

ATOM
748
CA
LEU
A
107
39.144
7.115
11.828
1.00
39.45
A

ATOM
749
CB
LEU
A
107
39.166
8.383
12.694
1.00
39.46
A

ATOM
750
CG
LEU
A
107
40.507
8.908
13.220
1.00
38.61
A

ATOM
751
CD1
LEU
A
107
41.418
9.298
12.068
1.00
38.52
A

ATOM
752
CD2
LEU
A
107
40.252
10.105
14.120
1.00
37.16
A

ATOM
753
C
LEU
A
107
39.614
7.441
10.425
1.00
42.25
A

ATOM
754
O
LEU
A
107
40.442
6.732
9.848
1.00
42.75
A

ATOM
755
N
VAL
A
108
39.057
8.516
9.882
1.00
46.00
A

ATOM
756
CA
VAL
A
108
39.397
8.997
8.549
1.00
49.43
A

ATOM
757
CB
VAL
A
108
38.365
8.541
7.499
1.00
48.08
A

ATOM
758
CG1
VAL
A
108
39.032
8.443
6.146
1.00
48.02
A

ATOM
759
CG2
VAL
A
108
37.735
7.216
7.907
1.00
46.78
A

ATOM
760
C
VAL
A
108
39.389
10.529
8.612
1.00
53.19
A

ATOM
761
O
VAL
A
108
38.321
11.145
8.684
1.00
52.78
A

ATOM
762
N
VAL
A
109
40.576
11.136
8.601
1.00
57.34
A

ATOM
763
CA
VAL
A
109
40.708
12.596
8.664
1.00
61.10
A

ATOM
764
CB
VAL
A
109
42.177
13.052
8.480
1.00
61.46
A

ATOM
765
CG1
VAL
A
109
42.306
14.528
8.847
1.00
61.63
A

ATOM
766
CG2
VAL
A
109
43.115
12.193
9.320
1.00
62.28
A

ATOM
767
C
VAL
A
109
39.875
13.293
7.584
1.00
63.47
A

ATOM
768
O
VAL
A
109
40.196
13.206
6.394
1.00
63.73
A

ATOM
769
N
VAL
A
110
38.817
13.989
8.004
1.00
65.46
A

ATOM
770
CA
VAL
A
110
37.941
14.697
7.073
1.00
67.21
A

ATOM
771
CB
VAL
A
110
36.927
15.603
7.840
1.00
66.97
A

ATOM
772
CG1
VAL
A
110
35.873
16.155
6.878
1.00
67.04
A

ATOM
773
CG2
VAL
A
110
36.262
14.817
8.961
1.00
66.24
A

ATOM
774
C
VAL
A
110
38.775
15.570
6.119
1.00
69.20
A

ATOM
775
O
VAL
A
110
39.949
15.862
6.458
1.00
69.94
A

ATOM
776
OXT
VAL
A
110
38.248
15.956
5.046
1.00
70.58
A

ATOM
777
C1
CID
A
1
46.320
13.011
27.769
1.00
21.13

INH1

ATOM
778
C2
CID
A
1
46.849
12.548
26.529
1.00
21.31

INH1

ATOM
779
C3
CID
A
1
46.319
13.053
25.307
1.00
21.72

INH1

ATOM
780
C4
CID
A
1
45.283
14.011
25.313
1.00
21.74

INH1

ATOM
781
C5
CID
A
1
44.753
14.472
26.542
1.00
21.42

INH1

ATOM
782
C6
CID
A
1
45.261
13.981
27.804
1.00
22.49

INH1

ATOM
783
C7
CID
A
1
44.698
14.428
29.194
1.00
23.66

INH1

ATOM
784
C8
CID
A
1
44.052
15.860
29.277
1.00
25.69

INH1

ATOM
785
O1
CID
A
1
43.517
16.308
30.288
1.00
29.01

INH1

ATOM
786
O2
CID
A
1
44.409
16.731
28.309
1.00
30.64

INH1

ATOM
787
N1
CID
A
1
43.714
13.347
29.673
1.00
19.99

INH1

ATOM
788
C9
CID
A
1
42.570
12.996
28.781
1.00
18.95

INH1

ATOM
789
C10
CID
A
1
42.648
11.641
28.034
1.00
18.04

INH1

ATOM
790
C11
CID
A
1
43.669
10.654
28.259
1.00
17.01

INH1

ATOM
791
C12
CID
A
1
43.700
9.448
27.530
1.00
16.97

INH1

ATOM
792
C13
CID
A
1
42.708
9.210
26.564
1.00
17.64

INH1

ATOM
793
CL1
CID
A
1
42.737
7.786
25.674
1.00
14.96

INH1

ATOM
794
C14
CID
A
1
41.687
10.153
26.318
1.00
18.96

INH1

ATOM
795
C15
CID
A
1
41.659
11.354
27.046
1.00
17.55

INH1

ATOM
796
C16
CID
A
1
41.205
13.214
29.506
1.00
18.08

INH1

ATOM
797
O3
CID
A
1
40.363
13.973
29.015
1.00
18.82

INH1

ATOM
798
N2
CID
A
1
40.909
12.577
30.698
1.00
16.78

INH1

ATOM
799
C17
CID
A
1
41.690
11.680
31.447
1.00
17.03

INH1

ATOM
800
C18
CID
A
1
43.101
11.735
31.572
1.00
16.70

INH1

ATOM
801
C19
CID
A
1
43.977
12.786
30.947
1.00
19.45

INH1

ATOM
802
O4
CID
A
1
44.965
13.160
31.626
1.00
18.52

INH1

ATOM
803
C20
CID
A
1
43.769
10.744
32.353
1.00
17.26

INH1

ATOM
804
C21
CID
A
1
43.051
9.726
33.006
1.00
18.91

INH1

ATOM
805
I1
CID
A
1
44.145
8.343
34.119
1.00
19.64

INH1

ATOM
806
C22
CID
A
1
41.657
9.670
32.902
1.00
17.86

INH1

ATOM
807
C23
CID
A
1
40.966
10.637
32.123
1.00
17.23

INH1

ATOM
808
CL2
CID
A
1
46.930
12.505
23.805
1.00
20.99

INH1

ATOM
809
CL3
CID
A
1
40.751
8.456
33.699
1.00
20.31

INH1

END

HDM2-inhibitor complexes and uses thereof

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

Provisional Applications (1)